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1 Abstract 
The most recent cancer classification from NIH includes ~200 types of tumor that 
originates from several tissue types (http://www.cancer.gov/types). Although 
macroscopic and microscopic characteristics varies significantly across subtypes, the 
starting point of every cancer is believed to be a single cell that acquires DNA somatic 
alterations that increases its fitness over the surrounding cells and makes it behave 
abnormally and proliferate uncontrollably. Somatic mutations are the consequence of 
many possible defective processes such as replication deficiencies, exposure to 
carcinogens, or DNA repair machinery faults. Mutation development is a random and 
mostly natural process that frequently happens in every cell of an individual. Only the 
acquisition of a series of subtype-specific alterations, including also larger aberrations 
such as translocations or deletions, can lead to the development of the disease and this is 
a long process for the majority of adult tumor types. However, genetic predisposition for 
certain cancer types is epidemiologically well established. In fact, several cancer 
predisposing genes where identified in the last 30 years with various technologies but 
they characterize only a small fraction of familial cases. This work will therefore cover 
two main steps of cancer genetics and genomics: the identification of the genes that 
somatically changes the behavior of a normal human cell to a cancer cell and the genetic 
variants that increase risk of cancer development. The use of publicly available datasets is 
common to all the three results sections that compose this work. In particular, we took 
advantage of several whole exome sequencing databases (WES) for the identification of 
both driver mutations and driver variants. In particular, the use of WES in cancer 
predisposition analysis represents one of the few attempts of performing such analysis 
on genome-wide sequencing germline data. 
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2 Introduction 
The purpose of this work is to delineate a workflow to analyze and classify genes that are 
important for cancer progression both at the germinal level (cancer predisposing genes, 
CPGs) and somatic level (somatic driver genes, SDGs). We generally refer at variants as 
those hereditable germline Single Nucleotide Polymorphisms (SNPs) that happen in the 
normal DNA of the person and they can increase or not the risk of developing cancer. 
We call mutations, all those Single Nucleotide Variants (SNVs) that can be seen in the 
tumor but are not part of the original genome of the individual. To be more precise, we 
refer to the latter as somatic mutations since the term mutation is sometimes used to 
define pathogenic germline variants, especially in clinical settings (for example when 
referring to BRCA1 mutants). In general, mutation, compared to variant, assumes a 
negative connotation when referring to pathogenic alterations. This introduction 
represents a brief historical summary of the main milestones in cancer research 
concerning DNA alterations in cancer. This history runs on a parallel track with the 
history of cell biology, as a lot of what we know now on how a human cell behave is 
nothing but a byproduct of cancer research.  
2.1 Cancer as an evolutionary process 
The somatic evolution of cancer is a theory that states that cancer is the effect of the 
accumulation of mutations over time from a single aberrant cell of origin that passes the 
mutations to its next generation. This cell of origin, ultimately evolve in a tumor via 
mutations that confer a selective growth advantage with respect to its surrounding cells. 
In 1902, the German biologist Theodor Boveri introduced for the first time the concept 
of chromosomal aberration as a possible cause for a cell to become malignant, by 
reviving some observations made by David von Hansemann in 1890 (Boveri, 2008).  This 
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hypothesis came from the observation that in sea urchins, all chromosomes are necessary 
for a proper embryonic development. Quoting from his seminal work: 
‘ We may therefore regard it as probable that individual chromosomes have different 
properties in vertebrates too, and it is this assumption that forms the basis of the tumour 
hypothesis I have put forward. A malignant tumour cell is – and here again I take up the 
ideas of Hansemann – a cell with a specific abnormal chromosome constitution ‘. 
The idea of tumors as cells with chromosomal defects came as a sort of side note in his 
work, since the experiments carried out on sea urchin were aimed at demonstrating what 
is called the Boveri-Sutton hypothesis that chromosomes are responsible for mendelian 
inheritance. Therefore, it is noteworthy that the biology of cancer was born together with 
the biology of the cell. Boveri’s ideas on oncogenesis, summarized in 1914 Zur Frage der 
Entstehung maligner Tumoren (On the Origin of Malignant Tumors, Williams & 
Wilkins. Philadelphia, PA, USA, 1914) were mostly speculative rather than 
experimental. Chromosomal inheritance was definitely ruled out by Thomas Morgan a 
year later and the term somatic mutation was introduced by Tyzzer approximately in the 
same period of time (Tyzzer, 1916). Unfortunately, Boveri died in 1915, without 
knowing that his seminal ideas were shaping cancer research for the next 100 years. In 
1919, Whitman associated anaplasia, the condition of a cell that loses the morphological 
characteristics of mature cells, with the concept of somatic mutations (Whitman, 1919). 
He also sets the somatic mutation mechanism as the cause of uncontrolled proliferation 
and aberrant cell division, as postulated by Boveri himself. 25 years before the discovery 
of DNA as the molecule of inheritance and 50 years before the first experiments on cell 
cycle regulation, cancer was already seen as an evolutionary mechanism that starts from 
a single aberrant cell that proliferates and passes the mutations to the next generation of 
cells (clonal evolution). In Whitman words: 
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‘ This cell, the cancer cell, is thus a ‘new kind of cell’. In modern terminology it is, 
strictly and literally, a mutated cell. Since the process is, or at least may be, repeated 
itself from time to time, and here and there, in a tumor, it follows that the tumor cells 
themselves are by no means all alike in their biologic properties; that, on the contrary, 
an ever recurring process of mutation is taking place, with a tendency, however, to 
deviate more and more from the normal type. This explains why metastatic tumors, for 
example, are often more, but never less, malignant than the primary tumor, as well as 
other related phenomena of tumor growth ’. 
2.2 Accumulating driver mutations 
In the beginning of the 20th century, scientists referred at mutations as chromosomal 
aberrations, because DNA structure and function was still unknown. In this view, two 
fundamental concepts of somatic tumor evolution were still missing. First, the idea of 
accumulation of mutations over time was first observed by two statistical models by 
Nordling in 1953 and Armitage and Dolls in 1954 (Armitage and Doll, 1954; Nordling, 
1953)  that for the first time clearly stated that age is the main risk factor for cancer death 
and that multi-mutations (at least 7 in Nordling model) must occur to develop the 
disease. Secondly, what kind of mutations must occurs to develop the various subtypes of 
cancer was mostly unknown until 1971 (Knudson, 1971). Knudson observed that the 
heritable form of retinoblastoma occurred at a much earlier age than the non-heritable 
form and he explained this observation by speculating that at least two mutational events 
were necessary for the development of this cancer. Patients that present with the 
heritable form of retinoblastoma harbor a germline mutation since conception and 
require only one DNA mutation in a somatic cell to develop the cancer. In contrast, in 
the non-hereditary type of retinoblastoma, two DNA mutations need to occur in a 
somatic cell in order to initiate oncogenesis. It represented the first explanation of the 
mechanism of mutations in cancer that over 10 years later will be identified as RB1, the 
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first tumor suppressor gene (TSG) (Murphree and Benedict, 1984). TSGs are entities with 
three main characteristics: 
• Their normal function is to prevent tumor formation by inhibiting cell cycle and 
ultimately tumor growth. Generally, they can induce apoptosis, promoting DNA 
repair or arrest the cell cycle 
• The mutations affecting these genes must disrupt the normal function of the 
protein 
• Mutations on tumor suppressors are generally recessive, in the sense that one 
single healthy copy of the gene is sufficient to maintain the normal behavior of 
the cell 
 The second category of genes that promote tumorigenesis is called oncogene (OG) and 
the first evidence of this class of genes and related mutations has been fully understood 
10 years after the work of Knudson on retinoblastoma. Oncogenes are cancer genes that 
when mutated increase or modify their activity within the cell and promote cell growth 
and survival. In 1979, Bishop and Vamus discovered c-Src in chickens, a gene that when 
mutated resembles a viral form called v-Src that can be found in Rous Sarcoma Virus 
(Stehelin et al., 1976). Once the oncogene is transfected back into a chicken, it can lead 
to cancer. This discovery led to the idea of the viral infection as a tumor-promoting 
factor and also to the definition of the first proto-oncogene. Nevertheless, the first 
“natural occurring” oncogene can be seen as HRAS (Reddy et al., 1982), that has been 
demonstrated to have oncogenic potential by itself in NIH/3T3 cell line. With this last 
discovery, we can define all the main characteristics of oncogenes: 
• The mutations affecting this class of genes are generally missense mutations, so 
that the resulting protein function changes but is not compromised 
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• The mutations affecting this class of genes alter the original function of the gene 
by changing it (shift-of-function mutations) or more commonly by enhancing it 
(gain-of-function) 
• Oncogenes are generally dominant, in the sense that one single altered copy is 
sufficient for an oncogenic effect 
• In some cases (like RAS family genes) one oncogene is sufficient to transform the 
normal cell into a neoplastic cell (Fasano et al., 1984) 
This brief historical context of mutational theory of cancer can be summarized in a series 
of milestones as such: 
1. Cancer is a somatic disease, originating from aberrant behavior of normal cells 
2. The aberrant behavior is given by alterations in the DNA structure or content 
3. Cancer is a multi-step process, given by the accumulation of mutations over time 
and therefore age is the main risk factor for carcinogenesis 
4. There exists a genetic predisposition towards the development of such alterations 
that can be inherited and creates tumors with early onset 
5. Cancer develops through two main forces: loss-of-function in tumor suppressor 
genes and gain-of-function in oncogenes 
2.3 Tumor heterogeneity 
What is still missing from these milestones is what is the concordance in terms of 
genomic makeup among tumor types and also among tumors within the same type. In 
other terms, what are the possible ways a cancer could develop? To answer this question, 
scientists were setting the basis of what is currently called tumor heterogeneity, so what 
are the intrinsic genomic differences between different tumor cells. This difference can 
be seen both between tumors (inter-tumor heterogeneity) and within tumors (intra-
tumor heterogeneity). The first attempt at a definition of tumor heterogeneity is strictly 
correlated to clonal evolution theory (Nowell, 1976). In 1976, Nowell wrote: 
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‘ The acquired genetic instability and associated selection process, most readily 
recognized cytogenetically, results in advanced human malignancies being highly 
individual karyotypically and biologically. Hence, each patient's cancer may require 
individual specific therapy, and even this may be thwarted by emergence of a genetically 
variant subline resistant to the treatment ’. Nowell not only pinpointed that each tumor 
has its own history and biology, but poses the bases of the direction of cancer medicine 
of the last 10 years. In fact, what we now refer to personalized or precision medicine 
implies by definition that we need to understand the specific genetic makeup of each and 
everyone disease in order to tailor a specific treatment. This incredible heterogeneity is 
probably the main reason why finding effective treatments for cancer turns out to be still 
a major challenge in cancer research. Clonal evolution generates branches that compose 
a tumor made of various genomes. When a drug is designed to kill certain kind of cells, 
those with a specific genome, it leaves the possibility to other minor branches to win the 
battle for survival and recreate a tumor resistant to that drug.  
2.4 Cancer genome landscapes 
Although the concept of tumor heterogeneity was known since the 70s, it is only with 
the advent of genome-wide studies and Next Generation Sequencing (NGS) that 
scientists start to understand fully the landscapes of possible mutational patterns in 
various tumor types. In 2000, Perou and colleagues delineate the first example of tumor 
landscapes using microarray data, by bridging the gap between macroscopic subtypes 
seen by a pathologist via immunohistochemestry and genomic subtypes derived from 
gene expression (Perou et al., 2000). The authors were able to recapitulate both primary 
and metastatic machinery and ultimately give a “name”, in their words a molecular 
portrait, to the tumor of each of the 42 patients analyzed in their work. In fact, in the 
conclusion they stated: 
‘ A striking conclusion from these data concerns the stability, homogeneity and 
uniqueness of the 'molecular portraits' provided by the quantitative analysis of gene 
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expression patterns. We infer that these portraits faithfully represent the 'tumour' itself, 
and not merely the particular tumour 'sample', because we could recognize the 
distinctive expression pattern of a tumour in independent samples. ‘ 
This first example used the most prominent genome-wide technique at that time, 
expression microarray. Somatic mutations detection was still extremely expensive and 
just a few targeted genes at a time could be analyzed using polymerase chain reaction 
(PCR)-based capillary sequencing techniques. The principle behind the identification of 
somatic mutations was, at its core, the same we use today with NGS: separately 
sequencing normal germline DNA and a tumor sample and call as somatic mutations 
every base that is present in the tumor but not in the germinal line. In 2007, Vogelstein’s 
group at the John Hopkins was able to delineate the first mutational landscape of two 
kinds of solid tumors, breast and colon (Wood et al., 2007). In this seminal work that 
looked at most of the coding genes in the human genome (20,857 transcripts from 
18,191 genes), they found an average of 70 mutations per sample, approximately ten-
times more than the estimation made by Nordling model in the 1953. Furthermore, they 
add three fundamental milestones to the somatic mutation theory: 
1. The landscape of mutations in cancer is formed by few mountains and many 
hills. Mountains represent genes mutated in more than 10-20% of the samples 
while hills represent genes mutated at a frequency of 5% or lower. 
2. Not all mutations are as important as the others. ~15/70 can be called drivers as 
they promote tumor growth and survival. The majority of them are simply 
passengers, so mutations that appear in the context of genomic instability of 
neoplastic cells and are simply dragged over the generations of cells being not 
under any selective pressure. 
3. While mountains are certainly driver, each tumor has its own hills. Hills are 
linked between each other in common pathways. 
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2.5 Driver VS Passenger: a problem of mutation rate 
Vogelstein’s work on cancer genome landscapes represented in fact the last of a series of 
other seminal works probably opened by Vogelstein himself in 2004. In the review 
Cancer Genes and the pathways they control (Vogelstein and Kinzler, 2004), the 
problem of understanding the entire molecular landscapes of cancer finally emerged in 
its paramount importance: 
‘ There are at least three major challenges that will occupy most cancer researchers' 
time over the next 10 years. The first is the discovery of new genes that have a causal 
role in neoplasia, particularly those that initiate and conclude the process. The second is 
the delineation of the pathways through which these genes act and the basis for the 
varying actions in specific cell types. The third is the development of new ways to exploit 
this knowledge for the benefit of patients ‘. 
Before the early years of 2000, a precise estimate of how much of the genome was 
mutated in cancer was mostly based on mathematical models about mutation progression 
(Goldman and Yang, 1994; Yang et al., 2003). The word driver itself was used mostly to 
define oncogenes and tumor suppressors behaviors through an automotive metaphor that 
is still used in every basic course in cancer genomics today. Mutations in oncogenes are 
like cars with a stuck accelerator and mutations in tumor suppressors are like cars with a 
dysfunctional brake (Vogelstein and Kinzler, 2004). The concept of passenger in the 
somatic mutation theory was therefore linked to driver when the first PCR-based work 
on hundreds of genes started to be published in the attempt to correct an estimation of 
the mutation rate that was largely wrong. Milestone works in this sense are the ones by 
Greenman in 2006 and 2007, based on the analysis of 518 kinase genes on a cohort of 
210 tumors (Greenman, 2006; Greenman et al., 2007). Mathematical models on somatic 
mutation processes could be applied and polished based on actual genome-wide data, 
taking into account previous modeling about phylogenetic (Goldman and Yang, 1994) 
and codon substitution rates and pathogenic effects (Yang et al., 2003). In the same 
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period, before the rise of the NGS era, another publication by Sjöblom et al. reached 
similar conclusions about the nature of driver and passengers through the analysis of 
~13’000 genes in 11 breast and 11 colorectal cancers (Sjöblom et al., 2006). The works 
of Greenman and Sjöblom were compared in a Nature editorial in 2007 (Haber and 
Settleman, 2007), showing the poor overlap in terms of specific mutations on kinases, 
despite the approaches were in fact very similar to each other. The necessity of a larger 
sample to discern the entire repertoire of driver genes was evident and finally brought on 
by the efforts of the Human Cancer Genome Project, whose main repository, The Cancer 
Genome Atlas (TCGA), is used over the entire Results section.  
2.6 Cancer genomics and human genetics 
The idea of passenger mutations was not completely new 10 years ago. There was already 
huge evidence of what is called hitchhiking in genetics. Some of the variations seen in the 
human genome can increase their allele frequency or go extinct simply by being “close” 
(in genetics vocabulary, in linkage disequilibrium, LD) with alleles under selective 
pressure. The term genetic hitchhiking was coined in 1974 by Mainard Smith and Haigh 
(Smith and Haigh, 1974) and brought back to attention by Gillespie with the pseudo-
hitchhiking model of genetic draft  (Gillespie, 2000). This model made the fortune of the 
Genome-Wide Association Studies (GWAS) era that relies on the possibility to find 
regions of the genome associated with a disease by simply looking at few SNPs all along 
the genome. Under LD model, each SNP can also account for the entire surrounding 
region that is inherited together according to its LD-block. When a SNP is found 
associated with a trait, it is possible to calculate where the real pathogenic variant could 
reside and this SNP will represent a proxy for the unknown pathogenic variant. The need 
of a map of human variation to understand common and rare haplotypes in any kind of 
diseases was of paramount importance and HapMap and 1000 Genome Projects were 
both born, along with the Human Genome Project, to serve this purpose. Again, the 
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same urge of map of human variations was already discussed by Dulbecco 20 years 
earlier when talking about the future of cancer research after viral models for the 
discovery of oncogenes (Dulbecco, 1986):  
‘ If we wish to learn more about cancer we must concentrate on the cellular genome [...] we 
have two options: either to try to discover the genes important in malignancy by a 
piecemeal approach or to sequence the whole genome of a selected animal spieces. [...] In 
which species should this effort be made? If we wish to understand human cancer, it should 
be made in humans because the genetic control on cancer seems to be different in different 
species ‘. 
Research on cancer predisposition had a burst in interest during the early 90s with the 
discovery of BRCA1 and BRCA2 responsible for the early onset of certain breast and 
ovarian cancer. The risk for a carrier has been estimated to be at least 5-fold higher for 
breast cancer by the age of 70 (Chen and Parmigiani, 2007). In 1990, the group of Mary-
Claire King at UC Berkley defined the region of susceptibility as being 17q21 (Hall et al., 
1990) and after a rush lasted four years, BRCA1 was finally cloned by University of 
Utah and Myriad Genetics (Miki et al., 1994). It was believed that after the discovery of 
other highly penetrant (but way more rare) susceptibility genes like PALB2, the 
remaining missing familiarity toward cancer could be only explained by combinations of 
common variants that announced the advent of GWAS. While genome-wide somatic 
studies on cancer were still in preparation around the 2010, when NGS technology was 
taking place, large-scale GWAS studies were conducted on cancer. In particular, the 
Collaborative Oncological Gene-Environment Study (COGS), developed a unified array 
for the study of three major hormone dependent tumor types, breast, ovarian and 
prostate cancer, that encompassed over 200’000 individuals by the beginning of 2013 
(Sakoda et al., 2013). The results of GWAS studies in cancer, despite the huge efforts and 
investments, are still controversial (Check Hayden, 2013; Visscher et al., 2012). 
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2.7 Cancer genomics in the NGS era	
Although similar in principle, there is a substantial difference between passenger 
variants and passenger mutations. While genetic draft is a mechanical phenomenon, 
somatic mutations are way more unpredictable. The probability for a base to be altered 
in a tumor could depend by a plethora of different events, which include genomic 
instability, carcinogens effect, viral infection or simply the downstream effects of other 
driver mutations. So, since Laura Wood and Bert Vogelstein molecular landscapes, one 
of the main tasks of cancer genomics was to distinguish driver from passenger mutations 
and create a catalogue of cancer genes with the final aim of developing personalized 
treatments. The first attempt at a catalogue for cancer DNA similar to what 1000 
Genomes represented for human DNA is COSMIC (Catalogue of Somatic Mutations In 
Cancer), established in 2008 under the Cancer Genome Project (CGP) (Forbes et al., 
2008). In the same year, Timothy Ley and colleagues showed the results of the first whole 
genome sequencing of a leukemia sample (Ley et al., 2008) performed using one of the 
first Next Generation Sequencing (NGS) technology, the Roche 454 pyrosequencing. 
NGS technologies dramatically changed the way cancer genomics was perceived and 
studied, by allowing hundreds of sample data to be aggregated and analyzed at the same 
time and showing how deep the heterogeneity within and between tumors was. 
Furthermore, a complete new set of tools and standards in bioinformatics were 
developed to support this new biological big data era (Li et al., 2009). Other tumor types 
followed: the first breast cancer (Shah et al., 2009), then lung (Pleasance et al., 2010) and 
prostate (Berger et al., 2011), analyzed with the Illumina Genome Analyzer II. This 
technology was routinely used for the second phase of The Cancer Genome Atlas 
(TCGA) to collect mutation data. This consortium, born in 2006, started with the idea of 
characterizing 3 tumor types, glioblastoma multiforme, lung and ovarian cancer. In 
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2009, with the decrease in sequencing cost, a 5-years project started with the aim of 
characterizing 20-25 tumor types. Currently, over 30 tumor types are included. 
This work will take advantage of these data, to further understand both cancer 
predisposition and cancer somatic development and ultimately divide what is driver 
from what is passenger in both germinal and tumor genomes. 
 
3 Material and Methods 
This work represents a collection of bioinformatics methodological approaches to tackle 
the identification of driver forces that lead to cancer risk and tumor formation in the 
DNA. Therefore, an in depth analysis of materials and methods was included in the 
results for each section, as they represents results per se. Nevertheless, there are a few 
common elements at the base of this works, mostly about data format, retrieval, and 
management. 
3.1 Data Format 
Each experimental approach in NGS bioinformatics has its own format for storing and 
analyzing data. While raw formats such as FASTQ and BAM files are common to all 
sequencing technologies, mutations and variants have their own specific representation. 
3.1.1 VCF format 
The Variant Calling Format (https://samtools.github.io/hts-specs/VCFv4.2.pdf) 
represents the first real shift in genome sequences storage from SNP-based arrays 
towards NGS technologies. In fact, it was born from the advent of the 1000 Genomes 
Project (Danecek et al., 2011) as a more appropriate format for large-scale genome 
sequencing compared to NCBI General Feature Format (GFF, 
http://gmod.org/wiki/GFF3), which is oriented to larger regions of the genome and 
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resembles the BED format, or PEDigree files (PED,  https://www.cog-
genomics.org/plink2/formats#ped) that still are the standard for genetics and genotype 
calls. At its core, it is composed by 4 columns, representing chromosome, position, 
reference and alternative allele, plus the genotype call of each sample included in the call. 
The main advantage over the aforementioned formats are: i) its ability to be directly 
connected to the reference genome (via the chromosome-position-reference system), ii) 
its ability to carry variant call measures such as depth of coverage along side with the 
genotype call itself and iii) compared to the PED format, an emphasis on 
variant/mutation (one for each row), that is necessary when working on millions of 
variant/mutation at a time. PED format put the emphasis on the subjects (one for each 
row), in a time where the number of variants mapped could be even less than the 
number of subjects genotyped. This shift from a sample-based to a variant-based format, 
allows an easy annotation of the file, with several optional field such as allele counts and 
ethnicity-wise allele counts introduced by the 1000 Genomes Project itself. 
3.1.2 MAF format 
The Mutation Annotation Format 
(https://wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+(MAF)+Specifi
cation), is a cancer-specific format for somatic mutations developed together with The 
Cancer Genome Atlas (TCGA) to show VCF files in a conveniently annotated version 
that include, by default, features such as gene name, mutation type 
(missense/indel/splice site etc.). The main difference with respect to VCF, is that the 
same mutation is repeated with a new row for every new samples that harbors it. This 
shift from a wide to long format facilitates readability and data manipulation (the 
number of columns does not change by adding new samples) at the cost of increasing file 
size. The number of somatic mutations is generally not too high (on average from 
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thousands to hundreds of thousands), even in whole-genome-sequencing, and file size is 
not an issue compared to a VCF storing germline variants with millions of records. 
3.2 Data Retrieval 
In the last 5 years, several freely available databases of sequencing data were released to 
the public. These resources represent an unprecedented opportunity for  analyzing DNA 
sequencing data with thousands of patients with mutations and variants at exome and 
genome scale. The main resources used in the three works presented here are: TCGA, 
ICGC, cBioPortal, COSMIC/CGC and ExAC. 
3.2.1 TCGA 
The Cancer Genome Atlas (TCGA) is an international consortium based in the United 
States born in 2006 from the collaboration between the National Cancer Institute (NCI) 
and the National Human Genome Research Institute (NHGRI). It represents an 
unprecedented effort to integrate RNA, mRNA, DNA, copynumber and epigenomic data 
from thousands of patients in ~30 cancer types. Data from this resource were used in all 
the three chapters of the results. In general, somatic mutation calls are freely available in 
MAF format that is extremely convenient for the high level analysis of the first two 
chapters of the results. The third section of the results instead, made use of raw bam file 
from 673 breast cancer germline samples that were analyzed from scratch. 
3.2.2 ICGC 
The International Cancer Genome Consortium (ICGC) was born in 2008 to coordinate 
worldwide cancer sequencing projects of over 50 cancer types. Its main datacenter and 
secretariat is based in Toronto, Canada. In recent years, it also absorbed large part of the 
TCGA database and the format used for mutation is very similar to the MAF format 
used by TCGA. Data from this consortium were used throughout all the presented 
works.  
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3.2.3 cBioPortal 
The cBioPortal for Cancer Genomics is an aggregation datacenter and analysis web-tool 
for cancer genomic analysis that gathers studies from 146 projects in over 50 tumor types 
at the time this work was written (Cerami et al., 2012). It includes almost every data from 
ICGC and TCGA plus other smaller studies. It represents one of most complete resource 
for exploratory analysis on cancer data and ships an R package called cgdsr for the fast 
retrieval of gene specific and clinical information. This package was wrapped and used 
inside our LowMACA R package to analyze pattern of mutations and is presented in the 
second section of the results of this work. 
3.2.4 COSMIC and CGC 
The Catalogue Of Somatic Mutation In Cancer (COSMIC) is a database created at the 
Wellcome Trust Sanger Institute in 2004 as an actual collection of somatic mutation in 
cancer that gather information from both sequencing and array based data to draw a 
map of the known somatic alterations of thousands of cancer samples (Forbes et al., 
2008, 2011). From this database, the Cancer Gene Census (CGC) was created as a source 
of the established cancer genes both at predisposition and somatic driver level (Futreal et 
al., 2004). Both COSMIC and CGC were used in all the sections of the results as an 
annotation and reference set of established somatic mutation and driver genes for 
various comparisons. 
3.2.5 ExAC 
The Exome Aggregation Consortium (ExAC) is one of the largest databases of human 
variants that is currently freely available. It is a collection of 60’706 unrelated individuals 
from 15 different studies with exome sequencing data from their germline DNA. The 
database also includes data from germline of TCGA patients that represents over the 
10% of the participants of the ExAC. These data were used in the third section of the 
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results as a control sets against breast cancer patients, after the removal of all cancer 
samples and samples not from European origin. In total, we used over 20’000 control 
individuals to characterize possible cancer predisposing variants (see section 4.3).  
3.3 Data Processing and Manipulation 
Mutations and variants acquired a common representation with the advent of NGS. 
While the formats reached a sort of standardization over the last years, methodologies to 
obtain such data did not. In particular, mutation call is one of the most controversial 
points in cancer genomics, with many different algorithms developed and results that 
hardly agree with each other, both at somatic and germline level (Alioto et al., 2015; 
Bodini et al., 2014; Hwang et al., 2015). While sections 1 and 2 of the results make use of 
precomputed mutations from ICGC and TCGA, with pipelines standardized at least for 
each tumor type, in the third section we had to developed the entire pipeline of 
preprocess by ourselves. Among the many available, we chose the Genomic Analysis 
Tool Kit (GATK) to preprocess our data from alignment to variant call (DePristo et al., 
2011; McKenna et al., 2010; Van der Auwera et al., 2013). In particular, a typical variant 
call pipeline is composed as such: 
1. FASTQ filter for bad quality reads 
2. Alignment using BWA (Li and Durbin, 2009) 
3. Picard markduplicates (http://broadinstitute.github.io/picard) 
4. Indel Local realignment (GATK) 
5. Estimate systematic error and base quality (GATK) 
6. HaplotypeCaller for variant calling (GATK) 
7. Combine multiple VCF and GenotypeGVCF (GATK) 
8. Variant Quality Score Recalibration for both SNPs and InDels (GATK) 
At this point we obtain the final VCF that includes all the samples. Further preprocess 
includes: i) Split multiallelic sites (Tan et al., 2015) ii) Annotate using ANNOVAR 
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(Wang et al., 2010) iii) Adjust ANNOVAR output to obtain a MAF-like format. Heavy 
formatting of variants were carried on using vcftools/bcftools (Danecek et al., 2011) and 
vt (Tan et al., 2015), while all data munching and statistics made use of R and data.table 
package for speed up (https://cran.r-project.org/web/packages/data.table). 
This brief summary gives an idea of the tools that can be used when parsing and analyze 
mutation data, but for a detailed explanation of the methodological set of each section, 
refer to the specific Materials and Methods paragraph in 4.1.4, 4.2.3, 4.3.3. 
4 Results 
4.1 DOTS-Finder: a comprehensive tool to assessing driver genes in 
cancer genomes 
This section is adapted from (Melloni et al., 2014) and it represents an attempt to create 
a comprehensive method for the identification of somatic driver genes. Following the 
seminal work from (Vogelstein et al., 2013), we developed a tool capable of detecting 
driver genes and separate them in the two main classes of driver genes, tumor 
suppressors and oncogenes, characterized by distinct patterns of mutation distribution. 
4.1.1 Abstract 
A key challenge in the analysis of cancer genomes is the identification of driver genes 
from the vast number of mutations present in a cohort of patients. DOTS-Finder is a 
new tool that allows the detection of driver genes through the sequential application of 
functional and frequentist approaches, and is specifically tailored to the analysis of few 
tumor samples. We have identified driver genes in the genomic data of 34 tumor types 
derived from existing exploratory projects such as The Cancer Genome Atlas and from 
studies investigating the usefulness of genomic information in the clinical settings. 
DOTS-Finder is available at https://cgsb.genomics.iit.it/wiki/projects/DOTS-Finder/. 
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4.1.2 Introduction 
In the last few years, there has been an enormous increase in the amount of data 
regarding somatic mutations in various cancer types, thanks to technological 
advancements and reduction of sequencing costs. The massive sequencing of several 
cancer genomes has led to the identification of thousands of mutated genes. However, 
only a minority of the identified mutations has a true impact on the fitness of the cancer 
cells, in terms of conferring a selective growth advantage and leading to clonal expansion 
(drivers), while the others are simply passengers, namely, mutations that occur by genetic 
hitchhiking in an unstable environment and have no role in tumor progression. 
Several statistical strategies have been developed to properly identify driver mutations 
and driver genes. These strategies can be roughly classified in four main categories: 
‘protein function’, ‘frequentist’, ‘pathway-oriented’ and ‘pattern-based’ approaches. The 
‘protein function’ approaches are based on the prediction of the functional impact of a 
specific mutation in the coding sequence of a protein (Reva et al., 2011; Shihab et al., 
2013b; Sim et al., 2012). Although they do not permit the identification of driver genes, 
they can predict the effect of the mutation on the protein product. The ‘frequentist’ 
approaches evaluate the frequency of mutations in a gene compared with the 
background mutation-rate (Dees et al., 2012; Lawrence et al., 2013; Wood et al., 2007). 
The ‘pathway-oriented’ approaches are based on the analysis of the co-occurrence of 
mutations in a pathway-centered view (Bashashati et al., 2012; Ciriello et al., 2012; 
Leiserson et al., 2013; Vandin et al., 2012) and are usually focused on searching for driver 
genes belonging to the most significant mutated pathways. Lastly, the ‘pattern-based’ 
approaches identify driver genes by assessing the type of mutations (e.g. 
missense/truncating/silent) and their relative position on an amino acid map across 
many cancer samples (Davoli et al., 2013; Tamborero et al., 2013a; Tian, 2011; Vogelstein 
et al., 2013). They exploit the known structural properties of mutations in tumor 
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suppressor genes (TSG) and oncogenes (OG). Nevertheless, the identification of driver 
mutations in cancer remains a major challenge in computational biology and cancer 
genomics. Indeed, discovering driver mutations is one of the main goals of genome re-
sequencing efforts, as the knowledge generated by exome-sequencing will translate from 
research to the clinic. The results of some of the cited tools are summarized in a recent 
database called DriverDB (Cheng et al., 2014) and also aggregated in one of the Pan 
Cancer analysis publications (Tamborero et al., 2013b). From their comparison, it is 
clear that all these approaches are complementary and only the integration of many of 
these strategies can improve the identification of driver genes. 
Here, we present an innovative tool called DOTS-Finder (Driver Oncogene and Tumor 
Suppressor Finder) that integrates a novel pattern-based method with a protein function 
approach (functional step) and a frequentist method (frequentist step) to identify driver 
genes. In addition, it allows the classification of driver genes in TSGs or OGs. The 
software is freely available and has been designed to return robust results even with few 
tumor samples. 
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4.1.3 Implementation 
4.1.3.1 Overview of DOTS-Finder 
 
Figure 1 DOTS-Finder workflow. Illustration of the three main steps and the databases used to identify 
driver genes. Starting from the top left, a MAF file is taken as input. This file can encompass patients with 
any particular kind of tumor or any stratification of homogeneous samples under specific criteria (e.g. 
smoker patients with lung cancer, patients <50 years of age, etc.). The workflow includes the following 
three steps (green arrows): 1) Preliminary step: the dataset is filtered, reannotated and aggregated by gene 
(from top-left to bottom-left); 2) Functional step: TumorSuppressorGene – Score (TSG-S) and OncoGene 
– Score (OG-S) are calculated (from bottom-left to bottom-right) 3) Frequentist step: four statistical tests 
are run on genes that exceed the TSG-S and OG-S threshold (from bottom-right to top-right). The center 
panel (Data Integration) lists the external sources used by DOTS-Finder. 
 
The DOTS-finder pipeline is illustrated in Figure 1. Our method can be applied to genes 
that are targeted by single nucleotide variants (SNVs) and small insertions and/or 
deletions (InDels). Given a set of mutations in an exome/genome sequence dataset, the 
output is a ranked list of genes that prioritizes the best candidate driver genes and 
classifies them as TSGs or OGs. The user can submit an input Mutation Annotation 
Format (MAF) file for a set of patients that can be grouped by different criteria. In the 
Preliminary step, the MAF file is reannotated and several descriptive statistics are 
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calculated. This produces a gene-based table with aggregated mutational measures. The 
next two main steps, a functional assessing procedure and a statistical confirming 
procedure, constitute the core of DOTS-Finder. In the former, putative candidate OGs 
and TSGs are identified by calculating a Tumor Suppressor Gene Score (TSG-S) and an 
OncoGene Score (OG-S), based on the type and location of the mutations occurring in 
each gene. These scores are inspired by the concepts expressed in a recent study by 
Vogelstein et al. (Vogelstein et al., 2013). The TSG-S is based on the ratio between 
truncating (i.e. inactivating) mutations and total number of mutations found in each 
gene, under the null hypothesis that this value is equal to the average truncating/total 
ratio of patients’ exomes. The OG-S is based on the entropy of the pattern of missense 
SNVs and inframe insertions/deletions calculated using a Gaussian density model on the 
protein product. In the latter step, the statistical confirming procedure, the two lists of 
possible OGs and TSGs undergo four tests to assess whether the mutational pattern in 
each gene shows a statistically-defined evidence of positive selection based on the 
mutation rate and the number of non-silent mutations, calculating their statistical 
probability of being true driver mutations. After correction for false discovery rate, all 
the genes with a q-value<0.1 are identified as candidate driver OGs or TSGs. The user is 
free to modify this threshold.  
DOTS-Finder is a comprehensive method that considers three main aspects of a mutated 
gene: it takes into consideration where the mutations are collectively found (pattern-
based approach), what is the effect of mutations on protein products (protein-change 
approach), and what is the frequency of these mutations in the sample (frequentist 
approach). Our method is able to overcome many of the problems derived from the 
application of each individual approach. First of all, the prediction ability of frequentist 
approaches such as MutSigCV (Lawrence et al., 2013) relies on the estimation of the so-
called background mutation rate (BMR). Nevertheless, a precise map of the BMR in the 
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whole genome is still unavailable and constitutes one of the unresolved challenges of 
cancer genomics. A plethora of genomic events, such as transcription and replication 
timing, are associated with the fact that part of the genome is more prone or less prone 
to mutation. In particular, experimental data of these two events showed a significant 
correlation with the probability of a mutational event (Lawrence et al., 2013). However, 
while these experiments should be context specific (tissue/patient specific), data on 
replication timing are hard to obtain for every patient and/or tissue. Finally, pure 
frequentist methods do not allow any classification of the type of aberrations in terms of 
gain or loss of function. A pattern-based approach can bypass the problem of achieving a 
correct BMR estimation by focusing on the position of the observed mutations and not 
on their frequency. Thus, the frequency simply becomes a statistical power boost and not 
the point of investigation. Vogelstein et al. (Vogelstein et al., 2013) provide a scheme to 
assess whether a gene can be considered an OG or a TSG, but a large amount of data are 
needed in order to evaluate rarely mutated genes. The Authors’ approach, as well as the 
method developed in TUSON Explorer (Davoli et al., 2013) have been used to 
collectively evaluate general cancer genes across tumor types, however, when applied to 
single tumor type, they were found to lack the statistical power to recapitulate the overall 
results. In particular, with these methods, the discrete calculation of an OG test requires 
many mutations in the exact same hotspots to reach statistical significance. On the 
contrary, our approach, which takes into consideration the proximity of mutations by 
using the Gaussian smoothing, is able to identify also small deviations from a uniform 
distribution. 
The main problem in assessing the value of our method is the absence of a gold standard 
in the identification of driver genes and the lack of benchmark studies. Indeed, the 
objects of our investigation are the driver genes of the different cancer types, which are 
still mostly unknown. However, to have an estimate of the prediction ability of DOTS-
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Finder, we decided to compare the aggregated predictions for 12 cancer types with the 
results of a well-documented global analysis from the Pan-Cancer 12 (Tamborero et al., 
2013b) (see section 4.1.5.10). In this analysis, the Authors combined the outputs of 
several approaches and we were able to compare our tool with the single output from 
MutSig, MuSiC, ActiveDriver (Reimand et al., 2013), OncodriveFM (Gonzalez-Perez 
and Lopez-Bigas, 2012) and OncodriveClust (Tamborero et al., 2013a). We also related 
the predictions of each method with the Cancer Gene Census (CGC) database (Futreal et 
al., 2004), a manually curated collection of driver genes. Notably, DOTS-Finder emerged 
as the best available tool because of its sensitivity to find both known and new candidate 
driver genes. 
Moreover, we have applied DOTS-finder to 34 tumor types and compared its output 
with the results of other approaches. Our approach shows results which are consistent 
with the literature for both high and low mutation rate cancers; DOTS-finder allows 
detection of new plausible driver candidates while excluding highly mutated genes not 
associated with cancer, the so-called “fishy genes”, such as the Mucins, Titin and most of 
the olfactory receptors.  
DOTS-Finder requires minimal input files, it is easy to use, and does not necessitate any 
programming skill or statistical knowledge. Indeed, we created a tool accessible to 
researchers in a wide range of fields. Compared with popular tools like MuSiC (Dees et 
al., 2012) and MutSigCV (Lawrence et al., 2013), we only require the availability of easily 
accessible MAF files. The users do not need to have bam files as in MuSiC, which are not 
publicly available or easily accessible. In addition, the users do not necessitate any 
proprietary software, as the source code is written in Python and contains some 
embedded R codes, which are two freely available languages. Since DOTS-Finder is 
released under the GNU GPLv3+ license, users are also free to modify the code and 
implement new features.  
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DOTS-Finder is an easy solution for investigating genomic information from existing 
exploratory projects like The Cancer Genome Atlas (TCGA), but it is especially useful to 
identify reliable driver candidates in small studies assessing the value of genomic 
information for clinical purposes, such as understanding and predicting chemoresistance 
or metastatic spread. Indeed, we performed a saturation analysis on the mutational data 
present in 238 bladder cancer patients using 9 subsampling fractions, and, as shown in 
section 4.1.5.11, DOTS-Finder can perform statistically better than our best competitor, 
MutSigCV Version 1.4, in terms of number of drivers found and precision-recall balance 
in small sample datasets. Our tool could recapitulate up to 40% of the results of the 
entire dataset with just 5%  (i.e. 12 patients) of the dataset. Thus, it can be used in the 
clinical research setting to help identifying driver genes that can assist patient 
stratification for prognosis and choice of treatment. We envisage that DOTS-Finder 
might facilitate the identification of candidate targets, which could be used to develop 
diagnostic, prognostic or therapeutic strategies, even in situations where the available 
data are scarce (e.g. rare tumors). 
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4.1.3.2 The Functional Step: finding tumor suppressor gene and oncogene 
candidates 
On the basis of previous proposals (Tian, 2011; Vogelstein et al., 2013), we developed 
scores to assess if a gene in a given tumor could be considered either a TSG or an OG 
candidate. A TSG is characterized by loss of function mutations. Typically, these 
mutations are truncating and tend to destroy the protein product or make it non-
functional. Frame shift mutations, SNVs creating a stop codon, non-synonymous 
mutations on the stop codon, translations in the start site, and splice site mutations are 
all considered of the truncating type. Ultimately, a TSG is characterized by truncating 
mutations in a non-specific pattern (Figure 1, Panel A).  
 
Figure 2 Mutational patterns of typical tumor suppressor genes and oncogenes. (A) Mutations of APC 
in Colorectal Cancer. This is the mutational landscape of a typical TSG with diffuse truncating mutations 
(in red) and a non-specific pattern of missense mutations (blue density plots). Truncating mutations cover 
85% of all the non-synonymous mutations on APC. (B) Mutations of KRAS in Colorectal Cancer. This is 
the mutational landscape of a typical oncogene with significant clusters of mutations, which are present in 
specific hot spots of the protein ideogram (blue density plots). In particular, KRAS tends to mutate on 
amino acids 12 and 13 (119/143 mutations). The total numbers of truncating sites and missense mutations 
are indicated in the panels. The mutations are mapped on the corresponding canonical protein ideogram, 
therefore, not all the mutations can be represented (e.g. splice sites mutations are not included in the 
figure). 
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An OG, on the other hand, is characterized by gain or switch of function mutations that 
confer new properties on the protein product or simply enhance the existing ones. 
Hence, the typical mutations affecting an OG are missense mutations on key amino acids 
or on specific domains. We consider a “missense type” mutation all the non-synonymous 
SNVs that do not create a stop codon and occur outside start codons or stop codons, and 
all the insertions and deletions not altering the reading frame (Inframe InDels). These 
mutations have a particular pattern, as they are generally clustered in one or more 
regions along the protein (Figure 2, Panel B). For example, in leukemias, IDH1 can bear 
different kind of mutations, but almost always at amino acid position 132 (Figure 3). 
 
Figure 3 Density plot of genes tested for oncogenetic characteristic. Three known highly mutated genes 
are presented showing data from COSMIC. TTN is a notorious “giant gene” that is often found mutated 
because of its length. It does not show any particular clusterization around hotspots and the information 
entropy of its mutations is therefore very high. PIK3CA and IDH1 retains visible clusters of mutations; 
three hotspots for the first one (entropy=6.433) and one unique hotspot on amino acid 132 for the second 
one (entropy=2.453) 
 
The Tumor Suppressor Gene Score (TSG-S) evaluates whether a gene harbors an 
elevated number of truncating mutations compared with the total number of mutations 
present on that gene. Given 64 codons in the DNA and 9 possible SNVs per codon (3 
nucleic acids × 3 possible changes) we have a total of 576 possible base changes. Only 23 
of them can be considered truncating (~ 3.9% of all the SNVs, weighted for the actual 
human codon usage) against the 415 non-synonymous single base changes that lead to 
missense variations and 138 silent mutations. If we take into account all the InDels that 
1 5000 10000 15000 20000 25000 30000 34350
TTN entropy=10.304
1 150 300 450 600 750 900 1068
PIK3CA entropy=6.433
1 100 200 300 414
IDH1 entropy=2.453
De
ns
ity
 o
f M
iss
en
se
 M
ut
at
io
ns
Amino acidic positions
 32	
corrupt the reading frame of a gene, we can estimate, based on our sample data, that the 
ratio between truncating mutations and total number of mutations in cancer is 
approximately around 14%, with a standard deviation of 4. This percentage ranges from 
a minimum of 9% in glioblastoma (GBM) to a maximum of 25% in pancreatic 
adenocarcinoma (PAAD), with high intra-tumor variability among patients. This 
discrepancy indicates that some tumors are more prone than others to acquire and 
maintain truncating mutations (Figure 4). 
 
Figure 4 Distribution of mutations per type across cancer types. In this figure we calculated the average 
percentage of truncating, missense and silent mutations in the patients of 16 different cancer types from 
TCGA data. These percentages can vary considerably across tumor types but we can assess that on average, 
14% of the mutations can be considered truncating, 21% silent and the vast majority, 65%, are missense. 
 
The TSG-S is calculated using a binomial distribution under the null hypothesis that the 
ratio between truncating mutations and total number of mutations found in each gene is 
equal to the average truncating/total ratio in patients’ exomes (Figure 5).  
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Figure 5 Calculation of TSG-Score. The TSG-S is calculated using the ratio between the number of 
truncating mutations and total mutations found in the gene. In the example, 3 mutations are truncating 
over a total of 6. This ratio is compared to the average ratio of truncating over total in the affected patients. 
 
The calculation of this score is set in the specific cancer-patient environment where the 
gene is found mutated, following the idea that a truncating mutation in a sample with 
few other alterations weights more than a mutation in a hypermutated sample. 
The OncoGene Score (OG-S) indicates whether a gene harbors an elevated number of 
missense mutations in certain regions of the gene. The Score is based on the Shannon’s 
entropy of the pattern of missense SNVs and inframe insertions/deletions, calculated 
using a Gaussian density model on the protein product. Every mutation is weighted for 
the actual Functional Impact provided by Mutation Assessor (a ‘protein function’ 
method) (Reva et al., 2011)  and compared with a random model estimated by a 
bootstrapping procedure. The score is able to catch the clusterization of mutations 
around significant hot spots in a gene.  
We set a threshold for the two scores based on the analysis of the Catalogue Of Somatic 
Mutations In Cancer (COSMIC) (Forbes et al., 2008), using as positive control the CGC 
genes that encompass somatic point mutations. To evaluate the quality of our scores 
with regard to the classification in driver and non-driver, and avoid making assumptions 
on the behavior of driver genes, we adopted two strategies. First, we did not consider any 
a priori set of true non-driver genes (negative control) and, second, we did not divide the 
Cancer Gene Census in OGs and TSGs. As mentioned before, the OG-S and TSG-S 
work on different levels and different mutation types, so we do not exclude the 
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possibility that the same gene might show oncogenic and tumor suppressor features at 
the same time in different tumors, or even in the same cohort of patients (see Atypical 
tumor suppressor genes and oncogenes section). 
Since the mutated genes reported in COSMIC are more than 18000, the known drivers 
in CGC accounts for less than 1% of all the mutated genes. These numbers indicate that 
the two classes are extremely unbalanced, and that a common “Receiving Operator 
Characteristic” analysis is not appropriate to address the goodness of our scores. We 
therefore calculated the Matthews correlation coefficient curves (MCC) for the two 
scores and maximize their values to obtain our thresholds (Figure 6). 
 
Figure 6 Matthews Phi correlation for the OG-Score and the TSG-Score. The plot shows the trend of the 
Matthews phi correlation for every possible cutoff of the classification of genes as oncogenes candidate or 
tumor suppressors. The OG-S and TSG-S are calculated on the COSMIC database v66 using as positive 
control the genes of Cancer Gene Census. The chosen cutoffs are the ones in which the two functions are 
maximized. 
 
Compared to other common measures like accuracy, the MCC is much more 
informative for strongly unbalanced classes (Baldi et al., 2000). Our thresholds were also 
rescaled for every tumor type in order to take into account the setting-specific mutation 
rate and the number of samples at our disposal. 
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4.1.3.3 The Frequentist step: assessing the possible drivers 
The genes that exceed at least one of the thresholds of the two scores, are classified as 
OGs or TSGs and four tests are then performed to assess if the mutational pattern in 
each gene shows a statistically defined “driver behavior”. This analysis is complex, as it 
requires the proper estimation of the BMR, which is specific for each gene in each tumor 
type and patient. Indeed, we foresee at least seven sources of background mutation-rate 
heterogeneity: i) the specific mutation-rate of each tumor type; ii) the specific number of 
mutations in each patient; iii) the GC-content, as most of the mutations found in cancer 
are point mutations occurring in GC spots; iv) the gene size; v) the gene-specific SNP 
frequency; vi) the replication time; vii) the levels of gene expression. However, there 
might be other unknown parameters that could also influence the background mutations 
rate of a gene. Our method does not need to take into consideration either replication 
timing or gene expression levels, since they both require a great amount of new 
experimental data. 
Briefly, the four tests used by DOTS-Finder are: 1) Higher Frequency Test. The rate of 
non-synonymous mutations per Mb in a gene is compared with the rate of mutations in 
the patients carrying mutations in that gene. 2) Non-synonymous versus Synonymous 
Ratio Test. Given the total number of mutations found in a specific gene, this test 
assesses whether the number of non-synonymous mutations is higher than the expected 
number of non-synonymous mutations. The expected value is calculated on the 
probabilistic ratio obtained by randomly placing the same number and type of mutations 
on the specific codon usage structure of the gene. 3) Tumor-specificity Test. This test 
prioritizes the driver genes in the different tumors, although it is not fundamental for the 
driver assessment. The frequency of non-synonymous mutations in the samples is 
compared with the frequency found in the COSMIC database across tumor types. The 
test verifies whether the frequency of non-synonymous mutations in a particular tumor 
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or situation is higher than the general frequency found in COSMIC. The idea is that 
some mutations are tissue-specific and might be driver only in certain kind of cancers. 
For example, NPM1 is a clear driver gene specific for leukemias; similarly, VHL is 
specific for renal cancer. 4) Functional Impact Test. This test is used to verify whether 
the functional impact score of the gene mutations, calculated by Mutation Assessor, is 
higher than the average score in the patients affected by a mutation in that gene. The 
four p-values obtained from these tests are combined using the Stouffer’s method with 
specific weights, in order to take into account both the dependencies between tests and 
their relative importance in the driver definition (see section 4.1.4.6). The resulting p-
value is then adjusted to correct for false discovery rate. 
4.1.4 Material and Methods 
4.1.4.1 Availability 
DOTS-Finder can be downloaded at http://cgsb.genomics.iit.it/wiki/projects/DOTS-
Finder under GNU GPLv3+. Full explanation on how to install DOTS-Finder, how to 
use it and how to interpret the results can be found at 
http://cgsb.genomics.iit.it/wiki/projects/DOTS-Finder/Documentation.   
4.1.4.2 Input Format 
DOTS-Finder accepts the following input formats: 
1. MAF format version 2.3 (10 May 2012) and 2.4 (6 March 2013). The 
program is also a complete MAF format validator in case of submission to the 
TCGA. The MAF file specifications can be found at 
https://wiki.nci.nih.gov/display/TCGA/Mutation+Annotation+Format+(MAF)+
Specification. 
2. MARF format. The Mutation Annotation Reduced Format is a short 
version of the MAF format with just 13 columns instead of the canonical 34. 
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3. Annovar CSV (Wang et al., 2010). This is one of the most common 
annotator for exome/genome sequencing data; it is not directly supported, but we 
provide a simple step-by-step conversion method to MARF format.  
4.1.4.3 Requirements 
DOTS-Finder runs on MacOS and Unix based machines. The code is written in Python 
and contains embedded R codes. DOTS-Finder uses embedded version of bedtools and 
liftOver, thus it cannot be available for Windows users. In order to work properly, these 
freely available languages must be already installed with their libraries and packages: 
• Python 2.7 
• R >= 2.0.0 
• CRAN package 'multicore' 
4.1.4.4 Mutation data 
We analyzed data from TCGA and COSMIC for a total of 8187 samples. The full 
database is the one used by TUSON Explorer (Davoli et al., 2013), available at 
http://elledgelab.med.harvard.edu/wp-
content/uploads/2013/11/Mutation_Dataset.txt.zip. We removed from the 
Central_Nervous_System_NS dataset the patients not coming from the 
oligodendroglioma cancer type and integrated the original datasets used by TUSON 
Explorer with data from samples of diffuse large B-cell lymphoma (DLBCL) (Lohr et al., 
2012) and chronic lymphocytic leukemia (CLL) (Wang et al., 2011). We also collect 
additional data from (Lawrence et al., 2014), available at www.tumorportal.org, 
including samples from other cancer types: multiple myeloma (MM) (Chapman et al., 
2011), rhabdoid tumor (RHAB) (Lee et al., 2012) and carcinoid (CARC) (Francis et al., 
2013). 
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4.1.4.5 Databases 
The method is guided in all the different passages by sources of information on proteins 
and genes derived from several public databases. The exon length of the gene is 
calculated using the RefGene hg19 UCSC table (Pruitt et al., 2009) as the minimum 
number of exons (in base pairs) required to encompass all the possible annotated 
transcripts for that gene. In case a gene of interest is not annotated on RefGene, the 
length is set to the average value (3192 bp). The raw frequency of mutation per gene is 
derived from COSMIC v66 (Forbes et al., 2011) and calculated among all the samples 
stored in the database across any tumor types (947213 samples). The number of amino 
acids is derived from the UniProt database (Consortium, 2013) while the domains 
structure is taken from the “superfamilies” found on the NCBI Conserved Domain 
Database (Benson et al., 2013). The Functional Impact Score used for the OG-S 
(OncoGene Score) is taken from the Mutation Assessor database (Reva et al., 2011). 
A Single Nucleotide Variation (SNV) can result into two different effects on the codon 
that will be transcribed: it can either change the amino acids (non-synonymous 
mutation) or mantain the same amino acid exploiting the redundancy of codons over 
amino acids (synonymous mutations). For every single base change (C>G, A>T etc.), we 
can derive how many changes lead to a non-synonymous variation or to a synonymous 
variation for every possible codon (Figure 7). 
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Figure 7 Effect of A>C transition on some codons. At top left corner, AAA codes for lysine and retains 3 
spots of possible A>C mutations. All these A>C transitions lead to a change in the codified amino acids 
and are therefore non-synonymous mutations. ACA codes for threonine and is composed by 2 adenines. A 
change in the first A, lead to CCA, a proline (non-synonymous), while last A brings ACA to ACC that is 
still a threonine and therefore a synonymous SNV. According to the entire map of possible changes (A>T, 
T>A, C>G, etc.), weighted by gene specific codon usage, we can derive a comprehensive landscape of 
effects 
 
We took the human codon usage from the NCBI GenBank (Benson et al., 2013) via the 
Kazusa website ftp://ftp.kazusa.or.jp/pub/codon/current/species/9606 to derive what we 
have called the 79 rule: in a random mutation process on human genome, where all the 
types of transitions and transversions have the same probability to appear, given n 
random mutations on a human genome, 79% of them will be non-synonymous. 
lim!→!  n!"!!!"#$#"%$&!n = 0.79 
or, in other words: n!"!!!"#$#"%$&!n!"#$#"%$&! ~3.78 
The number of non-synonymous mutations will be ~ 3.78 times higher than the number 
of synonymous mutations. 
A>C$
transi+on$
AAA" AAC" AAG" AAT"
ACT"
ATA" ATC" ATT"
AGA"
ACA"
3" 0"
1"
1"
1"
1"
1" 1" 1" 0" 1" 0"
0"2"
0"
1"
0"
0"0"
0"
1"
2"
AGT"
ATG"
2"
1"
X" ="number"of"non"synonymous"muta8ons" Y" ="number"of"synonymous"muta8ons"
 40	
	
Table 1 Predicted non-synonymous mutations over total mutations divided by SNV type. Read by row, 
this table describes the effect of SNVs on the non-synonymous over total mutations ratio using the 
number of non-synonymous and synonymous changes per codon as described in Figure 7. This table 
refers to the effect of random mutations on an entire reference exome. It can be seen as a way to describe 
the dangerousness of a specific base change. For example, a C>T transition only leads to a non-
synonymous SNV in 59% of the cases while a G>T transversion in 85% of the cases. 
 
The 79 rule derives from the average value of the weighted effects of all base substitutions 
(Table 1). For example, if we want to calculate the effect of the transversion A>C on the 
non-synonymous/total ratio (NSY/total!!!), we will have 
NSY/total!!! = nsy!!!  × W(nsy!!! + sy!!!) ×  W 
where nsy!!!  is the ordered non-synonymous variations vector (64x1) that a 
transversion A>C can cause, weighted for the human codon usage vector  W divided by 
the total amount of A>C transversions that can be found on the 64 codons (nsy!!! +sy!!! =  total!!!  ) weighted for the same codon usage. 
If we apply the same calculation to tumor sample datasets, like those provided by the 
TCGA, the results are surprisingly coherent with this simple probabilistic rule. The 
average ratio between non-synonymous and total mutations across patients for every 
tumor type spans between 0.74 and 0.81, suggesting that the mutational process is almost 
always random and therefore the large majority of mutations are passengers (Figure 8). 
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Figure 8 Non-synonymous mutations over total mutations distributions: the “79 rule”. The 79 rule (see 
Additional File 1: Text S2.e) states that under the hypothesis of a random mutational process, the 79% of 
the SNVs lead to non–synonymous variations. If we look at the real data, this random process is still valid 
on average, giving another confirmation that the majority of mutations are passengers and are not under 
selective pressure 
 
Each mRNA is composed by a distinctive percentage of codons that can vary 
significantly depending on the gene and can be completely different from the entire 
human codon usage. In addition, not all the types of SNVs have the same probability to 
be found. Transitions tends to happen more frequently and are generally less damaging 
compared to transversions (e.g. 2 out of 3 SNPs are transitions (Collins and Jukes, 
1994)).  
Moreover, the relative number of transitions and transversions in a sample are tumor 
dependent (Rubin and Green, 2009). For example, C>T transitions caused by misrepair 
of ultraviolet-induced covalent bonds between adjacent pyrimidines are frequent in 
melanoma, whereas C>A transversions caused by exposition to polycyclic aromatic 
hydrocarbons in tobacco smoke, characterize lung cancer (Lawrence et al., 2013). We 
therefore generalized the above formula for every gene-SNV couple:  
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NSY/total!!!! = nsy!!! × w!(nsy!!! + sy!!!) ×  w! 
where i > 𝑗  represents the SNV i to j with i, j ∈ (A,C,G,T) and i ≠ j , while w!  is the 
codon usage of the gene g. 
4.1.4.6 DOTS-Finder step by step  
Two main steps follow a preliminary analysis in DOTS-Finder: a functional assessment 
procedure and a statistical confirmation procedure. In the former, we identify a 
particular mutational pattern behavior that can be classified as “Oncogene”, “Tumor 
Suppressor” or sometimes both. In the latter the two lists of possible oncogenes and 
tumor suppressors undergo 4 tests to assess their statistical probability of being true 
driver mutations. 
1. Preliminary Step 
o Reannotation 
o Filtering 
o Descriptive Statistics 
2. Functional Step 
o OG-Score 
o TSG-Score 
3. Frequentist Step 
3.1 Test 1: Higher Frequency Test 
3.2 Test 2: Non-synonymous versus Synonymous Ratio Test 
3.3 Test 3: Tumor-specificity Test 
3.4 Test 4: Functional Impact Test 
1. Preliminary Step 
Before entering in the main DOTS-finder procedure, the MAF file is reannotated 
according to the refGene database and a few measures such as CG content, gene length, 
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number of amino acids and superfamily domains composition are added. This step is 
necessary to let every database coherently communicate to the others via the same 
annotation. 
The tool automatically cuts the non-protein coding genes based on HUGO gene name 
database (19094 genes) (Gray et al., 2013) and discards all the mutations in non-coding 
regions like RNA mutations, intergenic mutations (IGR) and intron mutations (Intron). 
The user can change this setting via command options. 
2. Functional Step 
To calculate the OG-S we need the genomic coordinates of the missense mutations and 
the functional impact of the mutations according to Mutation Assessor. We associate the 
respective functional impact to every SNV and we assign to the Inframe InDels the 
average functional impact for that position (no score is provided for InDels in the 
database). The mutations are then mapped on the gene length and weighted by their 
impact. The discrete distribution of the mutations is smoothed with a Gaussian kernel 
estimation using a bandwidth that follows the Silverman’s rule of thumb (Silverman, 
1986). Thus, mutations that map close in the protein sequence increase the probability 
density function (PDF), creating a mutational hotspot with a higher density than the 
sum of the single-base discrete probabilities. The probability that the mutational profile 
has not arisen from non-selected passenger mutations is given by the comparison of the 
Shannon entropy index built on experimental data with the one built on uniform 
random profiles. We define the OG-S as the information entropy calculated on 
experimental data (X!! ) compared with a bootstrapped uniform random distribution 
with the same numerosity (U!! ) divided by the bootstrap interquartile range (bootIQR): 
OGS! = H(X!! )− BootMedian(H(U!! ))BootIQR(H(U!! ))  
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where H(X!! ) is the sample entropy calculated on gene 𝑔 with 𝑚 missense mutations 
and H(U!! ) is the entropy of a uniform random sample of size 𝑚 on gene 𝑔. The OG-S is 
therefore a modified Z-score, used to obtain robust bootstrap results even with small 𝑚. 
The TSG-S reveals the characteristics of the driver genes that have diffuse truncating 
mutations in a non-specific pattern. To detect this particular pattern a large portion of all 
the mutations found on the gene must be truncating. The TSG-S is calculated as the −log!"(p− value)  of a one-tail binomial test (H!:p >  p! ) where the number of 
successes t! is the number of truncating mutations on gene g and the number of trials n! 
is the total number of mutations found on the gene. This ratio (p = !!!!) is compared with 
a p! calculated as: 
 p! = mean(T!!N!!) 
where T!! and N!! represent, respectively, the number of truncating mutations and the 
total number of mutations in patient 𝑖 where gene 𝑔 is mutated. 
We can define the TSG-S for a gene 𝑔 as: 
𝑇𝑆𝐺𝑆! = 𝑃 𝑋 ≥ 𝑥  𝐻! = 𝑛!𝑘!!!!!!  𝑝!!(1−  𝑝!)!!!! 
3. Frequentist Step 
The genes that pass at least one of the two thresholds (OG-S or TSG-S) are divided in 
the respective candidate categories (oncogene, tumor suppressor or both). Four 
statistical tests are run for these genes with specific modifications according to the 
categories they belong to. The four p-values obtained from the tests are pooled together 
using the Stouffer’s method (Stouffer S et al., 1949) with a pattern of weights that take 
into account both the dependencies between tests and their relative importance in the 
driver definition. These suggested weights are set in order to take advantage of the full 
information provided by the four tests, but they can also be user-defined. The result is 
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finally adjusted using the Benjamini-Hochberg procedure (Benjamini and Hochberg, 
1995). 
3.1 TEST 1: Higher Frequency Test 
This test compares the rate of non-synonymous mutations per Mb in each gene with the 
rate of mutations in the patients carrying a mutation in that gene. The alternative 
hypothesis to reject the equality of these two proportions is nsy!!l! ∗ S! >  NSY!!exome length 
Where nsy!!  represents the number of non-synonymous mutations found on gene g and 
tumor t, l! is the length of the gene in Mb, S is the total number of samples in tumor t 
and NSY!! is the average number of non-synonymous mutations found in the patients 
with a mutation in gene g. This number is divided by the number of base pairs of an 
average exome sequencing (30Mb). Because of the low probability of mutation per Mb 
(from 0.1/Mb in AML to a maximum of 100/Mb in melanoma) a Poisson single tail test 
is run to assess if the rate of mutation of the gene is higher than the average mutation 
rate among the patients. This test is the same for both the TS and the OG groups. We 
apply a weight equal to 0.5 in the Stouffer’s method because of the major relevance of 
this rate both in the literature (Dees et al., 2012; Lawrence et al., 2013; Wood et al., 2007) 
and for research/clinical purposes. 
3.2 Test 2: Non-synonymous versus Synonymous Ratio Test 
3.2.1 TEST 2 - OG : Non-synonymous versus Synonymous Ratio Test for Oncogenes 
This test verifies if the rate between non-synonymous mutations and synonymous 
mutations is significantly high in the gene. To avoid zero division errors (some genes do 
not show synonymous mutations), the proposed test is based on the equivalent non-
synonymous/total ratio. The rate of comparison is calculated on the expected ratio 
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obtained by randomly placing the same number and kind of mutations on the specific 
codon usage structure of the gene. 
Since the effect of an InDel cannot be predicted in this way, we assume it will always 
produce a non-synonymous effect. So the total amount of mutations on gene g and 
tumor t is divided in M!! = SNV!! + indel!!  
the SNV!! are divided by their respective base substitution (A>C , G>T etc.) and put in 
the vector bs!!  (12x1). We operate a vector product between bs!!  and NSY/total! 
calculated in our database in order to obtain the expected non-synonymous/total ratio in 
the SNVs. To obtain the final expected ratio we simply add the InDels we have 
subtracted before 
expected(NSYtotal!! ) =  SNV!! ∙ (bs!!× NSYtotal!)+ indel!!total!!  
Finally, we try to evaluate nsy!!total!! >  𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑(NSYtotal!! ) 
using a one-tail binomial test. 
3.2.2 TEST 2 - TSG : Non-synonymous versus Synonymous Ratio Test for Tumor 
Suppressor Genes 
This test assesses if the rate between non-synonymous mutations and synonymous 
mutations in the gene is higher than the average rate in the patients who present the 
same mutation. We evaluate if nsy!!total!! >  𝑚𝑒𝑎𝑛( NSY!!TOTAL!! ) 
where nsy!!  and total!!  represent, respectively, the number of non-synonymous 
mutations and the number of synonymous plus non-synonymous mutations found in 
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the gene g in tumor t while mean( !"#!!!"!#$!! ) is the average ratio calculated from all the 
samples with a mutation in the same gene. A one-tail binomial test is run in order to 
verify this inequality. This test is less precise than the previous one since the calculation 
of the null hypothesis ratio is made from a sample evaluation. Nevertheless this method 
of calculation of the null hypothesis is better for tumor suppressor candidates, since 
tumor suppressors are prone to have InDels and splice mutations that cannot be inserted 
in a probabilistic environment as we did for SNVs (the large majority of missense 
mutations are single spot mutations). 
For TEST 2, we apply a weight of 0.2 in the Stouffer’s method as this test has a lower 
statistical power and is linked to TEST 1; in fact, the total number of mutations depends 
on the sample size and the tumor specific mutation rate. 
3.3 TEST 3: Tumor-specificity Test 
This test verifies if the frequency of non-synonymous mutations in a particular tumor or 
situation is high compared with the general frequency found in COSMIC database.  
Again, we evaluate if nsy!!s! > F! 
where nsy!!  represents the number of non-synonymous mutations found in the gene g in 
tumor t, s! is the total number of patients/samples in tumor t, and F! is the frequency of 
mutation across tumor types provided by the COSMIC database, by running a one-tail 
binomial test. However, we only apply a weight of 0.1 in the Stouffer’s method, as this 
test is just used for ranking purposes in the chosen dataset. While we consider tumor 
specificity an important driver characteristic, we do not believe that not being tumor 
specific should be penalizing. For example, genes like TP53 or KRAS should be 
considered important driver even in tumors where they are not frequently mutated. 
3.4 Test 4: Functional Impact Test 
 48	
3.4.1 TEST 4 - TSG: Functional Impact Test for TSGs 
For every mutation in the gene we matched the respective patient it belongs to. We then 
compared the functional impact score of each mutation with the average score of all the 
other mutations in the patient. This test is used to assess if the distribution of the impact 
scores on the gene is stochastically higher than the average distribution. 
We evaluate if mean(FI!!) > 𝑚𝑒𝑎𝑛(FI!) 
 
where FI!! represents the average functional impact on gene g in patient i while FI! is the 
average functional impact in patient i without considering gene g. A Wilcoxon one-tail 
test for paired data was used to assess this inequality. Since no impact score is provided 
for truncating type mutations and silent mutations, in this work we applied the 
maximum score provided by Mutation Assessor to the first group (6) and the minimum 
to the silent mutations (0). 
3.4.1 TEST 4 - OG: Functional Impact Test for Oncogenes 
This test is like the above with the exception that since an oncogene is characterized by a 
majority of missense mutations, it is necessary to exclude all the truncating mutations 
from the calculation of the mean impact score, both at gene level and patient level. 
As for the non-synonymous versus synonymous ratio test, an adequate sample size is 
fundamental for reaching a sufficient statistical power. The functional impact test is 
therefore weighted 0.2 in the Stouffer’s method, the same as for TEST 2. 
4.1.4.6.1 Setting the threshold for TSG-S and OG-S 
The evaluation of our scores in classifying genes as driver or non-driver was set on the 
large database of COSMIC, using as positive control the genes of CGC (Futreal et al., 
2004). We carry out the analysis by calculating and maximizing the Matthews phi curves 
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for the two scores against the list of true drivers (Figure 6). The TSG-S curve is 
maximized at −log!"(p− value) of 12 (p-value=10!!") reaching a Matthew’s phi of 0.4 
for the positive control of CGC genes that encompass somatic point mutations. The OG-
S curve is instead maximized at Entropy Z− Score of 49 reaching a Matthew’s phi of 
0.35. The calculation of the threshold cannot be directly applied to smaller tumor 
specific datasets because it is based on a huge amount of data provided by COSMIC 
(more than 7000 samples) and our scores are number-of-mutations dependent. In 
particular, the OG-S decreases if it is calculated on few mutations because the 
interquartile range of the uniform tends to increase by bootstrapping small samples. 
Similarly, the TSG-S enhances its statistical power with the increase in the number of 
trials (i.e. the number of mutations). We therefore derived a TSG coefficient and an OG 
coefficient that are calculated as 
TSG!"#$$%!%#&' = COSMIC threshold for TSGCOSMIC mean number of truncating per gene 
 
OG!"#$$%!%#&' = COSMIC threshold for OGCOSMIC mean number of missense per gene 
These coefficients are multiplied for the mean number of truncating and missense 
mutations per gene in the single dataset during analysis in order to set specific tumor 
type thresholds. The mean number of missense and truncating mutations per gene is a 
way to aggregate both the information on the sample size (number of patients) and the 
mutation rate of the tumor type (number of mutations per patient). 
We set a lower bound for these thresholds: 1 for TSG-S (p-value=10!!) and 1 for OG-S 
(distance from the median uniform entropy of at least 1 interquartile range). For the 
OG-S, we also put an upper bound for this threshold at 3.5 as suggested in outlier 
analysis for the modified z-scores (Walfish, 2006). 
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4.1.5 Results 
4.1.5.1 Application of DOTS-Finder to individual cancer types 
We applied our methodology to 34 different cancer types (Colorectal Adenocarcinoma, 
Lung Squamous Cell Carcinoma, Uterin Carcinoma, Ovarian Adenocarcinoma, Lung 
Adenocarcinoma, Prostate Adenocarcinoma, Pancreatic Adenocarcinoma, 
Glioblastoma, Kidney Clear Cell Carcinoma, Kidney Papillary Cell Carcinoma, Kidney 
Chromophobe, Skin Melanoma, Low Grade Glioma, Esophageal Adenocarcinoma, 
Medulloblastoma, Stomach Adenocarcinoma, Head and neck squamous cell carcinoma, 
Oligodendroglioma, Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic 
Leukemia (CLL), Soft Tissue Sarcoma, Lymphoma B-cell, Biliary Tract, Astrocytoma, 
Neuroblastoma, Liver Hepatocellular Carcinoma, Lung Small Cell Carcinoma, 
Rhabdoid_Tumor, Multiple Mieloma, Carcinoid, Breast Cancer, Thyroid Carcinoma, 
Acute Myeloid Leukemia (AML), Bladder Carcinoma). We analyzed the overall output 
in section 4.1.5.2. In this section, we show the existence of a great variability among the 
different tumor types in terms of driver genes. In Table 2, we present the results of four 
cancer types: Breast carcinoma (BRCA) and Thyroid Carcinoma (THCA), described in 
sections 4.1.5.3 and 4.1.5.4, and Acute Myeloid Leukemia (AML) and Bladder 
Carcinoma (BLCA), described in sections 4.1.5.5 and 4.1.5.6. The rest of the DOTS-
Finder results can be seen in Appendix Table 1. We also compared the DOTS-finder 
output with the output of the following methods: i) the main TCGA publications (when 
available); ii) TUSON Explorer (Davoli et al., 2013) (considering all the genes with a q-
value <=0.1); iii) MuSiC (Tamborero et al., 2013b)(used for identifying significantly 
mutated genes in 12 cancer types); iv) MutSig (Lawrence et al., 2014) (used for 
identifying significantly mutated genes in 21 tumor types). Thus, we used the state-of-
the-art results from official TCGA publications and from the latest release of the 
applications described above. We were not able to use exactly the same input data of all 
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the publications, since TUSON Explorer and MutSig (as used in (Lawrence et al., 2014)) 
are unavailable. Our results show that DOTS-Finder can identify known cancer genes 
involved in each tumor, confirm new discoveries reported by other groups, and detect 
novel driver gene candidates which are mutated at low frequency and not identified by 
other methods Appendix Table 2. 
Acute Myeloid Leukemia Thyroid Carcinoma Breast Cancer Bladder Carcinoma 
S = 196 S = 326 S = 1046 S = 145 
MNSp = 11 MNSp = 19 MNSp = 36 MNSp = 177 
Gene 
name 
NS 
freq q-value 
Gene 
name 
NS 
freq q-value Gene name 
NS 
freq q-value 
Gene 
name 
NS 
freq q-value 
TSG TSG TSG TSG 
CEBPA 0.066 0 TG 0.049 8.00E-10 CBFB 0.021 0 ARID1A 0.241 0 
NPM1 0.276 0 EMG1 0.018 5.30E-08 CDH1 0.062 0 CDKN1A 0.145 0 
RUNX1 0.092 0 RPTN 0.025 9.05E-06 GATA3 0.095 0 KDM6A 0.214 0 
TET2 0.087 0 PPM1D 0.015 0.0054 MAP2K4 0.039 0 TP53 0.262 0 
TP53 0.077 0 TMCO2 0.009 0.0056 MAP3K1 0.070 0 ELF3 0.076 1.18E-10 
WT1 0.061 0 IL32 0.009 0.0152 PTEN 0.040 0 MLL2 0.262 1.18E-10 
RAD21 0.026 3.27E-06 DNMT3A 0.015 0.2896 TP53 0.338 0 EP300 0.152 
3.03E-
09 
PHF6 0.031 3.40E-06 ONCOGENE TBX3 0.022 
1.11E-
12 RB1 0.110 
2.26E-
08 
STAG2 0.031 1.38E-05 BRAF 0.561 0 MLL3 0.065 
5.93E-
12 SPTAN1 0.097 
3.03E-
06 
EZH2 0.015 0.0007 HRAS 0.037 0 AOAH 0.019 3.98E-10 MLL3 0.200 
6.14E-
06 
ASXL1 0.026 0.0014 NRAS 0.080 0 CTCF 0.021 7.90E-10 CREBBP 0.131 
1.16E-
05 
HNRNPK 0.010 0.0083 TG 0.049 3.47E-08 RUNX1 0.024 
3.19E-
06 STAG2 0.090 
7.55E-
05 
CALR 0.010 0.0142 DNASE2 0.009 0.0694 NCOR1 0.038 3.97E-06 FOXQ1 0.048 0.0060 
CBFB 0.010 0.0572 PRDM9 0.018 0.0816 RB1 0.021 6.09E-06 TXNIP 0.055 0.0079 
CBX7 0.005 0.0948 DICER1 0.009 0.1070 NCOR2 0.032 0.0003 FAT1 0.110 0.0370 
BCOR 0.010 0.1971 ZNF845 0.018 0.1070 STXBP2 0.010 0.0004 FBXW7 0.069 0.0428 
ONCOGENE PRG4 0.012 0.1085 AQP7 0.008 0.0017 GCC2 0.069 0.0800 
CEBPA 0.066 0 PTTG1IP 0.012 0.1085 ZFP36L1 0.012 0.0046 ZNF513 0.055 0.0911 
DNMT3A 0.260 0 
   
RBMX 0.012 0.0056 KLF5 0.062 0.1184 
FLT3 0.270 0 
   
GPS2 0.007 0.0095 GPS2 0.028 0.2599 
IDH1 0.097 0 
   
CASP8 0.015 0.0104 NHLRC1 0.021 0.2635 
IDH2 0.102 0 
   
CDKN1B 0.008 0.0125 ONCOGENE 
NRAS 0.077 0 
   
UBC 0.008 0.0155 TP53 0.262 0 
TP53 0.077 0 
   
MED23 0.013 0.0224 NFE2L2 0.076 6.08E-06 
U2AF1 0.041 0 
   
MYB 0.012 0.0407 ERBB3 0.117 1.08E-05 
      
CCDC144N
L 0.008 0.1268 RARG 0.069 
1.53E-
05 
      
GNRH2 0.003 0.2062 IRS4 0.014 0.6550 
      
HNF1A 0.009 0.7280 ELP5 0.014 0.6550 
      
ONCOGENE RPS6 0.021 0.6550 
      
AKT1 0.022 0 
   
      
PIK3CA 0.285 0 
   
      
TP53 0.338 0 
   
      
TBX3 0.022 9.01E-10 
   
      
SF3B1 0.017 3.36E-08 
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FOXA1 0.017 7.73E-05 
   
      
HIST1H3B 0.008 0.0001 
   
      
MEF2A 0.014 0.0002 
   
      
PIK3R1 0.025 0.0008 
   
      
ATN1 0.017 0.0425 
   
      
AKD1 0.018 0.0431 
   Table 2 Significantly mutated genes identified by DOTS-Finder in four cancer types. Legend: S = 
Number of Samples , MNSp = Median number of Non-Silent mutations per patient , NS freq = Non-
synonymous mutations frequency among samples , Underlined genes are near significance 
4.1.5.2 Driver genes and tissue specificity 
We used DOTS-Finder on samples from 34 tumor types and identified a total of 301 
driver genes Table 2 and Appendix Table 1. Only 57 out of 301 genes were found in 
more than one tumor type, and most of the 25 genes present in at least three tumor types 
are well-known cancer driver genes (i.e. TP53, PTEN, RB1, NRAS, IDH1, SF3B1, 
CTNNB1, BRAF, ARID1A, NFE2L2, MLL3, KRAS, KDM6A, CDKN2A, STAG2, 
SMARCA4, SMAD4, PIK3R1, PIK3CA, MLL2, IL32, CREBBP, CDKN1B, NPAP1, B2M). 
Interestingly, genes found only in two different cancer types maintain tissue specificity, 
like, for example, ATRX, mutated only in low-grade glioma and in glioblastoma, 
probably being an important driver gene in tumors of the central nervous system. In 
addition, 244 genes displayed cancer specific patterns, being mutated in a single cancer 
type. Thus, the majority of tumor suppressor genes (TSGs) and oncogenes (OGs) are 
tissue-specific. For example, NKX3-1 and AR are found only in prostate 
adenocarcinoma, OGG1 is specific for renal cell carcinoma and NOX4 is specific for 
glioblastoma. In addition, we also found that about 54% of the genes in our list (163 out 
of 301) were not present in the 300 TSGs and 250 OGs identified by TUSON Explorer. 
For example, Thyroglobulin (TG), a well-studied gene in thyroid cancer (Rubio and 
Medeiros-Neto, 2009), is absent. We hypothesize that many new driver genes that are 
infrequently mutated might be tissue specific. Thus, it is very important to analyze the 
mutation signatures of individual tumor types, especially of those cancer types for which 
large sample size is unavailable and which will not reach saturation in the next future. 
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4.1.5.3 Breast carcinoma  
We applied DOTS-Finder to the list of 1046 Breast carcinoma (BRCA) samples. We 
found a poor overlap between the TCGA official publication (Koboldt et al., 2012) and 
our results (Figure 9, Panel A), but all the known cancer genes for this tumor type are 
retained, while our results do not encompass any notorious “fishy gene” like RYR2 or 
OR6A2 (Lawrence et al., 2013), which are instead present in the TCGA publication. The 
TCGA publication also misses known breast cancer associated genes, like FOXA1 
(Robinson et al., 2013) and CASP8 (Catucci et al., 2011).  We identified 3 new driver 
candidates, not present in previous publications: AQP7, MEF2A and UBC. AQP7 
encodes the aquaporin 7, an integral-membrane protein that plays important roles in 
water and fluid transport and cell migration. Recent discoveries of AQP involvement in 
cell migration and proliferation suggest that AQPs play key roles in tumor biology 
(Verkman et al., 2008). MEF2A encodes a DNA-binding transcription factor that is 
involved in several cellular processes, including cell growth control and apoptosis. It was 
recently shown that NOTCH-MEF2 synergy may be significant for modulating human 
mammary oncogenesis (Pallavi et al., 2012). UBC is a member of the ubiquitin family 
and involved in cell cycle and DNA repair. The role of ubiquitination is well stablished in 
 54	
cancer, especially in breast (Ohta and Fukuda, 2004).
 
Figure 9 Comparative driver gene predictions in Breast Cancer and Thyroid Cancer. (A) The candidate 
driver genes predicted by DOTS-Finder in BRCA are compared against 4 previously reported predictions: 
MuSiC, MutSig, TUSON Explorer and the TCGA publication. The five-set Venn diagram shows the 
number of predicted genes that are in common between the different analyses and those uniquely 
predicted by each of them. The line delimiting each set and the name of the corresponding method are 
depicted in the same color. The diagram uses a graduated color ramp from light yellow to dark red to 
represent the overlap of an increasing number of tools that predict the same drivers. Although BRCA 
mutational landscape is highly heterogeneous among patients, all the methods agree on predicting the 
same 17 genes as drivers (darkest shade of red). In addition, DOTS-Finder is able to predict 7 genes that 
were never found by any method in BRCA. Also MutSig and TUSON Explorer retain unique predictions, 
respectively 11 and 5 possible driver candidates. This discrepancy is the reflection of the typical 
“mountains and hills” landscape of the BRCA genome, with few highly mutated genes (predicted by 
almost all the tools) and hundreds of low-frequency mutations (only identified by a specific tool). (B) 
Number of genes predicted by TUSON Explorer and DOTS-Finder in the THCA dataset. The former only 
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predicts a few driver genes (6); of these, two thirds are also identified by DOTS-Finder. Notably, our tool 
shows a much higher sensitivity than TUSON Explorer with 12 new predicted genes. 
 
4.1.5.4 Thyroid Carcinoma 
We applied DOTS-finder to the list of 326 Thyroid Carcinoma (THCA) samples from 
TCGA, identifying 12 driver genes. We could only compare the DOTS-Finder results 
with the results obtained by TUSON Explorer, since, to date, there are no published 
TCGA papers for Thyroid Carcinoma (Figure 9, Panel B). Three of our putative driver 
genes (TG, BRAF and RPTN), are also predicted by TUSON Explorer. TG and BRAF are 
known driver genes in THCA (Kimura et al., 2003; Rubio and Medeiros-Neto, 2009), 
while RPTN is a poorly characterized protein that has never been associated with THCA.  
We identified several putative driver genes that may have relevant functions in cancer 
development (Table 2): mutations in EMG1 have been recently identified in a screen for 
mediators of IGF-1 signaling in cancer (McMahon et al., 2010); germline mutations in 
PRDM9 are thought to influence genomic instability, increasing the risk of acquiring 
genomic rearrangements associated with childhood leukemogenesis  (Hussin et al., 
2013); PPM1D is an important interactor of TP53, is amplified in different types of 
cancers and encodes wip1, a protein involved in oncogenesis (Bulavin et al., 2002). 
Recently, mutations and variants of this gene were associated with DNA damage 
response (Dudgeon et al., 2013). Although only slightly above our threshold, we also 
detected PTTG1LP and DICER1 as putative OGs. Interestingly, pituitary tumor 
transforming gene (PTTG)-binding factor (PTTG1IP) encodes a poorly characterized 
proto-oncogene that has already been implicated in the etiology of thyroid tumors (Read 
et al., 2011; Stratford et al., 2005). Loss of DICER1 is associated with the development of 
many cancers; somatic missense mutations affecting DICER1 are common in non-
epithelial ovarian tumors and these mutations show an oncogenic behavior (Heravi-
Moussavi et al., 2012).  
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4.1.5.5 Acute Myeloid Leukemia 
We applied DOTS-Finder to the 196 samples in TCGA Acute Myeloid Leukemia (AML) 
dataset and we were able to confirm the large majority of findings from previously 
reported analyses (Kandoth et al., 2013; Lawrence et al., 2014; Network, 2013) (Figure 
10) and to discover three new driver candidates, as shown in Table 2. Unfortunately, we 
could not compare our results with TUSON Explorer, as AML samples were not 
analyzed. In particular, we identified as driver three genes with low mutations frequency 
(<=1%): CBFC, CBX7 and CALR. CBFC and CBX7 have been already implicated in AML 
pathogenesis. CBFC is the most common translocation target in AML, involved in a 
chromosomal rearrangement that results in the fusion of CBFB and MYH11 genes, 
associated with the acute myeloid leukemia subtype M4Eo (Kundu and Liu, 2001). CBFB 
has a role in hematopoiesis (Kundu et al., 2002) and it is a direct target of RUNX1 (Hart 
and Foroni, 2002), a well-known driver gene of AML. CBX7 is a component of the 
Polycomb repressive complex 1 and it is causally linked to cancer development (Klauke 
et al., 2013). Interestingly, we classified this gene as a tumor suppressor, and this finding 
is consistent with the fact that loss of CBX7 gene expression correlates with a highly 
malignant phenotype in thyroid cancer (Pallante et al., 2008) and reduces survival of 
colorectal cancer patients (Pallante et al., 2010) CBX7 is specifically expressed in 
hematopoietic stem cells and its overexpression enhances self-renewal and can induce 
leukemia (Scott et al., 2007). CALR was recently found mutated in some forms of 
myeloproliferative neoplasms, a group of disorders related to AML (Klampfl et al., 2013). 
Although near significance, we also detected BCOR, a transcriptional corepressor. BCOR 
mutations are implicated in myelodysplastic syndromes and AML with normal 
karyotype (Grossmann et al., 2011). In addition, BCOR has been recently found in acute 
promyelocytic leukemia as a novel fusion partner of RARA (Yamamoto et al., 2010). 
 
 57	
 
Figure 10 Venn diagrams of the set of candidate driver genes predicted by several tools in Bladder 
Carcinoma and Acute Myeloid Leukemia. (A) Comparison of driver genes predicted by five methods in 
Bladder Carcinoma. Only 8% of all the genes identified by at least one resource are identified by all 
methods. This percentage rises to 20% if we exclude the candidate driver genes coming from the TCGA 
publication. Nevertheless, there is a poor concordance among the methods as MutSig and DOTS-Finder 
identifying respectively 14 and 12 non-overlapping candidate drivers. (B) Comparison of driver genes 
predicted by four methods in Acute Myeloid Leukemia. The AML mutational spectrum has 50% of the 
genes shared by all the four resources analyzed. Nevertheless, DOTS-Finder was able to identify the 
following new driver candidates: CBFC, CBX7, CALR and BCOR. 
 
4.1.5.6 Bladder Carcinoma 
We applied DOTS-Finder to the list of 145 Bladder Carcinoma (BLCA) samples. We 
have identified 21 driver genes, of which 6 are also found in the official TCGA paper 
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(Guo et al., 2013) but their prediction is not properly comparable with our findings as it 
contains only 99 samples. Our results are instead consistent with MuSiC, MutSig and 
TUSON Explorer as shown in Appendix Table 2. Five driver genes were uniquely 
identified by DOTS-Finder and three of them (SPTAN1, TXNIP, RARG) have functions 
relevant to cancer development or have been previously associated with cancer. SPTAN1 
encoded protein has been implicated in DNA repair and cell cycle regulation (Metral et 
al., 2009). TXNIP acts as a suppressor of tumor cell growth and loss of TXNIP expression 
facilitates BLCA. Notably TXNIP might be an important target for the prevention or 
treatment of bladder cancer (Nishizawa et al., 2011). Lastly, RARG encodes a retinoic 
acid receptor that acts as a ligand-dependent transcription factor that regulates cell 
growth and survival (Altucci et al., 2007). In addition, we also detected the following 
genes near significance: the known tumor suppressors KLF5 and GPS2 and the 
oncogenes IRS4, RPS6 and ELP5. KLF5 encodes a member of the Kruppel-like factor 
subfamily, which plays important roles in cell proliferation and cell cycle regulation 
(Chen et al., 2006) and it has been described as a tumor suppressor in several cancer 
types (Chen et al., 2003). Mutations in GPS2 have been previously identified in 
medulloblastoma (Pugh et al., 2012). The insulin receptor substrate 4 (IRS4) and the 
Ribosomal Protein S (RPS6) may play a role in cancer development and progression via 
their effect on cell growth and proliferation. ELP5 may play a role in cancer due to its 
involvement in histone acetyltransferase activity (Winkler et al., 2002). 
4.1.5.7 Atypical tumor suppressor genes and oncogenes 
The concept of TSG and OG has evolved over time. In conventional wisdom, TSGs are 
nonfunctional in tumors and require biallelic loss of function to manifest tumorigenicity 
(Payne and Kemp, 2005); OGs are typically characterized by acquired or enhanced 
function and a single mutated allele is sufficient (Xu et al., 2013). Thus, three levels of 
information are required to classify a cancer driver gene as an OG or a TSG: functional, 
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structural and genetic. The functional level is defined by a gain or loss of a biochemical 
function. It requires understanding of the actual role of the gene in tumorigenesis and of 
the pathways in which it is involved. Functional changes result from and can be 
predicted based on the structural information; this is what we ultimately do by dividing 
mutations into truncating (TSG related) or missense (OG related) ones and analyzing 
their pattern. The genetic effect defines the dominant or recessive characteristics of the 
driver gene. At the genetic level, a mutated gene can be dominant or recessive depending 
on how many dysfunctional copies are required to exert its effect (Table 3). 
  FUNCTIONAL EFFECT 
  Gain Loss 
GENETIC 
EFFECT 
Dominant Typical OncoGene 
Dominant 
Negative 
TSG 
Recessive - Typical TSG 
Table 3 Genetic and Functional effect of mutations in oncogenes and tumor suppressors. A driver 
cancer gene is defined by a genetic effect (dominant, recessive) and a functional effect (gain or loss). These 
two components ultimately define the tumor suppressor and oncogene characteristics that we try to infer 
from the mutational landscape (structural effect) 
 
Typically, the functional information is missing or poorly understood for new driver 
candidates and the genetic information (allelic-specific) is not directly available in cancer 
sequencing studies. Thus, the OG and TSG classification must be inferred from the 
structural level. It is not surprising that our tool can classify many genes as being both 
TSGs and OGs within the same cancer type, or even put them into different categories 
according to the tumor context. This apparent misclassification might cast a light on the 
particular behavior of some genes. There are four possible structural scenarios of 
mutations in a gene, as shown in Table 4. The first two are the same ones shown in 
Figure 2: a clustered missense mutation landscape with no truncating mutations, 
implying a typical gain-of-function OG like KRAS, and diffuse and predominant 
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truncating mutations with no missense pattern like APC, underlying a loss-of-function 
TSG. 
  STRUCTURAL LANDSCAPE 
 Missense clustered no clustered Any 
 Truncating no diffuse diffuse Clustered 
BIOLOGICAL 
CLASSIFICATION 
Oncogene 
Typical (gain-of-
function) 
none found none found 
Atypical 
(gain of 
function 
through loss 
of 
inhibition).  
e.g. KRAS e.g. NPM1 
Tumor 
Suppressor 
Atypical (dominant 
negative, gain-of-
function) 
Typical (loss-of-
function) 
Atypical (possible 
dominant negative, gain-
of-function*) 
none found 
e.g. SMARCA4 in 
Lymphoma e.g. RB1 
e.g. TP53 in UCEC 
or DNMT3A in AML 
Table 4 Inference of biological classification by structural effect of mutational landscape. Inferring the 
biological role of oncogenes and TSGs in cancer via the mutational landscape can lead to borderline results 
in the classification. A careful confrontation with the literature can cast a light on the peculiar 
characteristics of driver genes in the different tumor types. *A mixed mutational landscape with diffuse 
truncating and clustered missense in the same tumor type must be carefully analyzed. We should 
understand whether truncating and missense mutations are mutually exclusive and what is the allelic 
status (heterozygosity or homozygosity) of the two different patterns. 
 
In Figure 11, we present four genes with atypical patterns. TP53 in endometrial 
carcinoma (Panel A) has a landscape of mutations that can be considered borderline for 
both the OG and TSG score definitions, with a consistent number of diffuse truncating 
mutations (around 20%) and a concentration of missense mutations on the DNA 
binding site. According to our tool, the duality of TP53 is revealed in many tumor types 
and can mask a possible dominant negative effect, as summarized in (Oren and Rotter, 
2010). Similarly, and strongly supported by the literature (Kim et al., 2013), DNMT3A in 
Panel B, presents diffuse truncating mutations and a visible missense cluster on the 
cytosine C5 DNA methylation domain. In both genes, a patient-specific mechanism, 
which can distinguish the two different patterns, is probably implicated. In Panel C, we 
analyze two different patterns of mutations in SMARCA4 in different tumor types. 
Although considered a TSG (Medina et al., 2008), SMARCA4 is classified as a true TSG 
only in lung adenocarcinoma, with 11 out of 18 truncating mutations diffuse all over the 
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gene body. In lymphoma, the situation is the opposite: none of the 6 mutations found is 
truncating, and 3 are clustered on amino acid 973 on the SNFN 2 domain of the protein. 
DOTS-Finder classifies this gene differently according to the tumor type, suggesting a 
dominant negative effect of SMARCA4 which is able to regulate its own expression with 
just one mutated copy (Magnani and Cabot, 2009), as previously described for this 
cancer (Medina and Sanchez-Cespedes, 2008). 
 
Figure 11 Mutational patterns of atypical tumor suppressor genes and oncogenes. (A) TP53 mutational 
landscape in uterine corpus endometrial cancer. DOTS-Finder classifies this gene as a TSG as well as an 
oncogene. While this gene retains many truncating mutations, which are diffused all over the gene body, it 
also encompasses a high number of clusterized missense mutations affecting DNA binding. (B) DNMT3A 
mutational landscape in Acute Myeloid Leukemia. The pattern of mutations shows diffuse truncating 
mutations and an evident missense cluster on the cytosine C5 DNA methylation domain. The two types of 
mutations (truncating and missense) do not share the same domains. This pattern could reflect a double 
mechanism of action of this gene in different patients. (C) SMARCA4 mutational landscape in lymphoma 
B-cell compared with lung adenocarcinoma. SMARCA4 is reported in literature as a typical loss-of-
function TSG and its mutational pattern in lung is consistent with this classification (diffuse truncating 
mutations). In lymphoma no truncating mutations are called, and half of the missense mutations affect 
amino acid 973. DOTS-Finder classifies SMARCA4 as a TSG in lung but as an oncogene in lymphoma, 
following its clustered missense pattern. We suspect a possible dominant negative effect in this second 
example (see Table 3). (D) NPM1 mutational landscape in acute myeloid leukemia. This gene is reported 
as a gain-of-function oncogene, however, it shows a peculiar mutational landscape: 99% of its mutations 
are truncating, but they are clustered on the c-terminal of amino acid 288. Mutation p.W288fs truncates 
the protein without deactivating it; NPM1 is instead delocalized from the nucleus to the cytoplasm. The 
total numbers of truncating sites and missense mutations are indicated in the panels. The mutations are 
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mapped on the corresponding canonical protein ideogram, therefore, not all the mutations can be 
represented (e.g. splice sites mutations are not included in the figure). 
 
The last example in Panel D refers to NPM1, which is a shuttling protein involved in 
AML. Although NPM1 is almost exclusively characterized by truncating mutations 
(53/54) and is classified as a TSG by DOTS-Finder, NPM1 is instead a typical 
gain/switch-of-function gene (Mariano et al., 2006). The truncating mutations are, in 
fact, clustered as p.W288fs, a four base insertion that deactivates the c-terminal and 
delocalizes the protein (Grisendi et al., 2006).  
4.1.5.8 The importance of considering subsets of samples 
Analyzing the pattern of genetic alterations in tumor subsets classified by clinical or 
other biologic parameters can reveal important insight in individual pathogenic 
mechanisms and suggest possible therapeutic avenues. For instance, in lung 
adenocarcinoma (LUAD), about 25-30% of the cases are not attributable to tobacco 
smoking as they are found in people that have never smoked (never smokers - NS). 
Studies have revealed that LUAD in NS is a completely different disease from any type of 
lung cancer arising in smokers (LUAD included), as it differs in terms of clinical and 
pathological features, with diverse prognosis and strategy of care (Rudin et al., 2009). 
The difference in the mutational landscape (Govindan et al., 2012) supports the 
hypothesis that NS lung adenocarcinomas are driven by distinct genetic mechanisms. To 
identify additional driver genes with a role in the development of lung cancer in NS, we 
applied DOTS-Finder to the somatic mutations of the 50 NS patients present in the 
LUAD samples of the TCGA. These samples constitute approximately 10% of the 
population; our driver candidate predictions are reported in Appendix Table 3. At the 
top of the list of predicted OGs is EGFR, consistent with the fact that EGFR is a key 
oncogenic player in LUAD NS. Beside the identification of very well-known cancer 
genes such as SMAD4, STK11, SETD2, MET, KEAP1, TP53 and KRAS, we also identified 
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several putative driver genes that might have relevant cancer development functions: 
somatic mutations in GRM1 disrupt signaling with multiple downstream consequences 
(Esseltine et al., 2013); mutations in RPL5 has been recently described as a potential 
oncogenic factor in T-cell acute lymphoblastic leukemia (De Keersmaecker et al., 2013); 
inactivating mutations in the SHA gene, which has a role as TSG, have been identified in 
familial paragangliomas (Bardella et al., 2011; Francis et al., 2013); WRN encodes a 
strand DNA breaks: defects in this gene are the cause of the aging-promoting Werner 
syndrome and copy number variations or epigenetic inactivation have been recently 
found in LUAD NS (Job et al., 2010) and non-small cell lung cancer (Agrelo et al., 2006) 
respectively. 
Similarly, kidney cancer can be classified in different histological subtypes, the most 
common being Kidney Renal Clear Cell Carcinoma (KIRC), Papillary Cell Carcinoma 
(KIRP) and Kidney Chromophobe (KICH). Applying DOTS-Finder separately on each 
kidney dataset Appendix Table 1, we observed a subtype-specific pattern of genetic 
alterations. KIRC and KIRP share only SETD2, KIRC and KICH have only TP53 in 
common, and there are no common driver genes between KIRP and KICH. By analyzing 
all the datasets together we can predict two new putative driver genes, GFRAL and 
STAG2, not appearing in the single analyses. Since the KIRC subset is predominant in 
terms of sample size, the aggregated analysis can recapitulate 69% of its genes, while it 
can only identify 50% of KICH and 27% of KIRP genes. In KIRP, we lose the following 
candidate driver genes, which then appear to be tumor specific: KDM6A, SRCAP, SAV1, 
DARS, OGG1, MET, ATP10A; similarly, in KICH we lose CDKN1A. 
4.1.5.9 Small sample size analysis. The --lax option 
DOTS-Finder sets the threshold for OG-S and TSG-S as a function of both the mutation 
rate of the analyzed tumor and the sample size of the input dataset (see section 4.1.4.6). 
These thresholds have a default lower boundary. Nevertheless, for very small sample 
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sizes, these thresholds can still be too high to let genes pass the functional step. We 
decided to introduce an option called --lax that ignores the imposed lower boundary and 
allows more genes to pass the functional step in the presence of a small sample size.  In 
Table 5 we show the analysis of two different tumors, the oligodendroglioma dataset (16 
patients) and the carcinoid dataset (54 patients) obtained using the --lax option of 
DOTS-Finder.  
	
Table 5 Application of the --lax option to two small cancer datasets. Results of DOTS-Finder obtained 
analyzing Oligodendroglioma and Carcinoid datasets with default option and with the --lax option. The 
thresholds imposed by DOTS-Finder can be too high to let any driver candidate to pass the functional 
step. With small sample size or very low mutation rate tumors, an option called --lax can be used to make 
DOTS-Finder less stringent in the first step of the analysis. Legend: NS freq = Frequency of non-
synonymous mutations among samples. Underlined genes are near significance 
 
  
 
In the left column of Table 5 we present the result of the analysis of 16 exome 
sequencings from oligodendroglioma patients (Yip et al., 2012). Without the --lax 
option, DOTS-Finder recapitulates the knowledge regarding this rare brain tumor by 
identifying mutations in CIC, IDH1 and FUBP1 (Alentorn et al., 2012). The same dataset 
upon the --lax option reveals other possible driver candidates, like the known cancer 
genes PIK3CA and NOTCH1, the never reported PDCD6IP, a gene expressed in the 
nervous system and involved in cell death, HIVEP2 and KCNH6, two genes previously 
reported in leukemia, and RIN1, an important Ras interactor. 
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In the right column instead are the results for the carcinoid tumor (Francis et al., 2013). 
CDKN1B has been already reported for this cancer type, but with the lax option on, other 
possible driver candidates have emerged. In particular, the known cancer-associated 
gene ATM, TP53BP1, an enhancer of TP53 activation known to be involved in DNA 
damage response, PRDM9, described in the main text, in thyroid cancer and near 
significance, and ERN2, a pro-apoptotic gene involved in translational repression under 
endoplasmic reticulum stress. 
4.1.5.10  Comparison of DOTS-Finder to existing tools using Pan-Cancer12 data 
We compared the candidate driver genes predicted by DOTS-Finder against the 
predictions made by 5 methods: 1) MuSiC (Dees et al., 2012), 2) MutSig (Lawrence et al., 
2013), 3) OncodriveFM (Gonzalez-Perez and Lopez-Bigas, 2012), 4) OncodriveCLUST 
(Tamborero et al., 2013a) and 5) ActiveDrive (Reimand et al., 2013), and described in a 
Pan Cancer comparative analysis of 12 different tumor types (Pan-Cancer12) 
(Tamborero et al., 2013b). All these methods, except MutSig, are publicly available and 
implemented as tools. Since the analysis described in Pan-Cancer12 contains the 
candidate driver genes derived from a cross-methodology that includes a pathway 
analysis and a series of sequential filters, we retrieved the output of each method from 
Synapse at the following accession numbers: syn1715784 for MutSig, syn1701498 for 
both OncodriveFM and OncodriveCLUST, and syn1713813 for MuSiC. As the original 
output of ActiveDriver was unavailable, we used the genes predicted by ActiveDriver 
that were present in the aggregated results. Then, we run DOTS-Finder on the Pan-
Cancer12 dataset syn1729383. Furthermore, we compared our results with the 
predictions made by an additional available tool, MutSigCV version 1.4 (Lawrence et al., 
2013), by  using  default parameters on the same input dataset (Figure 12). The predicted 
driver genes for all the above-cited tools can be found in Tables S1 in (Melloni et al., 
2014). For statistical comparison, we evaluated precision and recall of all the methods 
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against 162 genes belonging to the Cancer Gene Census (version 68). We selected these 
162 genes since they are the ones targeted by single nucleotide variants (SNVs) and small 
insertions and/or deletions (InDels) mutations. The other CGC genes are amplified, 
translocated or targeted by large insertions/deletions in cancer, thus being outside the 
scope of our study. To obtain a unique measure of accuracy of the predictions, we 
aggregated precision and recall through the F1-Score, a well-established balanced value 
of accuracy calculated as the harmonic mean of precision and recall. Since we have no a 
priori knowledge of the true negatives and we only know the true positives, measures 
that take into consideration only precision and recall are preferable in this context. In 
this sense, a method with a good balance between precision and recall ensures that the 
predicted genes that are not in CGC could be reliable driver candidates. For example, as 
shown in Figure 12, Panel D, a method like MuSiC shows a recall comparable to DOTS-
Finder, but a lower precision.  
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Figure 12 DOTS-Finder results compared to the Pan-Cancer12 analysis. (A) Six-way Venn diagram of 
DOTS-Finder and 5 other tools. This panel shows the number of putative driver genes that are predicted 
individually by each tool or in common by multiple tools. The diagram uses a graduated color ramp from 
light yellow to dark red to represent the overlap of an increasing number of tools that predict the same 
drivers. A full concordance between these methods can be obtained only for 12 genes among the 654 
uniquely identified by at least one method (they are present in region with the darkest shade of red). This 
is due to the fact that each method is implemented for assessing different aspect of drivers’ behaviors. 
Therefore, an approach that combines different complementary methods, as proposed by Tamborero et 
al., is certainly preferable. (B) Pan-Cancer12 aggregated results compared to DOTS-Finder and CGC. This 
panel shows the existing overlap between the list of high confidence drivers and candidate drivers 
provided by both Pan-Cancer12 analysis and DOTS-Finder, crossed with the entire list of CGC genes 
(522). DOTS-Finder is able to retrieve 4 new CGC genes (CALR, CREBBP, KDR, KIAA1549) that none of 
the other methods were able to confirm. Interestingly, CALR has been recently added to the CGC. In 
addition, 65 new genes are predicted by DOTS-Finder as possible driver candidates, including CBX7 and 
UBC, described in this paper. (C) Heatmap of the similarity between 7 methods. This heatmap is built on 
the number of overlapping genes between each pair of tools normalized by row. Therefore, the 
dendrogram on the left side of the plot indicates the similarity between pairs of methods compared to all 
the remaining ones. Results show that DOTS-Finder is close to MutSig and MutSigCV algorithms in terms 
of cross-predicted genes. It is instead very different from both MuSiC and OncodriveFM, which form an 
independent cluster disjointed from all the others. (D) Statistical comparison of all the methods against the 
162 CGC genes targeted by SNVs and/or InDels mutations. In this plot we compared the precision (X-
axis), recall (Y-axis) and F1-Score (harmonic mean between precision and recall; circles area) of 6 different 
available tools, including DOTS-Finder, against the 162 CGC genes used as a gold standard reference. In 
terms of F1-Score (harmonic mean between precision and recall), DOTS-Finder is the best performer. The 
aggregation of 3 different methods used by the latest MutSig strategy reaches an F1-Score of 0.45. However 
this strategy is not publicly available. DOTS-Finder and MutSig comprehensive approaches and the entire 
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Pan-Cancer12 analysis confirm that an approach that takes into consideration different sources of 
information is certainly preferable. 
 
This indicates that we can provide the same number of true outputs with fewer attempts. 
According to this measure, DOTS-Finder is the best tool among the available ones with 
an F1-Score of 0.36 (precision=0.37, recall=0.35) (shown in Figure 12, Panel D). 
4.1.5.11 Statistical power using a small number of cancer samples 
One of the main strength of DOTS-Finder is its ability to retrieve reliable results even 
using a small number of cancer samples as input. Our double step procedure ensures a 
higher sensitivity to the deviation from the null hypothesis of being a passenger-mutated 
gene. In order to assess this characteristic, we collected the data from the latest bladder 
cancer TCGA dataset (238 patients) and run our pipeline against MutSigCV 1.4 using 
default parameters. We decided to use MutSigCV for this statistical comparison, as it is 
the available method with the best performance after DOTS-Finder. We retrieved 31 
significant driver genes against the 26 of MutSigCV, with 16 common predictions. Then, 
we randomly down-sampled our dataset at several sampling fractions (5%, 10%, 15%, 
20%, 30%, 40%, 50%, 70% and 90%) and selected 5 different subsamples for each 
fraction. We end up with 9x5 subsamples made up of a minimum of 12 to a maximum of 
214 patients. We then run both DOTS-Finder and MutSigCV on all the 45 subsamples 
and collected the number of identified drivers. Our results show that DOTS-Finder is 
superior in terms of absolute output Figure 13, Panel A, especially for small sample size 
(from 12 to 48 patients).  
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Figure 13 Comparative saturation analysis and performance analysis for a range of sample sizes. (A) 
Comparative saturation analysis. Here we show the absolute output in terms of number of significant 
genes found by DOTS-Finder (blue line) and MutSigCV (red line) for every subset from each down-
sampling fraction. DOTS-Finder is able to provide a consistent output even with a very limited number of 
patients (a minimum of 10 genes identified with just 12 patients while MutSigCV retrieves 0 or 1 gene at 
best - always TP53). (B) Comparative F1-Score. In this panel we compared every prediction on the 
subsamples to the full output of each tool considering the whole dataset (N=238). Our predictions are not 
only consistent, but maintain an F1-Score distribution that is uniformly higher than MutSig at any 
downsampling level. This difference is much more evident for small samples. (C) Precision-Recall plot for 
DOTS-Finder. Here we present the precision-recall output of every subsample compared to the significant 
genes found on the entire dataset. With just the 5% of the entire dataset, DOTS-Finder is able to predict an 
average of 20% of the full output with a precision of almost 40%. 
 
Our tool is also able to recapitulate its own results in terms of precision and recall better 
than MutSigCV, at any level of downsampling (Figure 13, Panel B). However, this 
difference is more evident for subsamples with very small fractions (from 5% to 30%). 
Finally, as shown in Figure 13, Panel C, we can observe that DOTS-Finder can 
recapitulate up to 40% of the results of the entire 238 patients-dataset, using just 5% of 
the dataset (12 patients), with a precision of almost 50%. 
4.1.6 Discussion 
DOTS-Finder is the first published software that can identify driver genes and can 
classify them as TSGs and/or OGs and it can also be used to identify driver genes with 
atypical patterns of mutations (Figure 11). In addition, it is the first software that can be 
used by a vast and diverse scientific community as it is easy to install and use, does not 
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need the availability of property software, and does not require the use of low-level and 
hard to access files (e.g. as bam files, coverage files). 
We have applied DOTS-Finder on publicly available datasets containing the mutation 
profile of 34 cancer types. We have obtained plausible driver genes for many low 
mutation rate cancers like gliomas, acute myeloid leukemia and prostate cancer. Notably, 
we have obtained results that are consistent with the literature even with some high 
mutation rate tumor types, like Head and Neck Squamous Cell Carcinoma and Bladder 
Cancer, where the risk of falling into the “fishy genes” trap is higher.  
Our tool outperforms other available methods in terms of precision-recall, considering 
CGC as a gold standard. Importantly, DOTS-Finder has confirmed the predictions made 
by other methods and discovered novel driver candidates never identified before. 
Using DOTS-Finder, researchers can identify driver genes in large public databases and 
also in user-defined samples stratified for a given characteristic, as the software is 
specifically designed to identify driver genes even in small datasets (e.g. obese/normal 
weight, male/female etc.). The use of few samples in cancer is justified by the high 
molecular heterogeneity present in tumors. Indeed, we believe that the results produced 
by DOTS-Finder could be very useful for those researchers who want to identify driver 
genes in user-defined datasets, in order to investigate the significance or relevance of 
particular somatic mutations in relation to specific clinical questions. 
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4.2 LowMACA: exploiting protein family analysis for the identification of 
rare driver mutations in cancer 
This section of the results is adapted from (Melloni et al., 2016). DOTS-Finder concept 
was to create a tool able to detect driver genes and divide them between tumor 
suppressors and oncogenes. Nevertheless, there are many genes whose frequency of 
mutation is so low that any statistics would fail to detect them because of the lack of 
statistical power. Therefore, in order to distinguish drivers from passengers, the only 
straightforward solution would be to sequence more cases that is of course impractical 
from many different points of view (time, cost, etc.). Nevertheless, mutations are entities 
with a large context and many properties that can be exploited by aggregating them in 
larger mutations clusters. For examples, mutations can have predictable effects on the 
final protein product, or again, they belong to genes, which in turn, belong to pathways 
or families. Aggregating mutations increase statistical power at the expense of losing the 
granularity of each single mutation. In particular, the tool presented in this section, 
LowMACA, exploits protein families introducing multiple sequence alignment as an 
approach to find connections between genes that show similarity in the secondary 
structure. 
4.2.1 Abstract 
The increasing availability of resequencing data has led to a better understanding of the 
most important genes in cancer development. Nevertheless, the mutational landscape of 
many tumor types is heterogeneous and encompasses a long tail of potential driver genes 
that are systematically excluded by currently available methods due to the low frequency 
of their mutations. We developed LowMACA (Low frequency Mutations Analysis via 
Consensus Alignment), a method that combines the mutations of various proteins 
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sharing the same functional domains to identify conserved residues that harbor clustered 
mutations in multiple sequence alignments. LowMACA is designed to visualize and 
statistically assess potential driver genes through the identification of their mutational 
hotspots. We analyzed the Ras superfamily exploiting the known driver mutations of the 
trio K-N-HRAS, identifying new putative driver mutations and genes belonging to less 
known members of the Rho, Rab and Rheb subfamilies. Furthermore, we applied the 
same concept to a list of known and candidate driver genes, and observed that low 
confidence genes show similar patterns of mutation compared to high confidence genes 
of the same protein family. LowMACA is a software for the identification of gain-of-
function mutations in putative oncogenic families, increasing the amount of information 
on functional domains and their possible role in cancer.  In this context LowMACA 
emphasizes the role of genes mutated at low frequency otherwise undetectable by 
classical single gene analysis. LowMACA is an R package available at 
http://www.bioconductor.org/packages/release/bioc/html/LowMACA.html. It is also 
available as a GUI standalone downloadable at: 
https://cgsb.genomics.iit.it/wiki/projects/LowMACA 
4.2.2 Introduction 
As previously described, the identification of driver mutations in cancer can be enhanced 
by considering the position of the mutations on the proteins rather than their simple 
frequency in cancer cohorts (Vogelstein et al., 2013). For this reason, tools that combine 
frequency of mutations and their position on the genome have been recently developed 
for the identification of potential drivers in small cohorts of patients to increase 
statistical power (Davoli et al., 2013; Melloni et al., 2014; Tamborero et al., 2013a). 
Furthermore, other methods based on network analysis were developed to aggregate 
mutational information at the level of interaction pathways (Mutation Consequences 
and Pathway Analysis working group of the International Cancer Genome Consortium, 
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2015). Nevertheless, as pointed out in a recent simulation based on saturation analysis 
on publicly available cancer data, we are still far from a true understanding of the genes 
mutated in less than 5% of the patients for almost any tumor type (Lawrence et al., 
2014). Due to the lack of the required sample size, methods able to assess the role of 
rarely mutated genes are needed. LowMACA represents a solution to increase the 
information content of alteration patterns by summing up mutations on properly 
aligned amino acids in different proteins belonging to the same family. The 
accumulation of somatic mutations in specific Pfam domains has been already observed 
in cancer, introducing the concept of domain landscapes of somatic mutations in 
addition to the well-known genomic landscape (Nehrt et al., 2012; Peterson et al., 2010; 
Yang et al., 2015a).Nevertheless, these approaches only rely on the frequencies of 
mutated domains in cancer. We enhance this approach by adding the positional 
information of mutations within the domains, eventually increasing the statistical power 
of the domain level analysis. With LowMACA, we are able to assess various aspects of 
somatic mutations at the level of protein families, including clustering in hotspots, 
conservation of mutated residues, pattern similarity across proteins and co-occurrence 
or mutual exclusivity among positions resulting significant by LowMACA criteria. In 
fact, one of the significant improvements over existing methods is the ability of 
LowMACA to test single driver mutations and not only driver genes. All these unique 
aspects are illustrated here in the context of the Ras superfamily and in the analysis of a 
state-of-the-art set of high confidence and putative driver genes (Tamborero et al., 
2013b). 
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4.2.3 Materials and Methods 
4.2.3.1 Software Implementation and Overview 
LowMACA is a computational tool for the analysis and visualization of somatic 
mutation data in cancer. It allows to properly assess the significance of hotspots of 
mutations shared across protein families and to show the interconnectivity among 
mutational patterns via different visualization methods. The software comes as an R 
package, fully integrated in the R/Bioconductor environment through the use of the 
AAMultipleAlignment class from the Biostrings library. The multiple alignment is 
performed with a wrapper around a clustal omega executable (Sievers et al., 2011) or the 
EBI soap webserver (McWilliam et al., 2013). At the present time, LowMACA is the only 
tool that allows using clustal omega within R storing results within a Biostrings class. 
Importantly, the LowMACA package implements a user-friendly GUI built with the 
shiny package, exploiting the interactive functionalities provided by D3 javascript and 
google charts plotting libraries. The tool comes with a pre-built annotation package 
named LowMACAAnnotation, that integrates the information of HGNC (Gray et al., 
2014), UNIPROT un and Pfam (Finn et al., 2007) with the aim of guiding the user 
through the analysis of highly conserved classes of proteins belonging to common Pfam 
domains. The LowMACAAnnotation package creates a one-to-one match between 
UNIPROT canonical proteins and HGNC gene symbols and provides all the Pfam 
sequences of each protein entry. 
LowMACA implements two conceptually different workflows: a Hypothesis Driven 
workflow and a Data Driven workflow. 
The Hypothesis Driven workflow consists of: 
1) Selecting proteins belonging to the same family (we suggest Pfam as a 
guideline). 
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2) Selecting one or more tumor types and classes of mutations that will be 
analyzed (see Methods section Input Data). 
3) Retrieving mutations from specified cancer samples. 
4) Aligning selected sequences along with their mutations 
5) Calculating statistics and evaluating significant hotspots with different 
parameter settings 
The Data Driven workflow consists of: 
1) Providing a dataset of mutations from a cancer cohort in a format derived 
from TCGA standard maf files (see Input Data). 
2) LowMACA collects all the genes that harbor at least one mutation and 
align their domains according to Pfam. Subsequently, the mutations are mapped on 
every consensus sequence created (one per Pfam analyzed). 
3) LowMACA analyzes the mutational pattern of every protein by itself. 
4) The hotspots found at point 2 and 3 are unified in one table and the list of 
putative driver mutations is presented (detailed information can be found in the 
package reference manual: 
http://bioconductor.org/packages/release/bioc/manuals/LowMACA/man/LowMAC
A.pdf).  
4.2.3.2 Input Data 
According to the choice of a Hypothesis Driven or Data Driven workflow, LowMACA 
requires different kinds of input. In the first case, LowMACA expects as input a Pfam ID 
of interest (e.g. “PF00001”) and/or gene names, provided as Entrez Gene IDs (Maglott et 
al., 2005) or HUGO Gene Symbols (Gray et al., 2014). In case only a Pfam ID is 
provided, the LowMACAAnnotation package will look for all the genes that contain the 
specified domain, otherwise, only the chosen genes are retained. By selecting a Pfam ID 
of reference, only the portion of the proteins mapping to the Pfam domain will be 
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considered in the analysis. If a set of gene identifiers is selected without specifying any 
Pfam ID, the entire protein sequences are considered for the analysis. LowMACA admits 
also the use of non-ambiguous gene aliases. The LowMACAAnnotation package is 
designed to assign only canonical proteins to the relative gene creating a one-to-one 
unique match. LowMACA retrieves mutational data via the R/CRAN package “cgdsr” 
which queries the Cancer Genomics Data Server (CGDS) hosted by the Computational 
Biology Center at Memorial-Sloan-Kettering Cancer Center (MSKCC) (Cerami et al., 
2012; Gao et al., 2013). Mutation data coming from personal databases can alternatively 
be used, following the instructions provided within the manual of our R-package. Since 
LowMACA looks for hotspots of mutations, the package keeps by default only the 
mutations that modify the protein without altering the reading frame or creating stop 
codons (collectively identified as missense type mutations). Other mutation types, such 
as frame shift InDels, nonsense mutations or splice-site mutations (collectively called 
truncating mutations), can be retrieved by modifying the parameters. By default, 
LowMACA will take into account all the tumors present within the cBioPortal 
repository, but mutations from specific cancer types can be selected. In case a data driven 
workflow is chosen, the user has to provide only mutation data. These data are a direct 
derivative of a common maf file as specified by TCGA and contains the mutations 
annotated by their gene, their amino acid change, sample of origin and type of mutation. 
A detailed description can be found in the package reference manual: 
http://bioconductor.org/packages/release/bioc/manuals/LowMACA/man/LowMACA.p
df. 
4.2.3.3 Alignment and Mapping 
Amino-acid sequences selected as described above are aligned using the multiple 
sequence alignment software Clustal Omega (Goujon et al., 2010; McWilliam et al., 2013; 
Sievers et al., 2011). Although the Pfam database is a comprehensive archive of cross-
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species alignments, we only refer to human proteins and each Clustal Omega alignment 
represents a unique combination of conserved and not conserved residues. Using the 
original HMM model of the protein family is a limiting factor in this case, as we would 
lose portions of alignments specific to human proteins only. Moreover, Clustal Omega 
can handle alignments involving whole protein sequences, rather than only Pfam 
domains. From the output of the multiple alignment, a consensus sequence including the 
most represented amino acid found at every position is created that is representative of 
all the sequences under investigation. The mutations coming from aligned sequences are 
remapped directly on the consensus with the aim of obtaining a unique mutational 
profile. Considering that LowMACA specifically aims at highlighting mutations that fall 
on conserved residues, two measures of conservation are taken into account at this point. 
The first one concerns the specific positions of the alignment. LowMACA calculates the 
Trident conservation score for this purpose (Valdar, 2002), which is a mixed measure 
that encompasses three different aspects of a local alignment: 
1) The entropy of the residues at the specific position. The more different 
amino acids are aligned the less conserved is the position. 
2) The chemical similarity according to the substitution matrix BLOSUM62 
3) The relative frequency of gaps 
The second measure is global and involves the entire sequence. The alignment procedure 
of the LowMACA engine is delicate due to the fact that including dissimilar sequences in 
the analysis can invalidate the whole LowMACA workflow. For this reason, sequence 
similarity for every pair of amino acid sequences is calculated, based on the k-tuple 
measure (Wilbur and Lipman, 1983), and a warning is prompted whenever an amino-
acid sequence differs too much from the others (threshold = 0.2). 
These measures are a safety net to avoid false positive results due to low quality 
alignments and become extremely useful if the user decides to perform analysis with 
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sequences not belonging to the same family. LowMACA provides the Pfam based 
framework as a guideline, but in theory every mutation profile can be compared. 
4.2.3.4 Statistical Testing 
4.2.3.4.1 Testing the randomness of the global mutational profile 
Once the sequences are aligned and the mutations have been remapped on the consensus 
sequence, LowMACA measures the information contained in the mutational pattern 
using Shannon’s definition of entropy (Melloni et al., 2014) 
𝐻 𝑋 = − 𝑃 𝑥! 𝑙𝑛𝑃 𝑥!!!  
where 𝑃 𝑥! = !!!  is the frequency of mutations mapping to the position 𝑖  of the 
consensus alignment of length K and N is the total number of mutations. To statistically 
assess whether the pattern of mutations significantly differs from randomness, we 
compare 𝐻 𝑋  with the entropies of a bootstrap of one thousand random profiles. Each 
random profile is generated according to the following criteria: (i) the random profile 
has the same length of the consensus sequence generated from the analysis (i.e. K); (ii) 
the number of mutations that map on the random profile is equal to the total number of 
mutations that map on the consensus sequence (i.e. N); (iii) the probability of a mutation 
to fall onto a specific position of the random profile is proportional to the number of 
amino acids that map in the corresponding position of the multiple alignment. In this 
way, the more gaps are found in a position of the alignment, the lower is the probability 
that a mutation falls in that position in the random model. This last criterion is intended 
to correct the bias of finding more mutations in more conserved regions of the 
consensus. We fit the parameters of a Gamma distribution over the empirical 
distribution of the entropies calculated on the random profiles. This will be considered 
as the null distribution and used to assign a p-value to the global mutational profile. 
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4.2.3.4.2 Testing for the identification of hotspots of mutation 
LowMACA is also able to identify significant positions along the consensus sequence, as 
opposed to the large majority of driver gene identification approaches (Tamborero et al., 
2013b). The probability that the number of observed mutations 𝑛!on position i of the 
consensus sequence derives from a random pattern of mutations is calculated estimating 
the per-position null distribution of the number of mutations that are expected to fall on 
that specific position. The null distribution is modeled using the Gamma distribution 
whose parameters are estimated from the bootstrapped random profiles generated for 
testing the randomness of the global mutational profile. A per-position p-value that the 
observed number of mutations originated from the null distribution is then calculated 
and p-values of residues that fall onto conserved positions (Trident score > 0.1) are 
corrected to obtain per-position q-values using the Benjamini-Hochberg procedure for 
multiple testing correction (Benjamini and Hochberg, 1995). 
4.2.3.5 LowMACA Output 
Using a Hypothesis Driven workflow, LowMACA outputs a detailed report of the 
mutational landscape of the consensus sequence. It specifies if the entire mutation 
profile can be considered random (global p-value), and it reports all the mutation 
hotspots that exceed the random distribution (per-position p-value and relative FDR 
corrected q-value); see Statistical Model section. Mutations that fall onto significant 
positions of the consensus sequence can be retrieved in their original position with a 
reverse mapping provided by LowMACA. The mutational profile can be visualized with 
many LowMACA methods. These plotting capabilities are considerably extended 
through the GUI. The interactivity that this implementation allows is particularly useful 
to observe the dynamic connections among mutational profiles of different proteins. The 
following plot types are offered by the package: 
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1) A stacked barplot that specifies the relative frequency of mutation per 
sequence in each position (in the GUI this plot has interactive features). This 
representation also includes a graphical view of the trident score and a logo plot of 
the most represented amino acids at every position. 
2) A Protter style plot (Omasits et al., 2014) that represents the possible 
secondary structure of the consensus sequence with the significant positions found 
by LowMACA highlighted in red. 
3) An interactive network plot in which the nodes represent the single 
sequences and the edges are drawn based on the number of shared mutated residues. 
The thicker are the edges, the more positions are in common. This representation 
provides an overview of the similarity among sequences in terms of mutational 
profile. 
4) A heatmap of mutual exclusivity and co-occurrence of mutations at the 
entire sequence level and at single position level implemented with the R package co-
occur (Griffith et al., 2016). For example, it can represent mutual exclusivity between 
mutations in KRAS and NRAS and between KRAS G12 and NRAS G12 positions (see 
Figure 1A). 
The last two functionalities are only available through the LowMACA GUI. In a Data 
Driven workflow, the output is represented in a very similar way, but LowMACA takes 
care of analyzing all the Pfam domains through the mutations in the genes provided by 
the user in a single procedure. Every Pfam analysis can become a new LowMACA object 
and it can be viewed from a descriptive point of view as shown above in the Hypothesis 
Driven workflow. 
4.2.4 Results 
Our results are reported in three different sections. The first analysis is aimed at 
demonstrating the core concept of LowMACA using a known oncogenic family. Starting 
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from the cancer genes KRAS, NRAS and HRAS (that we will name RAS trio), similar in 
structure and mutational profile, we seek to extend this conservation to all the Ras 
superfamily members (in total, 133 different proteins belonging to the PF00071). We 
demonstrate how LowMACA can be used to show the oncogenic potential of different 
positions of the family and to encompass new putative driver genes through the sharing 
of conserved mutations (see section 4.2.4.1). We also evaluated mutual exclusivity of 
mutations that fall in specific positions of the consensus alignment (see section 4.2.4.2). 
Moreover, by collecting all the observed mutations that fall in PF00071, we show that 
LowMACA hotspots fall in positions that are expected to be damaging by 8 different 
predictors of phenotypic effect. Although LowMACA predictions and mutation damage 
assessments are in agreement with the other predictors, our tool is more specific in 
assessing driver mutations against a gold standard of known cancer driver mutations and 
disease associated mutations (see section 4.2.4.3).  The second analysis is aimed at 
assessing the state-of-the-art in driver genes at a domain level. By taking a curated list of 
high confidence drivers (HCDs) and a list of candidate driver genes (CDGs) derived 
from 5 different bioinformatic tools (Tamborero et al., 2013b), we study the 
relationships in terms of common mutations among these genes (see section 4.2.4.4). 
We show that 40% of all the HCDs share at least one domain with a CDG defining and 
expanding the same concept illustrated in the Ras example. Mutations that fall in known 
driver genes are shared both by other known drivers (like the tyrosine kinases EGFR, 
BRAF, FLT3 and JAK family) but also by less frequently mutated genes with a similar 
structure (like the receptor L domain genes ERBB2 with ERBB4). The third analysis 
shows, as a negative control, that silent mutations do not have the propensity to show 
significant pattern of mutations (see section 4.2.4.5). 
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4.2.4.1 Ras superfamily analysis 
We aligned and summarized the mutational landscape of the Ras superfamily, defined by 
PF00071 (Figure 14). This Pfam represents a large family of small GTPases that can be 
grouped in different subfamilies with specific biological characteristics (Wennerberg, 
2005). We performed our analysis in two steps. First, we aligned all the mutations of the 
entire family encompassing 133 sequences. Second, we performed the same analysis 
dividing the mutations by the four main subfamilies: 1) Ras subfamily, involved in cell 
proliferation (Pylayeva-Gupta et al., 2011), 2) Rheb subfamily, involved in neural 
plasticity (Li et al., 2008), 3) Rho subfamily, involved in cytoskeletal morphology (Hall, 
1998) and 4) Rab family, involved in cell trafficking (Stenmark, 2009). Analysis of the 
entire family found significant hotspots in the consensus alignment in positions 16, 17, 
102, and 282, as highlighted in Figure 14, Panel A. In this analysis, we discuss genes that 
have at least two mutations in any of the identified hotspots. These mutations are well 
conserved in the superfamily but appear mainly represented in the Ras subfamily. 
The main representative members of this proto-oncogenic subfamily are the known 
cancer genes that compose the RAS trio. Their mutations G12, G13, Q61 and A146, 
considered important drivers in many cancers (Janakiraman et al., 2010), map on the 
hotspots identified above. These three proteins share over 90% of sequence identity in 
the domain and are the most represented in terms of absolute number of mutations in 
these positions. Hotspots found in position 16 of the global alignment harbor mutations 
on residues G12 of RAP1B, on residue S13 of RERGL and G23 of RALB, which align with 
G12 of the RAS trio, while position 17 aligns with mutations on G85 in GEM, which 
aligns with G13 of the trio. Even if these proteins, (excluding the trio) are very rarely 
mutated, LowMACA identifies their alterations as putatively oncogenic (Figure 14, Panel 
B). All these proteins belong to the Ras subfamily, but a particular exception is 
represented by RERGL that harbors a recurrent S13F mutation: this protein is considered 
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part of the Ras subfamily but its sequence is very distant from the RAS trio (Figure 14, 
Panel C) and for this reason should be analyzed separately. 
 
Figure 14 Ras Family A) LowMACA results based on the alignment of the Ras superfamily (PF00071). 
The first barplot reports the most mutated proteins under significant hotspots in their original position. 
These hotspots are also highlighted in the second barplot with colored symbols. Labels in the second 
barplot report the position of the consensus, the FDR corrected p-value and the trident score of 
conservation (TS). The TS is reported only for hotspots identified in the alignment of all the 133 family 
members. Both barplots are truncated on non-informative positions. B) The panel shows a plot 
representing the mutual exclusivity between mutations that fall in the same position of the global 
consensus alignment. Significant patterns are highlighted with the color corresponding to the tumor type 
where the mutual exclusivity was found. We consider mutually exclusive the pairs with a corrected p-value 
below 0.05 using the R package cooccur C) The dendrogram is built on hamming distances between all 
human sequences of the Ras superfamily aligned via clustal omega. Genes that belong to the same 
subfamily, as described in (Hall et al., 1998), are represented with the same color. Significant hotspots 
(under gene names) are represented with the symbols used in Panel A. 
 
 
Another highly conserved mutation is located in the aligned position 102 that 
corresponds to mutations in Q61 in NRAS prevalently and is one of the residues 
involved in the binding function of all the Ras family members to GTP (Prior et al., 
2012). LowMACA analysis highlighted mutations aligned in position 102 also in other 
Ras members, in particular Q72 mutations in RRAS2. This gene has been extensively 
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analyzed at the transcriptional level but remains poorly investigated regarding the 
mutational context (Gutierrez-Erlandsson et al., 2013). RRAS2 has a role in pathways 
activated by the RAS trio, however, while the trio exerts its pro-proliferative activity via 
the activation of the Raf-ERK pathway of MAP kinases, RRAS2 activates this pathway 
poorly as it does not recruit Raf1 (Gutierrez-Erlandsson et al., 2013). Following the 
observation of several Q72 mutations in RRAS2, one might speculate on a possible 
activation of this gene in the same way as Q61 activates NRAS.  
Position 282, corresponding to an alanine in 146 in the RAS trio, represents a completely 
different case. This hotspot is extremely well conserved in all the members of the 
superfamily and represents the only case of a significantly mutated residue shared by two 
different Ras subfamilies (Ras and Rho). This mutation does not impair the affinity with 
GTP (like G12/13 and Q61) but rather seems to have an effect on the GTP-Ras steady-
state levels as reported by experimental assays (Janakiraman et al., 2010). RAC1, RHOA 
and RHOF emerge as putative oncogenes by this analysis, sharing mutations in this 
position. Among these, RAC1 and RHOA are already present in the Cancer Gene Census  
(Futreal et al., 2004), adding confidence to the hypothesis that also RHOF might play a 
role in cancer. Moreover, relatively elevated levels of RHOF were observed in 
lymphomas derived from the germinal centre (Gouw et al., 2005). 
Hotspots identified in the previous analysis correlate well with sequence similarity based 
on hamming distance (Figure 14, Panel C). For example, the aforementioned hotspots 
16, 17 and 102 belong specifically to the Ras subfamily, identified in orange in the 
dendrogram. This subfamily harbors two glycines in position 16 and 17 that are not 
shared by the entire superfamily. In fact, the 16/17 glycines can be substituted by the 
couple serine/glycine (Rab subfamily) or the couple glycine/alanine (Rho subfamily) 
(Wennerberg, 2005). The Rheb subfamily instead, composed of just two genes RHEB 
and RHEBL1, does not conserve any of the two marker residues and carries a distinctive 
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leucine in position 16. By analyzing mutations that fall individually in each of the four 
subfamilies, we were able to identify new putative oncogenes and new hotspots of 
mutation. In order to keep the reference with positions identified with the global 
analysis, we maintained the full alignment of all the proteins of PF00071 and then subset 
the genes of interest according to the four subfamilies (this alignment parameter is called 
“datum” in the LowMACA package).  
The analysis of the Rab subfamily (mostly represented in the central portion of the 
dendrogram in Figure 14, Panel C) highlights three new hotspots and 11 new putative 
oncogenes. Among these, RAB29 harbors 4 mutations in position 134 of the alignment 
that are predicted to be damaging by most of the functional predictor tools used in 
section 4.2.4.3 and reported in Appendix Table 4 (R79W in Colorectal cancer and R79L 
in Lung adenocarcinoma). The involvement of members of this subfamily in cancer has 
been widely demonstrated (Chia and Tang, 2009). 
The analysis of the Rho subfamily allowed the identification of new hotspots, which are 
mainly represented by RAC1 and RHOA. RAC1 marks a single hotspot found in position 
35 corresponding to mutations of the residue proline 29 (RAC1 P29). According to the 
most recent literature, P29 results altered in approximately 3.9% of TCGA skin 
cutaneous melanoma patients (Hodis et al., 2012) suggesting that RAC1 is a melanoma 
oncogene. The biological significance of the RAC1 P29 mutation remains unclear, 
although authors demonstrated that the mutation could destabilize the RAC1 inactive 
GDP-bound state in favor of its active GTP-bound state, creating a gain-of-function 
oncogenic event (Watson et al., 2014). In fact, the expression of RAC1 P29S in sensitive 
BRAF-mutant melanoma cell lines confers resistance to treatment with RAF inhibitors 
(Watson et al., 2014). Moreover, the P29S mutation has been reported in several cancers 
such as head and neck tumors (Stransky et al., 2011) and breast tumors (Forbes et al., 
2011). Other Rho subfamily members also share the hotspot 35: RAC2, RHOT1, RHOC. 
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Even though one single mutation was found for each gene in our dataset, this position is 
extremely well conserved (a proline is present in all four genes) and all the mutations 
were found in melanoma patients without a RAC1 P29 mutation (Appendix Table 4). 
The mutational hotspots 60 and 62, respectively corresponding to glutamate 40 and 
tyrosine 42 in RHOA, were observed in seven tumors (six head and neck, one breast) and 
affect the effector domain of RHOA. RHOA, is considered a gene encoding a protein that 
is clearly involved in cell proliferation (Lawrence et al., 2014). As for the case of RAC1, 
also RHOA shares its hotspots with other Rho subfamily members (these results are not 
reported in Figure 14 since only one mutation was found in our dataset). These genes 
include RHOH E39K for hotspot 60 and RHOC Y42C and RAC1 Y40S for hotspot 62. 
Both positions are still well conserved in the subfamily (Appendix Table 4).  
The analysis of the Rheb subfamily shows a significant number of mutations that fall in 
the hotspot 43. These mutations are mostly represented by Y35N hosted by RHEB and 
found present in Kidney Renal Clear Cell and Uterine Corpus Endometrioid 
Carcinomas in TCGA patients. Moreover, authors observed that mutations of RHEB 
(Y35N/C/H) increase phosphorylation of endogenous substrate S6 kinase (S6K1) of the 
mTOR signaling pathway (Grabiner et al., 2014), a protein kinase that plays key roles in 
cellular regulation (Wang and Proud, 2011). For the presence of the Y35N mutation, 
RHEB was recently highlighted as a novel cancer gene involved in cell proliferation 
(Lawrence et al., 2014), and cancer associated mutations in RHEB inducing mTORC1 
activity have been reported (Grabiner et al., 2014). The only other member of the 
subfamily (RHEBL1) shares a Y35H mutation in the same hotspot in one melanoma case 
in our dataset. 
4.2.4.2 Mutual exclusivity analysis 
In order to corroborate LowMACA results reported above, we performed mutual 
exclusivity analysis on significant mutations and hotspots. Mutual exclusivity between 
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mutations on genes of the same pathway is a critical measure to assess if the pathway is 
relevant for cancer. The reason is that after the first mutation occurs, there is no selective 
pressure for a second mutation in another gene of the same pathway (Vandin et al., 
2012). While generally performed gene-wise (Ciriello et al., 2012), the particular 
characteristics of LowMACA allow us to extend this concept to mutations that map on 
conserved residues within Pfam domains. If a putative driver mutation is found to be 
mutually exclusive with a known driver, its significance is enhanced as it possibly exerts 
the same function in cancer. We implemented mutual exclusivity analysis using the R 
package cooccur for a genomic analysis (Griffith et al., 2016), stratifying mutation data by 
tumor type. Our results revealed that hotspots in positions 16, 17, and 102 cover the 
large majority of mutually exclusive patterns (Figure 14, Panel A). This is a confirmation 
of the known exclusivity pattern of the mutations in KRAS and NRAS even among 
different positions within the genes themselves (Figure 15, right panel). In general, 
mutations in position 16 and 102 can be seen as a signature of two types of cancer: 
colorectal, characterized by KRAS G12, and melanoma, characterized by NRAS Q61 
(Figure 15, left panel) (Janakiraman et al., 2010). 
 
Figure 15 Mutual Exclusivity in the Ras Family. In these panels we show a plot representing the mutual 
exclusivity between mutations that fall in the same residue of individual proteins (left panel) and genes 
(right panel). Significant patterns are highlighted with the color corresponding to the tumor type where 
the exclusivity was found. We consider mutual exclusive the pairs with a corrected p-value below 0.05 
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using the R package cooccur. In the left panel we narrow down the patterns described in figure 1B, 
highlighting the major role of KRAS G12 and NRAS Q61. Notably, RAC1 P29 and RHOA Y42 (described 
in the main text as potential new driver mutations) retain a pattern of mutual exclusivity with NRAS Q61 
and KRAS G12, respectively. In the right panel it is possible to appreciate that mutual exclusivity between 
minor genes always occurs with the RAS trio. These genes cover many of the RAS subfamilies, in 
particular RAB3C (Rab subfamily), DIRAS2 and RRAS2 (Ras subfamily) and RAC1 and RHOA (Rho 
subfamily). 
 
These two highly frequent mutations allowed us to infer a possible driver role for less 
frequent mutations. For example, mutations in positions 26, 60 and 134 in colorectal 
cancer are mutually exclusive with position 16. Both hotspots are supported by this 
analysis in the Rab and Rho subfamilies. Similarly, position 102 is mutually exclusive 
with 26 and 35 in melanoma and 113 in thyroid cancer, further supporting the role of the 
aforementioned subfamilies. 
4.2.4.3 Comparison with functional impact tools 
We retrieved every amino acid substitution occurring in the RAS superfamily from the 
cBioPortal database (more than 10’000 different samples) and we annotated our 
predictions (if a mutation falls under a significant hotspot of LowMACA, as presented in 
the Ras superfamily analysis in section 4.2.4.1). The 2294 unique substitutions found in 
PF00071 cover 2264 positions and 130 proteins of the 133 RAS superfamily genes. 
LowMACA predicts as significant 150 mutated residues under 11 hotspots (Figure 14), 
which correspond to 215 different substitutions. We also annotated this dataset 
including the predictions of functional impact from 8 different tools using ANNOVAR 
(Wang et al., 2010). These tools include PolyPhen2 (Adzhubei et al., 2010), Mutation 
Assessor (Reva et al., 2011), Mutation Taster (Schwarz et al., 2014), SIFT (Sim et al., 
2012), MetaLR (Dong et al., 2015), LRT (Chun and Fay, 2009), FATHMM (Shihab et al., 
2013a) and RadialSVM (http://genomics.usc.edu/software/11-icages) and are aggregated 
in the dbNSFP database (Liu et al., 2013). The functional impact of an amino acid 
variation can be assessed in many different ways (across species conservation, 
stoichiometric similarity between original and substitute amino acid, change of protein 
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conformation etc.), but all the algorithms share a similar output, assessing if a mutation 
could be considered “tolerated” or “damaging”. We summarize this information as a 
damaging comprehensive score: the proportion of tools that predict the variation as 
damaging, ranging from 0 (all prediction as “tolerated”) to 1 (8 out 8 prediction of 
damaging mutation). In Figure 16, Panel A, we show how the 2264 positions are 
classified in terms of this damaging score. This score is calculated on the actual amino 
acid substitution and not on the position, so in case there are more possible variations, 
the median damaging score is considered (like in the case of KRAS G12 that can be 
substitute by V, A, K and other amino acids and a unique damaging score exists for every 
change). 
 
Figure 16 Comparison of LowMACA Ras mutations with functional impact tools. A) Distribution of 
damaging scores with respect to LowMACA classification in significant and non significant mutations B) 
Fraction of significant mutations in LowMACA for each class of damaging score. Damaging score is 
calculated as the fraction of dbNSFP tools (8 tools) that classify a specific mutation as damaging. 
 
There is a significant difference (p-value of the two tails t-test = 5.49e-08) between the 
score calculated on the positions not considered by LowMACA and those that fall under 
LowMACA hotspots. This can be interpreted as a positive concordance between the 
LowMACA predictions (based on actual data) on the RAS family and their impact on the 
protein they belong to as calculated by the dbNSFP tools. This simply means that in 
cancer, the most frequent mutations are also the most damaging. In Figure 16, Panel B, 
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we show how the predictions of LowMACA are distributed. The majority of our 
predictions fall beyond the majority voting of the tools (5/8 and higher). To better 
understand the difference between dbNSFP tools and LowMACA, we further annotated 
our dataset with four databases of manually curated variations in the human genome 
predicted as disease-associated. These four databases include two databases for disease-
associated variations, Humsavar (UNIPROT database of human polymorphism at 
protein level, www.uniprot.org/docs/humsavar), clinvar version 20140929 (Landrum et 
al., 2014) and two cancer-specific databases created by the Washington University, 
CiViC (Clinical Interpretation of Variants in Cancer, 
https://civic.genome.wustl.edu/#/home) and DoCM (Database of Curated Mutations 
http://docm.genome.wustl.edu/) . CiViC and DoCM are not published yet. We then test 
the predictions of LowMACA against the union of Humsavar and clinvar and against the 
union of CiViC and DoCM. In both cases, there is a significant positive association (p-
value << 0.01 and OR >>1) (Appendix Table 5), meaning that predictions made by 
LowMACA are strongly in accordance with known results. Furthermore, we can 
appreciate a good overall recall and accuracy against these databases: 74% (32/43) and 
95% (21/22) of recall for disease-associated and cancer-associated variants respectively 
with an accuracy of 15% and 10%. We performed the same analysis against those 
variants evaluated as damaging by more than 50% of the dbNSFP tools. Although still 
positively associated to pathogenic variations, the results are less striking (p-value 3.6e-
05 and 1.89e-03 for disease-associated and cancer-associated respectively). While still 
maintaining a good recall, the accuracy is extremely poor. This is not surprising since 
functional prediction tools are not intended to find mutations that actually occur in 
cancer or other diseases, but simply to assess if a possible variation could be harmful to 
the affected protein. LowMACA has the ability to discern those mutations that actually 
occur in patients, enhancing the accuracy of a true functional prediction. 
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4.2.4.4 Analysis of driver genes: comparison with available tools 
In this section, we analyzed the state-of-the-art driver genes identified with different 
bioinformatics tools under the lens of the protein families they belong to. In particular, 
we focused our attention on the 435 genes identified by a unifying approach as presented 
in (Tamborero et al., 2013b). In this study, driver genes are divided in two categories, 
291 High Confidence Driver (HCDs) and 144 Candidate Driver Genes (CDGs), 
according to several criteria, which include: 1) the number of bioinformatic tools that 
identify the gene as potential driver (5 tools were taken into consideration), 2) if the gene 
belongs to a list of manually curated cancer genes as provided by the Cancer Gene 
Census (CGC) (Futreal et al., 2004), 3) if the gene belongs to the same pathway in the 
KEGG database (Kanehisa et al., 2014). With this analysis we want to add address two 
questions: what Pfam domains are contained in driver genes and what are the candidate 
driver mutations shared between HCDs and CDGs according to LowMACA criteria. 
Since we are considering missense mutations, most of the tumor suppressors contained 
in the driver gene list will not be covered by LowMACA. In fact, tumor suppressors tend 
to lose their function during tumorigenesis and mutational landscapes are typically 
represented by sparse truncating mutations all over the gene body (Vogelstein et al., 
2013). In this case, no clear clusters can be seen at single amino acid level because for a 
gene to lose its protein function there are generally no preferential positions. 
Furthermore, many tumor suppressors are singletons in the Pfam database, in the sense 
that their main domain can only be found in the genes themselves or in few other 
members (e.g. P53 Pfam, PF00870, is only shared by three genes TP53, TP63, TP73, 
Suppressor APC, PF11414, belongs to APC and APC2 only). Nevertheless, highly 
mutated tumor suppressors like TP53, VHL, RB1 ARID1, PTEN and APC form actual 
hotspots that resulted significant in the LowMACA analysis (Zhao et al., 2013). To 
appreciate the full results, see Table S2 in (Melloni et al., 2016). Other known tumor 
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suppressors such as WT1, CEBPA or CDKN1A are instead missed by our analysis. The 
case of TP53 is particularly interesting as it tends to form clusters of missense mutations 
specifically on its P53 domain that probably exert oncogenic or dominant negative 
functions (Melloni et al., 2014). The fact that some tumor suppressors are identified and 
some are not depends in large part from the frequency of mutations. As the frequency 
increases, the sensitivity is enhanced and preferential positions of disruption emerge. 
Preferential mutation spots, even in tumor suppressors, are generally explained by 
possible dominant negative or oncogenic signature of certain tumor suppressors 
(Mahmoud et al., 1997; Papa et al., 2014) but also by a higher susceptibility to 
carcinogens of certain codons in these genes compared to other codons (Rivlin et al., 
2011). 577 different Pfam domains are covered by the driver gene list, approximately one 
tenth of the entire Pfam-A database: 440 in the HCD list, 223 in the CDG list and 86 in 
common (Figure 17, Panel A). To assess whether the overlap between the Pfam domains 
contained in the lists of CDG and HCD is greater than expected, we randomly sampled 
the same amount of genes that are contained in the two lists and measured the overlap of 
the contained Pfam domains. On average, we found a smaller overlap (57± 7), but also 
a smaller number of Pfam domains in the CDG-sized samples (194± 11) and in the 
HCD-sized samples (355± 15). 
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Figure 17 Other oncogenic Pfam families A) Venn diagram of the represented Pfam domains in the list 
of 291 high confidence drivers and 144 candidate drivers. A total of 577 different Pfam domains are 
covered by these genes with 86 Pfam domains shared between the two lists. B) Heatmap representation of 
significant Pfam domains in the “Kinase” network. Every row represents a patient of 17 different tumor 
types. A strong mutual exclusivity between tyrosine kinases, kinases and CH domain is shown. C) PI3K 
networks in driver genes. Every circle represents a distinct Pfam domain and the size represents the 
number of genes that contain the specified Pfam domain. Color indicates if significant hotspots were 
found in the LowMACA analysis (red is significant, green is not significant). Two domains are connected 
if they are found together on the same gene/protein. Edge thickness represents the number of genes that 
harbor both Pfam domains at the vertices (minimum 2). Blue color indicates mutual exclusivity and 
orange depicts significant co-occurrence. 
 
We conclude that driver genes contain more domains than the rest of the other human 
genes  (p=7e-9 and p=4e-3 for HCD and CDG, respectively, via z-test) but their overlap 
is not significant (p=0.38 via chi-squared test). The first two significant p-values can be 
interpreted as an expected enrichment in functional portions for the driver gene list 
compared to the rest of human genes. The not significant overlap instead could be 
interpreted as an enrichment of singletons caused by the great amount of tumor 
suppressors but also as a lack of connections between the two lists from the domain 
point of view. We performed LowMACA analysis in order to find significant hotspots of 
mutations at two different levels: 1) all the domains were analyzed by aligning the 
specific sequences of each HCD and CDG that harbors them and 2) the entire protein 
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was scanned for hotspots considering just its sequence, without any alignment. The 
second analysis was performed to look for protein-specific hotspots that could be found 
outside of the Pfam domains and to prevent the exclusion of genes that are not 
considered by the Pfam-A database (e.g. WT1). Obviously, conservation plays no role in 
this case. Our results identified hotspots of mutation in 11 out of the 137 Pfam domains 
that were found only in CDG (8%), 32 out of the 86 Pfam domains that were shared both 
by CDG and HCD (37%) and 188 Pfam domains that were found only in HCD (53%). 
The higher number of domains that were found significant in HCD compared to CDG 
reflects the increased number of mutations in each category. Overall, 52 out of 144 
candidates (36%) and 177 out of 291 drivers (60%) are supported by LowMACA 
analysis, either by single sequence analysis or Pfam analysis. Hotspots that are supported 
with single-sequence analysis (found in 140 genes for HCDs and in 35 genes for CDGs) 
highlight genes that do not need further support from Pfam companion genes for their 
identification. Pfam analysis added support to further 37 driver genes and 17 candidates. 
Compared to the number of genes identified on single sequences, the analysis of the 
Pfam domains increased the number of identified genes by 26% in HCD and by 50% in 
the CDG categories, reflecting the fact that LowMACA is particularly useful in 
identifying genes that mutate at low frequency. In fact, the major gain is found in the 
CDG category whose genes are typically less frequently mutated. To better characterize 
recurrence of Pfam domains within the CDG and HCD genes, we built a group of 
networks where vertices are Pfam domains and edges connect domains that are included 
together in at least two protein sequences (Figure 18).  
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Figure 18 Complete Network of Pfam domains harbored by driver genes. 577 different domains are 
included in the list of 453 driver genes from Tamborero et al. that are represented by each circle in the 
plot. In red, we highlight those Pfams that harbor at least one significant hotspot, in green those that 
resulted not significant. An edge connects two domains if at least two genes harbor both the Pfam domains 
at the vertices. Blue edges are drawn if the domains are mutually exclusive (Fisher test < 0.05 is light blue, 
< 0.01 is deep blue and OR < 1), yellow if co-occurrening (Fisher test < 0.05 is light brown, < 0.01 is orange 
and OR > 1), grey if not significant. Excluding domains connected by only one gene, 110 out of the 577 are 
represented in this figure. 
 
The three main connected graphs are represented by the “PkinaseTyr” network, the 
“PI3K” network (Figure 17, Panel C) and the “HelicaseC” network, which were named 
after their main hub. The “PkinaseTyr” network encompasses major oncogenes like 
BRAF, EGFR, FLT3 and ERBB2 for PF07714 (Pkinase_tyr, Additional file 2: Table S3 
highlighted in green) and STK11, CHEK2, MAPKinases (MAP3K1/3/4) and activin 
receptors (ACVR1B) for PF00069 (PKinase). We specifically analyzed the 10 domains 
which resulted significant with LowMACA and represent them as a heatmap (Figure 17, 
Panel B): mutated subjects in at least one of the Pfam sequences are depicted in red, 
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while subjects with a wild type domain are depicted in blue. For many tumor types, in 
particular bladder (BLCA, in black), breast (BRCA, in red) and colorectal (COADREAD, 
in orange), a clear mutually exclusive pattern is visible, where subjects with mutations in 
Pkinase have a wild type tyrosin kinase and vice versa (p=5.18e-60, Odds Ratio 0.26 
under Fisher exact test). In glioblastoma (GBM, in green), the majority of patients have a 
mutation on the Furin-like domain (PF00757), mutually exclusive with tyrosine kinases. 
The most studied missense mutation in this tumor type is in fact EGFR A289V/D/T, 
known for being resistant to anti-EGFR inhibitor used in lung cancer (Vivanco et al., 
2012). This alanine residue is perfectly conserved within the Furin-like domain among 
other epidermal growth factor genes and appears mutated also in ERBB2 and ERBB4, 
although not in glioblastoma. 
The “HelicaseC” network encompasses genes of various families, which are not strictly 
connected to each other at the functional level. The Helicase_C domain (PF000271) is 
the largest significant member of this module and encompasses HCDs as CHD4, 
SMARCA4 and ATRX with two highly conserved arginine residues mutated at low 
frequency in various tumor types. These mutations affect the corresponding arginine of 
CDH7, SMARCAD1 and DDX3X, which are considered as candidate drivers by the 
analysis of Tamborero and colleagues (Tamborero et al., 2013b). 
The “PI3K” network is instead a strictly interconnected module with a strong degree of 
mutual exclusivity between the domains that compose it (blue edges in (Figure 17, Panel 
C). The mutations in these Pfam domains belong for the large majority to three main 
HCDs (PIK3CA, PIK3CB and PIK3CG). In particular, PIK3CA is one of the most 
mutated genes in many types of cancers. The most relevant mutations appear to be in 
position 24, 27, and 28 of the multiple alignment of PF00613 (PI3Ka domain) that 
correspond to E542, E545 and Q546 in PIK3CA (Appendix Table 6). These mutations 
can be found conserved also in the other two HCDs at low frequency and a similar role 
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has been already assessed for PIK3CB (Pang et al., 2009). As we have shown, the overlap 
between Pfam domains in HCDs and CDGs is not significantly higher than expected 
from random sampling. This suggests that the current concept of driver genes could be 
biased due to inappropriate consideration of infrequently mutated genes within the same 
family. For this reason, we decided to extend our analysis to other possible candidates 
not present in the list of Tamborero et al. (Tamborero et al., 2013b) in the same way as 
we did for the Ras family. We thus analyzed all the proteins within the following Pfam 
domains: PF00794 (PI3K_rbd) PF00792 (PI3K_C2) PF00454 (PI3_PI4_kinase), PF02192 
(PI3K_p85B) and PF00613 (PI3Ka). These domains are all shared by the 3 
aforementioned HCDs and encompass the majority of their mutations. We found low 
frequency mutations in PIK3C2A, PIK3C2G and PIK3CD, other members of this kinase 
family, which were never considered as potential driver candidates before. The first two 
genes belong to the class II of PI3Ks and their role in human diseases is still unclear 
(Vanhaesebroeck et al., 2010). PIK3CD, instead, belongs to the same class I of 
PIK3CA/B/G and has been found amplified or overexpressed in cancer (Kok et al., 2009). 
4.2.4.5 Analysis of silent mutations 
We run as a negative control a LowMACA analysis using a database of silent mutations 
on the Pfam domains which were involved with a major role in the previous sections: 
Ras supefamily (PF00071), Pkinase_tyr (PF07714), Helicase_C (PF00271) and PI3Ka 
(PF00613). This analysis is aimed at assessing whether non-random pattern emerge from 
silent mutations. We downloaded TCGA data from TCGA original repositories and 
performed the analysis on this subset since the cBioportal database exclude silent 
mutations. The analysis of 676, 1144, 216 and 37 silent mutations that fall on the Ras, 
Pkinase_tyr, Helicase_C and PI3Ka, respectively, do not show any significant hotspot. 
On the contrary, 5 hotspots are identified in Ras domain, 10 in Pkinase_tyr, 2 in 
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Helicase_C and 3 in PI3Ka when analyzed with non-silent mutations (Figure 19). 
 
Figure 19 Barplots showing the stacking of silent and non-silent mutations within the 4 main Pfams 
discussed within the text (PF00071 - Ras superfamily, PF07714 - Pkinase_tyr, PF00271 - Helicase_C 
and PF00613 - PI3Ka). On the x-axis it is depicted the position in the global alignment, while on the y-
axis the mutation frequency of ach position. The blue dashed line represent the threshold of significant 
mutation frequency, which is different for each position of the global alignment. Bars above the dashed 
blue line are significant in terms of their p-vlaue. Red asterisks highlight the residues that are significant 
after Benjamini-Hochberg procedure for multiple testing correction of p-value, which is performed only 
on conserved positions (see Methods). For silent-mutations analysis, a database was collected from TCGA 
original repositories and supplied as external repository for LowMACA analysis (see software Vignette for 
further information). The analysis shows that no hotspots are identified in any of the Pfams checked with 
the use of the silent mutations database, while at least two hotspots per Pfam are identified when the 
repository of non-silent mutations is used (canonical analysis). In particular, 5 hotspots are identified in 
Ras domain, 10 in Pkinase_tyr, 2 in Helicase_C and 3 in PI3Ka. 
 
4.2.5 Discussion 
We developed LowMACA, a software aimed at characterizing low frequency mutations 
involving specific residues within the consensus sequence of protein families. 
LowMACA maps the mutations observed in different members of a protein family to the 
multiple alignment of the family members. The resulting consensus protein is suitable to 
summarize the mutation patterns of different proteins and increases the amount of 
information on functional domains and their possible role in cancer. All the mutations 
selected by LowMACA frequently fall upon specific positions of the consensus protein 
and these can be considered as “highly conserved” in cancer. 
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Moreover, we have identified patterns of statistically significant mutual exclusivity 
(mutex) among the identified mutations. The presence of these patterns helps to clarify 
the meaning of all the mutations belonging to specific pathways indicating exclusive 
roles of the involved genes in cancer. For example, the mutex analysis between RAC1 
and NRAS in skin melanomas (Figure 15) confirms the relevance of the role of RAC1, 
which is co-mutated with NRAS, in gain-of-function oncogenic GTP mediated events. 
The RAC1 P29L mutation has been experimentally expressed in C. Elegans neurons 
displaying defects in axon guidance and branching errors that were not seen in 
equivalent transgenic lines expressing wild-type Rac1. Loss of function of the Rac1 gene 
did not show any pattern of alteration of axon guidance, demonstrating that Rac1 P29L 
is a gain of function mutation (Alan and Lundquist, 2013). These results suggest that a 
sort of “code switch” between mutations in NRAS and in RAC1 occurs, probably 
generating different patterns of cell migration. Translating the experimental 
observations concerning RAC1 from a neuronal system to cancer is not straightforward. 
However, it is tempting to speculate that cancer can orchestrate a complex mechanism of 
choices depending on the environmental context where it develops. The mutex analysis 
between Rho members and the RAS trio in cancer represents an example of how one out 
of the many mechanisms underlying cell growth and metastatic processes can provide a 
selective advantage to cancer cells.  
The identification of mutex patterns concerning other proteins belonging to the Ras 
family suggests that beyond KRAS, HRAS and NRAS other minor genes, such as RRAS2, 
could play a “Ras-like” role in promoting pro-proliferative activity via the activation of 
the Raf-ERK pathway of MAP kinases (Gutierrez-Erlandsson et al., 2013) in uterine and 
cervical cancers (Figure 15). This finding supports the hypothesis that RRAS2 has a 
vicariant role in wild type KRAS cancers. Other mutual exclusivities have been observed 
between HRAS and RHOA, in head and neck squamous cell carcinoma (HNSC) and 
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between DIRAS2 and KRAS in colorectal cancer. The phenomenon by which minor 
proteins in a family domain can harbor the “same” mutations harbored by known 
drivers is observable also in other Pfam domains encompassed in the PI3K family. These 
findings highlight a possible role of minor members of this kinase family in cancer (e.g. 
PIK3C2A, PIK3C2G and PIK3CD). LowMACA allows focusing on this phenomenon and 
helps formulating a possible explanation: cancers cells that gain a selective advantage 
from major driver mutations in one type of cancer may gain a similar selective advantage 
from corresponding mutations in closely related proteins in other types of cancer where 
the related protein plays a prominent role due to tissue specific differences in gene 
expression or environmental constraints such as exposure to therapeutic agents. In 
extending LowMACA analyses to other Pfam domains we also demonstrated the 
existence of liaisons among genes considered high confidence drivers with other genes 
that are considered candidate drivers. The presence of low-frequency mutations in 
ERBB2 and ERBB4 that correspond to known driver mutations in tyrosine kinases such 
as EGFR, BRAF, FLT3 and JAK further strengthens this concept. 
Nevertheless, Ras subfamilies also show specific hotspots that reflect the subtle 
differences played by genes of each subfamily in cellular homeostasis. The Rho subfamily 
genes have roles in regulating cytoskeletal dynamics and deregulation of Rho proteins 
contributes to tumorigenesis and metastasis, while Ras subfamily proteins mainly 
function in regulating cell proliferation (Wennerberg, 2005). 
LowMACA is intended as an algorithm that emphasizes low-frequency mutations in 
genes containing a Pfam domain. Nevertheless, we cannot generalize this concept to all 
driver genes. For example, genes such as TP53, VHL, RB1 or APC, show distinct patterns 
of somatic driver mutations that are not shared by other members of their family (like 
TP63 and TP73 or APC2). These tumor suppressors should be considered as singletons 
and this characteristic underlines the difference between tumor suppressors and 
 101	
oncogenes. Thus, LowMACA is particularly useful for the identification of gain-of-
function mutations in putative oncogenic families. 
LowMACA emphasizes the role of genes mutated at minor frequency in cancer, which 
are often neglected by current analyses. The possibility to classify patients associated to 
signatures of low-frequency mutations identified by our software represents a promising 
route for future work. At the same time, a more accurate classification of driver genes 
may shed light on molecular mechanisms underlying cancer that until now were not yet 
considered. 
 
4.3 A knowledge-based framework for the discovery of cancer 
predisposing variants using large-scale sequencing breast cancer 
data.  
 
This last section of the results represents an attempt to apply a genomic-based approach, 
like the ones seen in the first two sections, to a typical case-control genetic study on 
exome sequencing data. What is generally performed in a genetic case-control 
framework is to seek for SNPs with a strong imbalance in terms of allele count between 
cases and controls, taking into account how rare or common is the SNP in the 
population. While this seems to be the most unbiased approach, it is hard to reach the 
required statistical power when using exome sequencing data because the number of 
SNPs to test is extremely high (possibly millions of tests) and the cost to reach an 
adequate sample size is impractical. What we know is that cancer has a double 
“mutation” mechanism. It is not only a familial disease but also a somatic disease, with 
changes in DNA at the somatic level that, as pointed out in Rhaman 2014, are 
substantially overlap with each other. At least half of the known cancer predisposing 
genes are also known somatic driver genes and that suggests that what we know about 
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the somatic changes can be used to get more insights into predisposition. The search of 
somatic mutations that correspond to germline variants was the starting point of this 
section that has been further expanded to design a complete framework for predisposing 
variants discovery. 
4.3.1 Abstract 
The landscape of cancer predisposing genes has been extensively investigated in the last 
30 years with various methodologies ranging from candidate gene to genome-wide 
association studies. However, sequencing data are still poorly exploited in cancer 
predisposition studies due to the lack of statistical power when comparing millions of 
variants at once.  
Here, to overcome these power limitations, we propose a knowledge based framework 
trained on the characteristics of known cancer predisposing variants and genes. Under 
our framework, we take advantage of a combination of previously generated datasets of 
sequencing experiments to identify novel breast cancer predisposing variants comparing 
the normal genomes of 673 breast cancer patients of European origin against 27,173 
controls matched by ethnicity. 
We detect several expected variants on known breast cancer predisposing genes like 
BRCA1 and BRCA2 and 19 variants on genes associated with other cancer types, like 
RET and AKT1. Furthermore, we detect 185 variants that overlap with somatic 
mutations in cancer and 50 variants associated with 41 possible loss-of-function-genes, 
including PIK3CB and KMT2C. Finally, we find a set of 19 variants as potentially 
pathogenic and negatively associated with age at onset that have never been associated to 
breast cancer. 
In this study we demonstrate the usefulness of a genomic-driven approach nested in a 
classic case-control study to prioritize cancer predisposing variants. In addition, we 
provide a resource containing variants that may affect susceptibility to breast cancer. 
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4.3.2 Introduction 
Breast cancer is one of the most common cancers with greater than 1,300,000 cases and 
450,000 deaths per year worldwide (Koboldt et al., 2012) and it is estimated that ~5-10% 
of women have germline mutations that lead to hereditary predisposition to breast 
cancer (Ripperger et al., 2008). Specific mutations in BRCA1 and BRCA2 are known to 
be responsible for inherited susceptibility to breast cancer in families with early-onset 
disease(Campeau et al., 2008). In particular, it has been demonstrated that the risk for 
first-degree relatives of an affected person is increased by two-fold and BRCA1/2 
mutation carriers account for just 20% of this enhanced risk (Ripperger et al., 2008). 
Mutations in other genes, such as PALB2, PTEN and TP53, have been associated with 
increased risk of breast cancer. Unfortunately, many familiar breast cancers (~50%) are 
still unexplained at the genetic level and many predisposing variants are yet to be found 
(Fachal and Dunning, 2015).  
Historically, beside the use of linkage analysis, which requires families with a penetrant 
phenotype, the analysis of candidate genes has allowed the discovery of the majority of 
well-known cancer predisposing genes (Rahman, 2014). Conversely, genome wide 
association studies (GWAS), which have been extensively used, have the ability to 
discover cancer predisposing genes on a genome wide scale with a pure data driven 
approach but suffer from lack of precision (Ward and Kellis, 2012). In fact, the results of 
GWAS can only indicate regions where the real pathogenic variants actually reside. The 
use of whole-exome sequencing (WES) and whole-genome sequencing (WGS) data, 
although able to overcome the aforementioned limitations of GWAS, has been poorly 
exploited due to power limits imposed by testing millions of variants simultaneously. 
Furthermore, Next Generation Sequencing (NGS) data are more expensive and less 
reliable in terms of accuracy of the genotype call, so that a statistical power comparable 
to the largest GWAS studies is technically unreachable (Zheng et al., 2013). Nevertheless, 
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WES or WGS have the advantage that they can identify rare variants that may influence 
cancer risk while the concept of linkage disequilibrium (LD) used by GWAS mainly 
relies on common single nucleotide polymorphisms (SNPs) with minor allele frequency 
(MAF) generally greater than 5%. Actually, we can hypothesize that only a fraction of the 
heritability can be ascribed to common genetic variants while rare variants can convey 
the remaining heritability (Kiezun et al., 2012).  
A straightforward case-control comparison on allele frequencies would be both 
underpowered and incomplete, since most rare potentially pathogenic variants would be 
excluded because they lack the required statistical power. Thus, we propose a 
computational framework that is trained on our knowledge of the characteristics of 
known cancer predisposing genes and variants. Under our framework, we studied the 
normal genomes coming from 673 breast cancer patients of European origin from The 
Cancer Genome Atlas (TCGA) against over 27’000 control genotypes unselected for 
cancer phenotype from the Exome Aggregation Consortium (ExAC) database with 
matched ethnicity (Figure 20). 
We filtered and integrated allele-counting comparisons with custom annotations coming 
from the state-of-the-art databases, somatic mutations data and GWAS studies to assess 
the probability of facing a true pathogenic variant. In particular, we take advantage of the 
characteristics of somatic driver genes (like their gain or loss-of-function) to emulate a 
candidate gene analysis. Cancer is in fact a unique case where disease causes and disease 
predisposition are strongly tightened, with a clear definition of gain-of-
function/oncogenes and loss-of-function/tumor suppressor genes (Rahman, 2014). 
Giving cancer unique characteristics, we were able to prioritize a set of genes and 
variants with a top-down approach in contrast to GWAS analysis: first, we isolate the 
best candidates through fine-mapping and second, we rank them using statistical 
analysis. 
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Figure 20 Workflow scheme for the whole analysis. Blue cylinders represent data (both obtained from 
available databases or processed during the analysis), hexagons are the analyzed datasets of cases and 
controls, while red squares and triangles represent analysis and output. Flag shapes represent post process 
annotation and statistical testing. Brown trapezoids represent the three main analysis branches presented 
in this paper. 
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4.3.3 Materials and Methods 
4.3.3.1 Control Data 
We used the aggregated results from the ExAC database (http://exac.broadinstitute.org/) 
as control population (Lek et al., 2016). This resource aggregates data from more than 
60’000 samples with germline genotype data, of which 33’370 were classified as of 
European origin. The original data source is both from population studies (1000 
Genome Project, HapMap, Exome Sequencing Consortium) and from disease related 
studies (including part of the TCGA). To overcome the overlap with tumor samples, we 
used the data cleaned from any cancer sample, for a total of 53’105 samples of which 
27’173 are of Caucasian origin. 
4.3.3.2 Case Data 
We downloaded from the TCGA (http://cancergenome.nih.gov/) the original BAM files 
of the normal sample for all the 695 women and men of Caucasian origin diagnosed with 
breast cancer. We used 673 (7 men and 666 women) out of the 695 samples discarding 
whole genomes and samples not derived from blood specimens. We analyzed the BAM 
files, following the exact same GATK pipeline and the same level of sensitivity used by 
ExAC (see section 4.3.3.4). We retrieved from the TCGA open access database, the 
available clinical information for these patients, including age and sex. 
4.3.3.3 Annotation Data 
To better characterize our variants, we took advantage of several external databases and 
in-house datasets for annotation. In particular, we used ANNOVAR to obtain 
information on gene, protein change, and type of variant (missense mutations, 
truncating mutations, InDels etc.) (Wang et al., 2010). Only variants found within the 
coding sequence and classified as non-synonymous were retained. ANNOVAR also 
annotated the variants with the 9 different tools for prediction of phenotypic effect 
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(SIFT, Polyphen2_HDIV, Polyphen2_HVAR, LRT, MutationTaster, MutationAssessor, 
FATHMM, RadialSVM, LR) that are included in dbNSFP (Liu et al., 2013). We 
summarized this information as a comprehensive deleteriousness score calculated as the 
proportion of tools that calls a particular variant as damaging or probably damaging. 
Finally, ANNOVAR provided information about the presence of the variant as a somatic 
mutation in the COSMiC database (Forbes et al., 2011) and if the mutation is present in 
the ClinVar database (Landrum et al., 2014). This information was integrated with 
custom annotations from other public resources. We integrated our annotation by 
checking for the presence of the variant in the cBioPortal database (Cerami et al., 2012) 
for the same amino acidic change and in other database of known disease causing and 
cancer related mutations: CIViC (https://CIViC.genome.wustl.edu), DoCM 
(http://docm.genome.wustl.edu/) and Humsavar 
(http://www.uniprot.org/docs/humsavar). These resources provided the evidence of 
overlap between our case variants and somatic mutation in cancer. The annotated genes 
were flagged if they belong to three categories according to biological and cancer related 
characteristics: genes known to be predisposing for cancer, genes known to be driver in 
cancer at somatic level and genes involved in DNA repair. The first list was created based 
on the most recent literature, including (Futreal et al., 2004; Rahman, 2014; Vogelstein et 
al., 2013; Walsh et al., 2010) and represents the state–of-the-art of the knowledge on 
cancer predisposing genes (323 genes). The list of known somatic drivers was created 
using an in-house tool for detecting driver genes (Melloni et al., 2014) and adding the 
most recent literature and state-of-the-art tools (Davoli et al., 2013; Dees et al., 2012; 
Futreal et al., 2004; Lawrence et al., 2014; Vogelstein et al., 2013) for a total of 413 genes. 
Finally a comprehensive list of genes involved in DNA repair was retrieved from (Lange 
et al., 2011) including 166 genes. In total, we considered as our target gene list a total of 
758 unique genes. In addition, we also tried to classify these genes as potential oncogenes 
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or tumor suppressors based on the joint results of (Davoli et al., 2013; Melloni et al., 
2014; Rahman, 2014; Schroeder et al., 2014; Vogelstein et al., 2013). The tools and 
literature used in this classification are the ones able to distinguish between tumor 
suppressor and oncogenes based on their mutational pattern or experimental results. In 
case of discordant results, the gene is considered both as tumor suppressor and 
oncogene. In total, we were able to classify 119 genes as oncogenes and 235 genes as 
tumor suppressors based on the results of both literature and bioinformatics algorithms. 
It is noteworthy that, when the same gene is found both as predisposing gene and 
somatic driver, known predisposing loss-of-function genes corresponds to somatic 
tumor suppressors and known gain-of-function genes to driver oncogenes. The extent of 
this overlap between cancer predisposing genes and somatic driver genes has been 
estimated to be over the 50% of the cancer predisposing genes list (Rahman, 2014). 
We retrieved a dataset of known breast cancer associated SNPs from GWAS studies 
included in the Human Genome Research Institute’s Catalog of Published Genome-wide 
Association Studies (version 2016-05-08) (Welter et al., 2014). A p-value of 5X10-8 was 
used as threshold. We manually selected the publications included in the catalog under 
the ontology “breast cancer” with a study in a fully European origin cohort during 
discovery phase and presenting SNPs associated with the disease and not with some of 
its characteristics. For example, we removed studies about drug resistance, 
chemotherapy adverse events or levels of proteins in breast tissue. These variants are not 
directly associated with the disease but represent a flag for a probable region where the 
disease-causing variant could be found. In total we collected a list of 130 SNPs from 23 
studies. Using HapMap recombination data (Frazer et al., 2007), we created the 
boundaries of such regions as all the DNA regions surrounding the GWAS SNPs below a 
recombination rate of 20 cM/Mb (Machiela et al., 2015). If one of our variants fall into 
one these regions, its distance from the flag GWAS SNP is annotated. In fact, there is no 
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direct relationship between physical distance and genetic distance but since we are inside 
low recombination regions, we can consider bp distance as a proxy for cM distance. 
4.3.3.4 Data Preprocess 
Case data preprocess was based on the whole GATK pipeline used by the ExAC 
consortium (Lek et al., 2016). This included Picard MarkDuplicates, local realignment 
around InDels, base quality recalibration, haplotype call, joint genotyping and variant 
quality score recalibration (http://picard.sourceforge.net/) (McKenna et al., 2010). Our 
pipeline included also splitting multiallelic sites and left aligning them both for case and 
controls in order to obtain a perfect match of Chromosome, Position, Reference and 
Alternative alleles. Working with biallelic sites is generally preferred, especially during 
annotation. A multiallelic site in fact, would have complete different variant effect 
according to the alternative alleles. The genotype call was retained if the genotype quality 
was higher than 20 and the depth of sequencing was higher than 10. Such filter was used 
to obtain robust genotype calls. Even if breast cancer is way more common in women 
compared to men, our case dataset is composed by 7 men and 666 women. We therefore 
fixed the ploidity for men on chromosome X in non-pseudo autosomal regions. For 
every heterozygous call, only the most probable allele was retained and one single allele 
was counted for every homozygous call. We used bcftools/vcftools, variant tools (vt) and 
in-house scripts (Danecek et al., 2011; Tan et al., 2015) to process the post-call data. 
We created a custom allele counting procedure so that for every biallelic variant, the 
reference count was constant for every possible alternative allele. This procedure is not 
standard but allowed us to test every alternative allele against the exact number of 
reference alleles called at the site and it is useful in case of filtering for any criteria 
because the number of reference alleles is never lost and we could easily re-aggregate the 
data to create a multiallelic test as explained in the Statistical Analysis section. 
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4.3.3.5 Statistical Analysis 
As mentioned in the introduction, statistical power is a critical issue in genome wide 
case-control studies. In particular, exome data are even more underpowered compared 
to GWAS since potentially millions of variants can be tested at a time. The initial call 
from all the 673 samples included millions of variants that were filtered to keep only 
coding and non-synonymous events. Since we did not perform any imputation and we 
applied a strict quality filter after the raw calls, retaining only exonic variants was the 
best way to maximize coverage in a dataset composed for the large majority by exome 
sequencing data (including all cases). At this point, we divide the testing procedure into 
different branches (Figure 20): 
1. Frequency and annotation based analysis 
2. Loss-of-function gene-wise testing 
3. Age-dependent polygenic modeling 
4.3.3.5.1 Frequency and annotation based analysis 
The frequency and annotation based analysis is made up of simple annotation and 
filtering step-wise procedure (as summarized in Figure 22). Rare (control MAF below 
1%) non-synonymous variants were retained and only the ones with a case MAF greater 
than the control are kept. Subsequently, only damaging mutations with a deleterious 
score of at least 0.5 (majority of tools for prediction of phenotypic effect considering the 
mutation as damaging) were selected. The pipeline is then divided in two branches. On 
one side (left arm of Figure 22) we sought for those variants that classified as somatic in 
any type of tumors using COSMIC and cBioPortal databases. On the other side, we took 
into consideration only variants that fall into LD blocks of previously annotated breast 
cancer associated SNP in GWAS studies. 
4.3.3.5.2 Loss-of-function gene-wise testing 
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The LOF testing is a gene-wise test that seeks for imbalance in allele count in truncation 
events between cases and controls. In this testing procedure, we looked for truncations, 
frame shift InDels or nonsense mutations that retain by definition a higher probability of 
creating a loss-of-function event. In this context, we wanted to emulate the way driver 
somatic tumor suppressors genes are generally discovered, using the frequency of any 
rare truncation controlled by the same frequency in control cohort (Davoli et al., 2013; 
Melloni et al., 2014; Vogelstein et al., 2013). We first filtered out common events (over 
5% in the control cohort) and then we performed, for every variant, a simple one-tail 
fisher count test between minor/major allele count between cases and controls. For every 
gene, we aggregated all the p-values obtained from the tests using Stouffer method 
(Stouffer S et al., 1949) to obtain a single value per gene. In this procedure a weight that 
is proportional to the inverse of control frequency, was applied so that the more a variant 
is rare, the higher is the weight applied in the aggregation step. Finally, we retained only 
genes belonging to our target gene list with an FDR corrected p-value below 0.05.  
4.3.3.5.3 Age-dependent polygenic model 
The Age-dependent polygenic model branch is instead a stepwise procedure. Like for the 
LOF procedure, we calculated a minor/major fisher count test variant-wise between 
cases and controls, including all variants, without applying any filter to the MAF of the 
control cohort. For multiallelic sites, reference and alternatives composed a matrix of 
2*(n+1) where 1 represents the reference counts and n the number of different 
alternative alleles. A bootstrap version of fisher test was used in this case. The calculated 
p-values were added as an explanatory variable in the step-wise procedure. We also run 
other commonly used human genetics statistical tests to be added as explanatory 
variables, both gene-wise and variant-wise. Using RVtest, we were able to run SKAT-O, 
CMC, Kbac tests for the gene-wise level and Wald and SingleScore tests for the variant-
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wise level (Zhan et al., 2016). All the aforementioned tests used the 1000 genome original 
genotype calls as control cohort, since we need the full genotypes in order to run them 
and they were not available for the ExAC database. 
The workflow is composed by: 
1) Creating a set of variants that accounts for every variation in our case samples 
reported as pathogenic in at least one of the following databases: Humsavar, 
DoCM, ClinVar or CIViC. Variants were further subset for a manually curated 
list of cancer related keywords. This list included both direct cancer or neoplastic 
events predisposition as well as cancer related syndromes (like Li-Fraumeni or 
Von Hippel Lindau syndromes) for a total of 38 variants in 24 different genes 
(Appendix Table 7) 
2) Creating a set of negative controls from the list of ClinVar annotated variants that 
have been tested as non-pathogenic. 
3) Implementing a random forest classifier using a dichotomous response variable 
(pathogenic, non-pathogenic) with a training set that included all the variants in 
point 1) and 2) (Breiman, 2001). The features used for classification are reported 
in Figure 23 and included all the tests described above, MAF in cases and 
controls, number of homozygous and heterozygous calls, deleteriousness score 
and a dummy variable describing if the variant was a truncation event or a simple 
missense variant. A tree based algorithm like the random forest is particularly 
powerful in problems where the interaction of various features is a critical point 
for the model. The output of this analysis was the relative number of trees 
classifying a variant as pathogenic. We call this score Pathogenicity Score. 
5) The variants that did not belong to the training set were selected and we filtered 
for the ones that show a Pathogenicity Score of at least 0.5 (majority voting in the 
random forest procedure) 
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6) The final step of the model was to correlate our variants with the age at initial 
pathological diagnosis. The variants found at point 5) switched from being subjects to 
become explanatory variables with a value of 0, 1 and 2 according to the state of double 
major allele, heterozygous or homozygous minor allele. With such a dataset, we build a 
robust elastic net linear model by running 100 models in parallel under various subsets 
of the dataset (Zou and Hastie, 2005). This procedure guarantees that the average beta 
values and the number of times a feature is in all the elastic net models remain stable. A 
penalized linear model like the elastic net is preferable for its ability of assessing the 
direction and the magnitude of the contribution of each variant. In the case of the age for 
example, we are interested in understanding what are the variant with a negative beta or, 
in other terms, the ones that contributes to the decrease of age at onset. Considering that 
a male patient has a risk of getting cancer one hundred times less than a female of the 
same age, a male patient age is rescaled with a logit function in order to correspond to 
the same risk of a younger woman. To build the risk function at age classes, we used data 
from the Cancer Research UK report 1996-2011, available at 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/breast-cancer. 
4.3.4 Results 
4.3.4.1 Pathogenic and Breast Cancer Related variants 
We first asked whether known breast cancer predisposing variants were present in our 
dataset. We collected from the literature a list of 17 known breast cancer susceptibility 
genes (Table 6) (Rahman, 2014; Vogelstein et al., 2013; Walsh et al., 2010). We expected 
to find some pathogenic variants in these genes, as they comprise a part of the known 
genetic cause of breast onset. 
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Gene 
Somatic 
Driver 
Gene 
Total 
Number of 
variants 
Number of 
Pathogenic 
Variants 
Number of 
Truncating 
Variants 
Number of highly 
damaging 
mutations 
ATM X	 21	 		 		 5 
BRCA1 x	 18	 2	 		 3 
BRCA2 X	 21	 5	 		 2 
BRIP1 		 5	 1	 		   
CDH1 X	 3	 1	 		   
CHEK2 x	 6	 2	 1	   
MRE11A 		 4	 		 		 1 
NBN 		 5	 1	 2	   
PALB2 		 1	 		 		   
PRKAR1A 		 		 		 		   
PTEN X	 		 		 		   
RAD50 		 5	 		 		   
RAD51C 		 3	 		 1	   
STK11 x	 3	 		 		   
TP53 X	 4	 		 		 1 
Table 6 List of the most important breast cancer predisposing genes and variants found in our case 
dataset. The second column reports if the gene is considered also a somatic driver gene (breast cancer 
somatic driver genes are reported with a bold capital X).  Other columns report the number of non-
synonymous variants found in total, the number of variants considered pathogenic and the number of rare 
truncating variants (control minor allele frequency below 1%) that are not already included in the list of 
pathogenic variants. The last column shows instead all the missense variants that are not considered 
pathogenic with a very high deleteriousness score (8/9 tools to predict functional damage report the 
variant as damaging). Our pathogenic reference is ClinVar and Humsavar databases. 
 
Considering both known pathogenic and truncating variants on these 17 genes (Table 6), 
we obtained a total of 16 different mutations that cover 36 out of 673 of our cases (~5%). 
We decided to take into account also rare truncating variants because they are generally 
considered de facto pathogenic when the gene exerts its oncogenic function via loss-of-
function. This is the case for all the known predisposing genes in breast cancer and, in 
general, for the large majority of Cancer Predisposing Genes (CPGs) (Rahman, 2014). 
The frequency of the identified variants in the breast cancer dataset is compatible with a 
sample of sporadic cases, especially given the fact that many potential pathogenic 
variations are still not reported in databases like ClinVar (Landrum et al., 2014). 
Furthermore, the complete lack of any variation on PTEN and PRKAR1A can be 
explained by the rarity of finding mutations on these genes. The cancer syndromes 
connected to these genes (Cowden Syndrome and Carney Complex) are in fact 
extremely infrequent in the population: the first has an incidence of 1 in 200’000 
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individuals (Hobert and Eng, 2009), the latter a total prevalence of few hundreds 
reported cases (Stratakis et al., 2001). It is noteworthy that 8 out of 15 of the genes 
reported in Table 6 are also known somatic driver genes and 5 of these 8 genes are 
specifically considered driver in breast cancer. All of them are predicted or possess 
tumor suppressor functions. The second question we asked was whether other cancer 
pathogenic variants could be found in our case dataset. It is in fact known that many 
cancer predisposing genes can lead to complex tumor syndromes in which more than 
one tumor type can arise (Rahman, 2014). Known examples are the aforementioned 
BRCA1 and BRCA2 that are linked to both breast and ovarian cancer (Petrucelli et al., 
2010) or the more recent discovery of PALB2, connected to breast and pancreatic tumors 
(Jones et al., 2009; Rahman et al., 2007). We therefore seek for all those variants 
connected to additional cancer or cancer syndrome genes and we found 28 different 
variants on 24 genes. Among them, the 19 variants with a control MAF below 1% are 
reported in Table 7.  
Variant	
Control	
MAF	
Case	
MAF	
log2	MAF	
Ratio	
Summary	of	ClinVar	and	Humsavar	
Annotation	
COL7A1	-	R1538C	-	
(3,48619779,G,A)	 0.002%	 0.07%	 5.35	 Malignant	Melanoma	
RET	-	V804M	-	(10,43614996,G,A)	 0.017%	 0.54%	 4.96	 MEN2A	Syndrome|Thyroid	Carcinoma	
AKT1	-	E17K	-	(14,105246551,C,T)	 0%	 0.08%	 4.47	 Colon	Ovary	and	Breast	Cancer	
FANCC	-	R185*	-	(9,97912338,G,A)	 0.006%	 0.07%	 3.76	 Fanconi	Anemia	
FLCN	-	H429fs	-	(17,17119708,-,G)	 0.054%	 0.70%	 3.68	 Renal	Cell	Carcinoma	
MSH6	-	T955fs	-	(2,48030639,-,C)	 0.213%	 2.61%	 3.62	 Lynch	Syndrome	
ELAC2	-	R741H	-	(17,12896274,C,T)	 0.072%	 0.23%	 1.66	 Prostate	Cancer	
RET	-	Y791F	-	(10,43613908,A,T)	 0.244%	 0.69%	 1.50	 MEN2A	Syndrome|Thyroid	Carcinoma	
FLCN	-	R239C	-	(17,17125879,G,A)	 0.033%	 0.08%	 1.20	 Renal	Cell	Carcinoma	
PKHD1	-	T36M	-	(6,51947999,G,A)	 0.075%	 0.15%	 0.98	 Colorectal	Cancer	
GALNT12	-	D303N	-	
(9,101594229,G,A)	 0.185%	 0.30%	 0.72	 Colorectal	Cancer	
PRF1	-	N252S	-	(10,72358722,T,C)	 0.501%	 0.82%	 0.72	 Non-Hodgkin	Lymphoma	
SDHD	-	G12S	-	(11,111957665,G,A)	 0.992%	 1.04%	 0.07	 Cowden	Disease	3	
TSC1	-	H681Y	-	(9,135779052,G,A)	 0.561%	 0.52%	 -0.11	 Neoplastic	Syndrome	
AR	-	R727L	-	(X,66937326,G,T)	 0.083%	 0.07%	 -0.16	 Prostate	Cancer	
SDHD	-	H50R	-	(11,111958677,A,G)	 0.975%	 0.82%	 -0.25	 Cowden	Disease	3	
MUTYH	-	Y165C	-	(1,45798475,T,C)	 0.256%	 0.15%	 -0.78	
MYH-associated	polyposis|Endometrial	
Carcinoma	
APC	-	R396C	-	(5,112154969,C,T)	 0.155%	 0.08%	 -1.00	 Gardner	syndrome	
ASCC1	-	N290S	-	(10,73892817,T,C)	 0.173%	 0.07%	 -1.22	 Esophageal	Carcinoma	
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Table 7 List of rare cancer-related pathogenic variants (control MAF below 1%). This list includes 
all those genes that are not considered breast cancer predisposing but are connected to other types of 
cancer or cancer syndromes. 
 
Although only 13 variants out of 19 have a minor allele frequency in the cases higher 
than controls, the results from this simple annotation are quite unexpected. For example, 
we found COL7A1, a collagen gene linked to epydermolysis bullosa that is a severe skin 
syndrome with elevated life-time risk of melanoma (Martins et al., 2009). MAF 
frequency in our dataset is at least 1 order of magnitude higher than in controls. We also 
detected two variants on RET, a gene connected to MEN2A syndrome with an extremely 
high penetrant risk of thyroid cancer (Eng, 1999) that to our knowledge has been 
connected to breast cancer at the level of expression and thus as a possible therapeutic 
target (Morandi et al., 2011). Evidences of a connection to another thyroid cancer related 
syndrome (MEN1) have been recently demonstrated in breast cancer (Dreijerink et al., 
2014), but a suggestion to a link to MEN2A is completely novel and it would represent 
an unusual case of an gain-of-function mutation linked to breast cancer risk. 
Interestingly, we identified 3 truncating or frameshift alterations on FANCC, FLCN and 
MSH6, three loss-of-function genes respectively associated to Fanconi Anemia (as 
PALB2, BRCA1 and RAD51C reported in Table 6) (D’Andrea, 2010), renal cell 
carcinoma (Stamatakis et al., 2013) and Lynch Syndrome (Baglietto et al., 2010), with no 
previous direct connections to breast cancer. Lastly, we discovered AKT1 E17K, a variant 
linked to many cancer types, including breast cancer, at the somatic level. It is reported 
in databases such as ClinVar or OMIM (that are generally focused on hereditary genetic 
traits) because it is considered a high frequency somatic driver mutation (Bleeker et al., 
2008). This gene has also been connected to a minority of Cowden Syndrome cases along 
with PIK3CA because it belongs to the same pathway as PTEN, whose mutations are 
causative of 85% of the cases (Hobert and Eng, 2009). This variant is particularly relevant 
because it represents both a case of gain-of-function mutation in a breast cancer 
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oncogene that is frequently seen somatically mutated in tumors and also a risk associated 
germline variant in our dataset.  
 
Figure 21 Distribution of pathogenic and truncating variants on breast cancer genes in our case 
dataset of 673 breast cancer patients. This oncoprint plot reports three classes of high confidence breast 
cancer predisposing genes (rows) and each column represents one of the samples with at least one of these 
mutations. In blue, we report variants on known breast cancer predisposing genes (complete list in Table 
1). A star is reported if the variant is a truncation but is not reported as pathogenic in databases ClinVar or 
Humsavar. Otherwise the variant is present in these databases. Pathogenic variants that affect genes related 
to cancer or cancer syndromes but are not strictly listed as breast cancer pathogenic are reported in black 
and include genes like RET (thyroid cancer) or APC (colon cancer) 
 
To summarize our findings, we draw a heatmap of all the aforementioned variants in our 
dataset (Figure 21). If we sum up all the cases with at least 1 of these mutations, we 
approximately cover the 20% of our dataset with 19 non breast related pathogenic 
variations, 12 pathogenic breast related and 4 truncating variants on breast CPGs. It is 
noteworthy, that MSH6 alone covers the 5% of patients, although the MAF is much 
lower because this calculation considers also missing genotype calls and heterozygous 
and homozygous calls. We can also notice that co-occurent mutations are quite rare: 
only 13 out of 135 samples have more than one variant, while the remaining 122 are hit 
by a single variation. Furthermore, variant frequency in the dataset is extremely 
unbalanced: the top 7 variants in Figure 21 cover the 15% of the patients while the 
remaining 28 the missing 5%. 
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4.3.4.2 Analysis of rare variants in target cancer genes 
The most simple and straightforward way of prioritizing predisposition candidates is to 
look at rare variants, which can be defined as variants with MAF < 1% in the controls. 
We concentrated our efforts on non-synonymous variants (~70’000) and we filter for 
rare variants where the prevalence in the cases is higher than controls, retaining only 
~50’000 variants (see Figure 22).  
 
Figure 22 Analysis of rare variants. This flowchart represents the step-wise procedure in the central arm 
of Figure 20 and is performed by filtering from 73544 coding non-synonymous variants to 16014 rare 
variants (MAF < 1%) with a deleteriousness score over 0.5 and where MAF in the cases is higher than 
controls. Rare variants are prioritized into two branches: on the left variants falling in GWAS breast cancer 
LD blocks are retained, on the right, variants overlapping with cancer somatic mutations from COSMIC or 
cBioPortal are reported. For both datasets, overlaps are reported at the initial level and after filtering for 
variants belonging to our list of 758 target genes (known cancer predisposing genes, known somatic driver 
genes and DNA repair genes). Final common list of 6 variants on our target gene list that was found both 
as overlapping with somatic mutations and falling into a GWAS LD block is reported. 
 
Then, we filtered out variants with a deleteriousness score lower than 0.5 or, in other 
words, where 4 or less of the 9 methods included in dbNSFP evaluated the variant as 
possibly damaging (see section 4.3.3.5.1) (Liu et al., 2013). The dataset at this is point is 
composed by over 16'000 variants to prioritize and we look for two specific 
16’014 	
With Deleteriousness Score 	
Higher than 0.5	
52'276	
With Case MAF > Control MAF 	
59'575	
rare variants (control MAF < 0.01)	
73'544	
coding non-synonymous variants	
437	
falling	in	
GWAS	breast	
cancer	
associated	
SNP	blocks	
2441	
Variants	
overlapping	
with	somaBc	
mutaBons	185	
variants	
belonging	to	
Target	
Genes	
73	 2368	364	
Overlap	p-value:	0.19	
6	 178	13	
TET2	–	4:106164793T,C	
NF2	–	22:30069387,C,T	
RAD51B	–	14:68352609,G,A	
RAD51B	–	14:68352608,C,T	
EP300	–	22:41574637,	C,T	
EP300	–	22:41573050,T,G	
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characteristics: we explored what are the rare variants that overlap with cancer somatic 
mutations and we also check if some of them fall into regions of low recombination 
(thus, possible LD) with breast cancer associated SNPs from GWAS studies to further 
confirm our results. We used COSMIC and cBioportal databases to create the largest set 
of somatic variants from WGS and WES studies, including over 50 different tumor 
subtypes, and we look for a perfect match between our variants and these somatic 
mutations (Forbes et al., 2011; Gao et al., 2013). To create GWAS blocks we designed 
regions around 130 manually selected SNPs from the NHGRI-GWAS catalog (see 
section 4.3.3.3) (Welter et al., 2014). 2441 variants on 16'000 are also found somatically 
mutated from cBioPortal database or COSMIC database. Among those matched 
variants, only 73 falls into GWAS regions over a total of 437 (Figure 22 and Appendix 
Table 8).  The overlap of these two groups is apparently random as this is not 
significantly different from a bootstrap of random overlaps (p-value of permutation Z 
test = 0.19). This result suggests two important aspects of this section: first, the missing 
enrichment of somatic mutations in GWAS associated regions confirmed the results of 
Machiela et al. (Machiela et al., 2015) and secondly while GWAS are designed to work 
on common variants, somatic mutations are usually rare. Thus these two types of 
analysis represent two different layers of hereditability. 
Since somatic mutations in cancer are mainly passenger, a simple overlap with a somatic 
mutation cannot suggest a real involvement in cancer predisposition (Vogelstein et al., 
2013). Therefore, we decided to further subset our 2441 SNPs to include only variants on 
a list of manually curated target genes (see section 4.3.3.3) with a higher probability of 
being real drivers. Only 6 variants in 4 genes ended up having all the characteristics 
included in this analysis. These variants form a list of highly valuable candidates (Figure 
22) as theorized by one of the ICOGS flagship paper (Michailidou et al., 2013). In 
particular, RAD51B is a known breast cancer associated gene (Golmard et al., 2013) 
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TET2 variant discovered in our dataset is only ~80kb away from an ICOGs SNP 
rs9790517. In addition, TET2 has already been associated with breast cancer at the RNA 
level (Yang et al., 2015b) and it is considered a known somatic driver in leukemia and 
melanoma (Ficz and Gribben, 2014). Another ICOGs variant (rs132390 on EMID1) is in 
a low recombination region along with NF2 R335C variation. NF2 has been associated to 
the hereditary neurofibromatosis syndrome 2 and mutates both at germinal and somatic 
level in breast cancer (Schroeder et al., 2013). The same ICOGs SNP has been found in 
LD with CHEK2, a known breast cancer associated gene. Although our HapMap data do 
not support this linkage disequilibrium, we found a variant on this gene (rs201206424) at 
approximately the same distance as the NF2 variant described above (~400kb) 
(Michailidou et al., 2013). This CHEK2 variant has also been found as somatically 
mutated in breast cancer. Two different alterations were found on EP300 in LD with the 
ICOGs SNP rs6001930. EP300 has a well-established role as a tumor suppressor but it is 
poorly investigated as a breast cancer predisposing gene (Gayther et al., 2000). 
Excluding the aforementioned 6 SNPs, 37 variants are monomorphic in the ExAC 
database that represents our control (Appendix Table 9). The first positions sorted by 
MAF ratio are occupied by truncating variants on PIK3CB, KMTC2 and NBN. The first 
two genes are known somatic drivers, and in particular the second one has also been 
classified as a tumor suppressor (as the truncating mutation suggests). The same genes 
will be considered, as a whole, as significant loss-of-function genes in the next section of 
the results (see section 4.3.4.3). NBN instead, has been already associated with increased 
risk of breast cancer via the Nijmegen syndrome being part of an important DNA repair 
pathway (Varon et al., 1998). Nevertheless, the specific frameshift mutation found 
(I166fs), has never been associated with this syndrome before but has been found 
somatically mutated in breast cancer using our annotation. The most relevant result of 
this analysis branch is probably the variant E17K on AKT1 (rs121434592) that has been 
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already described in the previous section. This gene is a known somatic driver kinase 
and this mutation has been found in 46 different samples in the cBioPortal database in 
many different tumor types, including breast. E17K is also reported by CIViC and 
DoCM databases list of curated somatic driver mutations (Bleeker et al., 2008). This 
variant, along with ATM R337C (rs138398778) is reported in the list of cancer hotspots 
curated by Chang et al. (Chang et al., 2016) and they both represents a case of known 
somatic driver mutation that can be considered a cancer predisposing variant. In 
addition, we found other germline variants present in more than 2 samples in COSMIC 
or cBioPortal on the following genes: HNF1A, FGFR3, ASXL1. Interestingly, all these 
genes are included in our list of cancer predisposing genes or somatic driver genes and 
none of them has been connected to breast cancer predisposition before. 
4.3.4.3 Analysis of loss-of-function genes 
We decided to focus on possible loss-of-function genes involved in predisposition to 
breast cancer because the large majority of cancer predisposing genes are in fact recessive 
loss-of-function variants (Rahman, 2014). In particular, we wanted to explore the 
existing overlap between somatic driver tumor suppressors and loss-of-function 
predisposition to breast cancer following a somatic driver gene discovery pipeline as 
discussed in the previous section. It is known that truncating mutations plays a major 
role in targeting potential tumor suppressors (Vogelstein et al., 2013), so we selected 
from our dataset only the truncating variants under a softer filter of frequency of 5% in 
the control population, for a total of 2522 different truncating events on 1931 different 
genes. On this reduced dataset, we looked for imbalance between control and case 
frequency in any of the truncation spots with a gene-wise testing procedure (see section 
4.3.3.5.2). After testing and correcting for false discovery rate, we filtered for candidate 
genes in our 758 target gene list to seek for really potential overlapping 
driver/predisposing genes and to emulate a candidate gene analysis. Only 94 genes have 
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at least one truncating variant with a frequency in control cohort below 0.05, of which 41 
passed the p-value threshold (Appendix Table 10). As a proof of concept, known breast 
cancer predisposing genes like BRCA1, BRCA2 and CHEK2 are in fact selected by our 
procedure. Other known breast cancer predisposing genes, such as TP53 or PALB2, are 
instead not found truncated in our dataset because they are too rare for our detection 
power in a non-familiar selected dataset (Table 6) (Antoniou et al., 2014). Nevertheless, 
TP53 has one missense variant included in the list of the 176 overlapping with somatic 
mutations and this particular variant has never been reported as pathogenic before 
(rs138729528), being completely novel in our control dataset. Among the 41 significant 
LOF candidates, FGFR3, PIK3CB, HNF1A and KMTC2 were also highlighted as 
somatically mutated by the previous analysis but in this case we were able to add a 
defined loss-of-function role. In addition, another member of the homeobox family 
(HNF1B) has one of the lowest p-values. This gene has been connected to predisposition 
to ovarian cancer, but no association with breast cancer has been previously described 
(Shen et al., 2013). With similar characteristics, we found the anaplastic lymphoma 
kinase (ALK), a known driver gene and predisposing gene in lung cancer and 
neuroblastoma, with few evidence of association with breast cancer (Siraj et al., 2015). 
The majority of the genes in this list harbor 1 to 2 different truncation points. CRIPAK 
appears to be a particular exception with 27 different truncations in various point of the 
gene body. This abundance of frameshifts and non-sense variants at various points of the 
protein can be partially explained by the fact that CRIPAK is intronless and like other 
genes with this feature (like CDR1 or AD7C-NTP) it tends to accumulate these variations 
for evolutionary reasons (Okamura et al., 2006) and is probably a false positive result.  
4.3.4.4 Polygenic age-dependent model 
In the last section of the results, we moved from a pure case-control study to a more 
association-like study. In all the previous analysis, we always put a filter on the 
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frequency, selecting rare (control MAF < 1%) or low frequency variants (control MAF < 
5%). In this analysis, exploiting a trait that can be considered complex as age at 
pathological diagnosis, we used every non-synonymous variant in our dataset (Figure 
20). As explained in section 4.3.3.5.3, we implemented a double step machine learning 
approach composed by 1) a tree-based classification with variants as subjects 
(dimensionality reduction step) 2) a penalized linear model regressing age to the 
genotypes of the cases, so that the variants become now covariates (feature selection 
step). In the first step, the final goal is to assign a “Pathogenicity Score”, or in other 
words, a probability value that represents how similar to the prototypes in the training 
set and far from the negative set our variants are. These two sets are represented by 
known pathogenic variations and a series of variants tested as simple polymorphisms. 
An interesting side effect of the procedure is also that we could assign a score of 
importance to the features that are responsible for the classification machinery. We 
started with a dataset of prototypes (our training set) composed by 38 pathogenic and 
706 non-pathogenic variants (see section 4.3.3.5.3). The overall model on the training 
set reports a very low out-of-bag error of 3.5% in the classification process with an area 
under the ROC curve of 0.84 (see Figure 23, Panel B). 
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Figure 23 Polygenic age-dependent model breakdown. A) The feature rank of the Random Forest model 
according to the mean decrease of Gini index is reported. At the top, the most important variable is 
deleteriousness score (see Panel C). B) ROC curve on random forest training model. An AUC of 0.84 is 
reached under the supervision of the training dataset formed by reported pathogenic and non-pathogenic 
variants according to a dataset of curated cancer predisposing variants. C) The top predictor in our 
random forest model is reported without the influence of the other variants. Although it cannot represent 
the real tree scheme of the model, there is a clear positive trend between increased deleteriousness score 
(X-axis) and the number of trees classifying a variable as pathogenic (Y-axes). Furthermore, the 
pathogenic score starts increasing after the 0.56 threshold (5 over 9 predictors of phenotypic effect 
classifying the variant as damaging). 
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Using this algorithm, we could learn the main characteristics of pathogenic and non-
pathogenic variants, as shown in Figure 23, Panel A, and we used these characteristics to 
classify a test set of unknown variants. The mean decrease in the Gini index represents 
the ability of each feature to separate the class pathogenic from the non-pathogenic as 
the amount of homogeneity gained after each node split that contains the feature under 
exam. Using our random forest model, we then classified the unknown variants in the 
test set. We tried to represent the behavior of each top feature in the classification 
problem by comparing the feature value with the corresponding probability of 
pathogenicity assigned by the random forest model. This probability is calculated as the 
proportion of trees that classify the variant as pathogenic in a total of 100’001 trees built 
in the training procedure. For example, the random forest model has the tendency of 
assigning high probability to more deleterious variants, as a clear linear trend is visible 
between deleteriousness and RF score assignment (see in Figure 23, Panel A). In fact, the 
majority of the known pathogenic variants (the red dots) fall into the top two 
deleteriousness score category compared to the non-pathogenic variations (the blue 
dots) that appear to fall in every category without a specific pattern. Interestingly, the 
results of widely used test of associations like SKAT or SingleScore do not seem to 
provide sufficient adherence to pathogenic variations, according to the Gini Index 
ranking (Figure 23, Panel A) and justify our use of a more genomic and knowledge-
based approach rather than a pure statistical method. However, to develop the random 
forest model, the prototypes we used for pathogenic and non-pathogenic variants are not 
exclusively breast-related and have no direct connection to our dataset. Thus, we decided 
to define the variants as features that could be associated with patient characteristics.  
If we used the whole dataset, we would end up with a matrix in form of 673 samples (one 
for each patient) and more than 70’000 features (one for each variant). This model would 
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suffer from a heavy curse of dimensionality. In order to reduce the number of features 
entering in this second clinical model, we set a standard threshold of 0.5 in the 
pathogenicity probability coming from the random forest that allows a high level of 
specificity (almost 100%) while still retaining a good sensitivity (~60%). This threshold 
allows retaining a variant with some evidence of being pathogenic and discarding the 
majority of non-pathogenic noisy variants. A variant is retained in the clinical model if: 
1. The Pathogenicity Score is greater than 0.5 (majority voting in random forest 
procedure) 
2. It is not part of the training set 
With this filter we ended up with 4045 variants entering in the second step and therefore 
reducing the risk of an inflated dimensionality. The model we used for the polygenic 
analysis is a robust elastic net. More details about the procedure can be found in section 
4.3.3.5.3. We run a regression model of age at initial pathological diagnosis to the 
genotype of our subjects. The controls are therefore not included in this procedure. 
While in the first procedure the output was represented by the Pathogenicity Score, in 
this case we ranked the features (now the variants) as being negatively associated with 
age. The result of the elastic net model can be influenced in case the number of subjects 
is lower than the number of features (4045 variants as features and 673 age values as 
subjects). That is why we used a permutation based multi model that allows a robust 
ranking. Furthermore, like any other shrinkage method, not all the features are retained, 
in order to reduce the degrees of freedom of the model. The variants are ordered by the 
number of time a feature is retained in the model with a negative beta since the higher 
the number of times, the lower the age when the variant is present. Final results include a 
list of 19 variants retained in at least 10% of the 100 models, of which 15 with a negative 
beta in more than 50% of the 100 models (Table 8). 
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Variant	 Approved	Name	
Control	
MAF	
Case	
MAF	
Protein	
Change	
Mean	Beta	
ElasticNet	
Negative	Beta	
Percentage	
MRPL24	-	1,156708335,C,T	
mitochondrial	
ribosomal	protein	
L24	 0.0000%	 0.074%	 W54*	 -2.78	 1.00	
CST4	-	20,23667825,-,C	 cystatin	S	 0.0129%	 0.300%	 V81fs	 -5.09	 1.00	
PARD6A	-	16,67696278,C,T	
par-6	family	cell	
polarity	regulator	
alpha	 0.0018%	 0.078%	 R256*	 -1.86	 1.00	
TRIOBP	-	22,38121788,-,C	
TRIO	and	F-actin	
binding	protein	 0.0059%	 0.471%	 S1075fs	 -3.64	 1.00	
ZNF85	-	19,21132125,C,T	 zinc	finger	protein	85	 0.0000%	 0.085%	 R205*	 -4.36	 1.00	
FOXP4	-	6,41553185,A,G	 forkhead	box	P4	 0.0018%	 0.091%	 K147R	 -8.04	 1.00	
PKHD1	-	6,51890490,A,C	
polycystic	kidney	and	
hepatic	disease	1	
(autosomal	recessive)	 0.0000%	 0.075%	 M1373R	 -5.33	 1.00	
SURF1	-	9,136218808,A,T	 surfeit	1	 0.0000%	 0.081%	 L179Q	 -6.49	 1.00	
HIST2H2AB	-	1,149859084,TT…GT,-	
histone	cluster	2,	
H2ab	 0.0000%	 0.074%	 T121fs	 -3.59	 0.97	
STIM2	-	4,27004586,G,A	
stromal	interaction	
molecule	2	 0.0000%	 0.081%	 V281I	 -1.65	 0.97	
CPA3	-	3,148597632,C,T	
carboxypeptidase	A3	
(mast	cell)	 0.0000%	 0.074%	 R178*	 -5.47	 0.94	
TMCO3	-	13,114188422,-,G	
transmembrane	and	
coiled-coil	domains	3	 0.0326%	 0.742%	 A469fs	 -1.93	 0.93	
SERPINF2	-	17,1649022,CCTG,-	
serpin	peptidase	
inhibitor,	clade	F		 0.0000%	 0.080%	 A62fs	 -1.74	 0.84	
PYGL	-	14,51383751,G,A	
phosphorylase,	
glycogen,	liver	 0.0037%	 0.149%	 R276C	 -0.08	 0.71	
FNIP2	-	4,159790466,C,A	
folliculin	interacting	
protein	2	 0.0016%	 0.101%	 S893*	 -0.86	 0.58	
CPPED1	-	16,12758817,G,A	
calcineurin-like	
phosphoesterase	
domain	containing	1	 0.0000%	 0.074%	 R149*	 -0.14	 0.44	
OR52B4	-	11,4388943,G,A	
olfactory	receptor,	
family	52,	subfamily	
B,	member	4	
(gene/pseudogene)	 0.0018%	 0.076%	 R195*	 4.81	 0.09	
SCN10A	-	3,38755496,G,A	
sodium	channel,	
voltage	gated,	type	X	
alpha	subunit	 0.0037%	 0.074%	 R1155C	 1.62	 0.08	
ZNF683	-	1,26694960,G,A	
zinc	finger	protein	
683	 0.0000%	 0.089%	 R35*	 1.18	 0.03	
Table 8 Results from the polygenic age-dependent model. A double-step machine learning algorithm 
selects variant based on a series of pathogenic prototypes and then further selects them using a 
permutation based multi-model regression over age at onset. Variants in this set are negatively associated 
with age and are divided in three layers: on top, variants negatively associated in at least 80% of the models 
and with an average beta less than -1.5, in the middle, variants retained in at least 40% of the model with 
poor average beta, at the bottom, variants found negatively associated only in a few model. 
 
We noticed several desired features of the final set of variants. First, without imposing a 
filter on the control MAF, we selected for rare variants in the population, so that all our 
19 variants have a MAF in the control set way below the 1% threshold and a MAF in the 
cases above the corresponding one in the controls. Furthermore, more than a half of 
these variants are completely novel in the ExAC dataset. Second, 13 of the 19 variants are 
classified as truncation events and all the other 6 missense events have a deleteriousness 
score higher than 0.8, thus evaluated as almost certainly damaging. Lastly, another 
confirmation of the importance of evaluating somatic events overlapping with germline 
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mutations is the fact that we noticed a double enrichment in variants found also as 
somatic.  
Among the initial dataset of 73’354 variants, only the ~13% of them are found as somatic 
events in COSMIC or cBioPortal. After the random forest procedure, this frequency 
increases up to ~17% among the 4045 retained variants (p-value of binomial test: 8.78e-
11) and after the elastic net selection to the ~26% (although not significant, 5 of the 19 
variants are also found as somatic).  
None of the genes found using this procedure belong to the list of target genes nor are 
found within breast cancer associated SNPs low recombination regions and there are 
very few literature reports of a known involvement in cancer, making their selection a 
completely novel finding (Table 8). Excluding variants on TMCO3, TRIOBP, PYGL and 
CST4, all the remaining 15 involved one single sample in our dataset, therefore so rare 
that any simple statistical approach would probably not detect them. Like briefly 
mentioned before, this set of variants and genes are mostly not involved in cancer, except 
for PKHD1, a gene involved in polycystic kidney disease and a high risk of renal cancer 
that has also been mentioned in the first section of the results for another known 
pathogenic variant (Sharp, 2005). Other genes reported in Table 8 with some evidence of 
cancer involvement includes STIM2, which have been associated to allelic loss in 4p in 
several tumor types, including breast (Shivapurkar et al., 1999) and FOXP4, an 
important member of the forkhead box transcription factor that are widely known to be 
involved in tumorigenesis and cell-growth (Myatt and Lam, 2007). Although not directly 
implicated in tumorigenesis, other genes appears to be promising candidates being part 
of families involved in cancer, including SERPINF2, a member of serpin family that has a 
clear role in cancer cell survival (Valiente et al., 2014) PARD6A, member of the PAR 
family, involved in cell cycle gatekeeping and interactor of other major cancer pathways 
like MAPK and PI3K (Marques and Klefström, 2015) and finally HIST2H2AB, part of 
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the cluster 2 of histones whose parallel family in cluster 1 is highly mutated in many 
cancer types (Lawrence et al., 2014; Timp and Feinberg, 2013) 
4.3.5 Discussion 
The use of NGS technologies has revolutionized the study of human cancers by allowing 
the simultaneous identification of multiple somatic mutations but it can also offer the 
possibility to look for the presence of cancer susceptibility variants and 
genes. Interestingly, taking advantage of sequenced normal genomes of cancer patients, 
recent studies have suggested that the susceptibility due to rare variants in sporadic 
cancers can be much more common that previously anticipated (Schrader KA et al., 
2016). However, it remains challenging to determine the pathogenicity and the clinical 
significance of these germline variants since many of them are rare and not well 
characterized. Our study represents one of the first attempts to prioritize germline 
variants that may predispose to breast cancer using sequencing data.  
We developed a computational framework based on the characteristics of somatic 
mutations to identify putative cancer predisposing variants. In particular, we provided 
an analysis of rare variants and we detected 185 variants that overlap with somatic 
mutations in cancer. Furthermore, we carried out an analysis of truncating mutations on 
suspected tumor suppressors, revealing known and new possible loss-of-function 
candidates. We detected 50 variants associated with 41 possible loss-of-function-genes, 
including PIK3CB and KMT2C. Lastly, we built a robust age-dependent polygenic model 
that involves a mixture of supervised and regression based algorithm to uncover variants 
at any frequency level. With this model, we identified a set of 19 variants potentially 
pathogenic and negatively associated with age at onset belonging to genes that have 
never been associated to breast cancer. Furthermore, we checked if any of the identified 
candidate variants falls into GWAS known breast cancer susceptibility regions. 
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In our study we detected several expected variants on known breast cancer predisposing 
genes like BRCA1 and BRCA2, which are a confirmation of the validity of this study. We 
also identified 19 variants on genes that are known to be predisposing for other cancer 
types or cancer syndromes, like RET and AKT1, that have never been previously 
associated with breast cancer predisposition. 
To our knowledge, there are few examples in the literature attempting an analysis on 
predisposing genetic makeup in cancer that exploit sequencing data (Kanchi et al., 2014; 
Lu et al., 2015). While these works design an in depth analysis of known predisposing 
genes, they lack of a sufficiently extended control dataset, using respectively ~400 normal 
controls against a dataset of ovarian cancer cases of approximately the same size (Kanchi 
et al., 2014) and ~1000 samples against ~4000 cases of various cancer types (Lu et al., 
2015). The use of the ExAC database, that comprises over 27'000 control samples, 
allowed a higher resolution that we emphasize at the level of the single variants within a 
candidate predisposing gene, discerning variants of scarce significance from true 
candidate pathogenic variations. Furthermore, we introduce more variables in our 
knowledge-based approach, including also over 20 years of breast cancer GWAS data 
and patients' characteristics like age of onset. In particular, the latter information is used 
as a new explanatory variable to further enlarge our set of candidates beyond the limits 
of already known cancer-related genes and not only as a confirmation of association 
between early onset and known predisposing genes. 
We know that our analysis have several limitations. First, to improve our understanding 
on the association of rare variants to breast cancer hereditability, we should sequence a 
larger number of individuals and possibly extend our analysis to other ethnicities. For 
example, we should use an independent longitudinal cohort to clarify the prevalence of 
the identified variants or a smaller cohort of suspected familial cases. Secondly, genomic 
data could be associated to patients’ family history, since in the TCGA clinical data this 
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information is missing. Lastly, we have provided a valuable resource of potential new 
cancer-related variants that could be characterized from a functional point of view.  
In this study we have developed a genomic-driven approach able to prioritize cancer 
predisposing variants using a case-control genetic scheme. We demonstrate the use of 
public available sequencing data to better characterize known susceptibility genes and to 
identify novel cancer predisposing variants. The opportunity to classify individuals 
according to their risk of developing hereditary-based cancer, will improve clinical 
management of breast cancer patients in terms of genome-tailored prevention strategies, 
programs for early diagnosis and possible treatments. 
5 Discussion 
Although each section is independent from each other, this work has a clear common 
background and objective. As anticipated in the introduction, one of the most important 
targets of NGS genomics was to create a sort of catalogue of what is driving cancer in 
human. The three sections can be therefore summarized in 3 sentences: 
1. Distinguish driver genes from passengers and divide them in tumor suppressors 
and oncogenes (section 4.1) 
2. Focusing on oncogenes, expand the reservoir of cancer genes by finding 
connections in secondary structure between proteins. Even very low mutation 
frequency could have a functional meaning by transferring knowledge between 
proteins (section 4.2) 
3. Apply an approach similar to the first two sections to a dataset of germline 
variants (section 4.3) 
The common thread in fact, despite the type of data, either somatic or germline, remains 
the hunt for cancer genes and to distinguish driver mutations or pathogenic variants 
from passenger mutants. Since the first articles about genome-wide mutation profiles in 
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cancer (2006-2007), the necessity of a clear picture for each tumor type cancer gene has 
become a major challenge in cancer genomics, in particular under the grand design of 
the personalized medicine field. As anticipated in section 2.5, from the bioinformatics 
point of view, the real game changer was the possibility to obtain sufficient data to reach 
statistically meaningful conclusion. Around 2013, when a sufficient amount of the 
TCGA data was made available, it was soon realized that even hundreds of samples were 
not sufficient to disentangle the extraordinary heterogeneity in the mutational spectrum 
of the various cancer types. In particular for highly unstable and fast-mutating tumor 
types like melanoma or lung cancer, where variability is even more accentuated. In the 
course of a few years, the subject of distinguish drivers from passengers will probably 
drying over because we are probably reaching a point of saturation of what can be 
discovered through this data and techniques. It is true of course that we lack of a 
sufficiently large sample size to overcome the variability issues but it also true that the 
first genomic and personalized based clinical trials have shown poor results and this 
should be the fundamental reason behind this research field (Tourneau et al., 2015). 
What is probably still missing is the knowledge around other level of the same kind of 
data. For example, the lessons learnt from the TCGA experience (a project that is now at 
its conclusion) could be applied to data from metastases, where mutational spectrum is 
even more elusive than the primary and only small size studies have been published. 
Another very close field that could benefit from driver and passengers analyses is the 
clonal evolution field and how mutations evolve and spread in that layer of heterogeneity 
that is called intra-tumor. The “discovery phase” on primary tumors has probably 
reached its peak, but the entire experience and tools could be transferred to new areas of 
interest.    
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5.1 Driver gene discovery 
At the time DOTS-Finder was conceived, there was already an explosion of interest in 
creating tools for driver discovery. Our vision of mutational process, in fact, is the result 
of a long evolution of DNA from normal cell up to point of sequencing. The order of the 
events is unknown and particularly hard to reconstruct, since what we know from exome 
or genome sequencing is a snapshot of a heterogeneous tumor at a precise moment in 
time. The need of statistical methods to distinguish noisy passenger mutations from 
important drivers was therefore a necessity to understand how a tumor evolved, what 
pathways were mainly involved and ultimately, how to restore the normal phenotype. 
Many approaches were already present that tackled this problem from various angles 
(frequency, position of mutations, severity of the mutations, etc.) but an overall view was 
evident. Driver genes can be elusive if mutated at very low frequency, so that a positional 
approach that tries to check for mutational pattern, rather than mutational frequency, 
have proven to be a very effective compared to simple frequency based methods (see 
section 4.1.2). In fact, the research of patterns of mutations sounds more “ratiometric”, 
although statistically more disputable, since it relies on a clear side effect (or better the 
original cause) of oncogene and tumor suppressor behavior. Nevertheless, there is a 
plethora of other factors to take into account, like length of the gene, position of the gene 
along the genome, expression levels, replication time. The positional approach, in this 
sense, is less greedy in terms of required information because it closes the gene in its own 
environment and do not need the estimation of a global background mutation rate. 
Expression or replication time data are not necessary and gene length is taken 
automatically into account. Nevertheless, it is not sufficient to distinguish all oncogenes 
and tumor suppressor, so that’s why we implemented the two-step approach.  
In section 4.1.5.11, we show instead one of the main feature of DOTS-Finder. Compared 
to our best competitor (MutSigCV), DOTS-Finder is superior in terms of accuracy and 
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recall when subsets of various sizes are used instead of all the available data (Lawrence et 
al., 2013). This feature allows calling driver genes even in a situation of scarce evidence of 
not being passenger. Large sequencing studies like TCGA encompass thousands of 
patients of the most common tumor types, but rare tumors do not have the same 
amount of free data, both for a difficulty in finding patients diagnosed with that 
particular disease but also because of smaller investments compared to major tumor 
types like breast or lung cancer. Driver discovery tools are not particularly useful in 
everyday bioinformatics work, because they represent the very final step of an analysis 
on mutation data that is hardly performed more than once. Furthermore, a tool that 
needs hundreds of samples to reach a sufficient statistical power becomes useful only for 
very large and expensive studies. Pilot studies with sample size around 20-30 patients are 
way more common and so DOTS-Finder can become handy in situations like these. 
Another important point that has been emphasized during DOTS-Finder development is 
both the small amount of data preprocessing in order to run the tool and very little 
system requirements. DOTS-Finder was originally developed in python but soon we 
realized that R could overcome certain mathematical passages more easily (in particular 
related to oncogene and tumor suppressor scores) and python was used mostly as a shell 
for the whole architecture. MutSigCV, for example, is written in Matlab, which is not 
freely available. Moreover, tools like MuSiC or OncodriveFM require demanding input 
file or a certain amount of data preprocessing that we specifically avoid (Dees et al., 2012; 
Gonzalez-Perez and Lopez-Bigas, 2012). MuSiC, being in fact only a part of a larger 
toolset, can only work with the original BAM files that are both hard to obtain in many 
cases and more difficult to manage compared to VCF or MAF. OncodriveFM instead 
requires calculations of SIFT and Polyphen2 scores and therefore requires a non-
standard input format. DOTS-Finder tries to overcome such difficulties requiring a 
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standard MAF input file (see section 4.1.4.2) and uses python under virtualenv and R 
implementation with very few dependencies. 
The creation of this tool was therefore powered by i) the need of a more comprehensive 
approach to discover cancer driver that could be superior to the sum of its parts ii) 
simplicity, in the sense that the data required to run the tool is minimal iii) to create an 
instrument that could be really used for a pilot study on a few cases. 
5.2 Oncogenes and driver mutations discovery 
LowMACA was born under different premises compared to DOTS-Finder. The first 
attempt at the realization of this tool was having the possibility to characterize families of 
proteins rather than unique genes. Driver discovery tools are generally aimed at a global 
analysis on a set of specific samples but they lack the possibility to interrogate a specific 
set of genes given all available knowledge across tumor types. LowMACA set up uses a 
list of genes and Pfam IDs as input and mutation data are collected for the requested 
input only. Compared to DOTS-Finder and other similar tools, this tool is indeed way 
more usable on a regular basis. In the same way a web resource can be useful to check the 
mutations of a specific gene, LowMACA was created under a similar concept. What we 
did was to rely on a web resource (the cBioPortal) that updates constantly its database, so 
that mutations could be downloaded on the fly to check for potential driver mutations 
(Gao et al., 2013). What is new in LowMACA is the possibility to aggregate genes under 
the same Pfam or on other criteria and align them to form a new consensus protein 
where all the mutations of the original genes are remapped. Again, usability is a crucial 
point like it is for DOTS-Finder, but switching the input data from mutation to genes 
makes it even more appealing from the standing point of a usage on the long run. For 
LowMACA, the whole implementation was packed in an R library in order to maintain 
compatibility with the database package cgdsr from cBioPortal. Furthermore, an 
accompanying data package was implemented too, that greatly simplify the task of 
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searching for families of genes. The entire Pfam along with Uniprot is automatically 
available to the user and a perfect one-to-one match between gene symbols and 
canonical proteins was created to uniform sequence databases and dictionaries (Finn et 
al., 2007; Gray et al., 2014; The UniProt Consortium, 2014). Moreover, a Shiny 
implementation of the package was created outside of the Bioconductor repository that 
further simplifies the possibility of an on-the-fly analysis. A completely web-based 
implementation was in fact discarded as a viable possibility because the calculations 
performed by R are sometimes too complex and time consuming to fit usual web timing. 
LowMACA also introduces a few new ideas into the driver discovery universe. In 
particular, being an aggregating method, it tries to overcome the limits of rare mutation 
boundaries. A very simple but effective analysis of what is in fact the required sample 
size to be confident enough to distinguish any driver from passenger can be found in 
(Lawrence et al., 2014). The statistical power of MutSig (and by inference of any other 
driver discovery tool) is inversely proportional to the mutation rate of the specific tumor 
type, so that a tumor like melanoma, with a very high number of mutation per patient 
would require thousands of sequenced cases to be completely saturated in term of driver 
genes discovered. LowMACA, by aggregating mutational profiles, represents a sort of 
shortcut that has been proposed in various forms in recent years, in particular via 
pathway or network analysis (Ciriello et al., 2012; Vandin et al., 2012). The advantage of 
LowMACA over pathway analysis is that the position of the mutation is retained and 
doesn’t lose its meaning. This allowed us to be able not only to collect information over 
driver genes but also on driver mutations, finding connections between genes that are 
not clearly visible unless the sequences and mutational profiles are blatantly similar (see 
the case of KRAS, NRAS and HRAS). In fact, the special case of the RAS trio served as a 
proof of concept that a similar mechanism do exists and that mutations are also cancer 
specific in terms of gene and position (see section 4.2.4.1) within the same gene (a 
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particularly interesting case is represented by EGFR in lung and brain tumors, as shown 
in section 4.2.4.4). Nevertheless, there are certain limitations. LowMACA, for example, 
uses an amino acidic dictionary based on secondary structure connections. This choice 
creates a series of inherent biases, that can be summarized as i) the Pfam database, based 
on predicted similarities given by an HMM model ii) the alignment algorithm that could 
get stuck in local minima, in particular in the case of hundreds of sequences aligned at 
the same time iii) the difficulty of judging the alignment goodness of each single base. 
Under this view, pathway analysis does not suffer from these biases, since it works on a 
more biological level that is constituted mostly by literature findings and partially by 
predicted connections. For example, in the case of HotNet2, an efficient network-based 
driver discovery tools, the pathway architecture is not even superimposed (Leiserson et 
al., 2015). It is the algorithm itself that creates the network reducing any source of 
external bias caused by erroneous database entries. These drawbacks are therefore 
insurmountable in case we want to investigate single mutations using secondary 
structure similarities and a couple of safety nets have been implemented. First of all, the 
Valdar score can be fine tuned according to user specification in order to accept a 
minimum level of similarity for each base aligned (Valdar, 2002). Secondly, the 
possibility to aggregate mutations using a Gaussian density was borrowed from the 
oncogene score of DOTS-Finder framework without any imposition on the choice of 
bandwidth (in DOTS-Finder, the bandwidth was set with Silverman’s rule of thumb 
(Silverman, 1986). Both Valdar score and bandwidth can be easily changed in the Shiny 
based application following user specifications. 
As explained above, LowMACA is dedicated to exploratory analysis rather than 
deterministic results like normal driver discovery tools, as many parameters can be used 
at the same time to fine-tune the results. In particular the choice of which are the genes 
to align is of paramount importance. In the section dedicated to RAS family we show a 
 138	
way to overcome the limits of Pfam by using literature to separate a large family (around 
130 different proteins) into more homogeneous subfamilies, mixing de facto secondary 
structure similarities with defined biological functions. Three possible follow-ups of this 
work come from this possibility: 
1. Deconstruct Pfam families following other criteria or even implement a more 
stringent HMM to create user-defined families. For example, subdividing large 
families into more biologically meaningful clusters, like we did for the RAS 
superfamily. 
2. Implement new dictionaries, for example using amino acid motifs. In this case 
the sequences to align become shorter and as a result, families increase in size. 
3. Changing alphabet. Amino acids are convenient to work with because there 
exists an intrinsic stechiometric similarity that facilitates alignment evaluation. 
Furthermore, databases such as GenBank or Pfam are a useful precompiled 
resource. Using directly genomic regions based on nucleobases alphabet, other 
kind of structures can be analyzed, in particular outside of the coding region, like 
for example, binding site motifs. 
Even though LowMACA was able to show connections between proteins via their 
mutational patterns, it does not answer to the question of why a gene mutates way more 
frequently than others in the same family. This is the case of the RAS family too, where 
KRAS is the leading gene and all the others follow. If the structure and the function are 
the same or at least very similar, why KRAS mutates and RRAS2 does not? We think 
there are at least three possible scenarios to disentangle this question that involve the 
probability of mutation and the function of the proteins: 
1. If the probability of mutation is constant in the family and the function of all the 
proteins is truly interchangeable, it could be a matter of expression. A mutation 
on KRAS or RRAS2 could be seen with same probability but the selective growth 
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advantage is much stronger in the first case because KRAS is more expressed and 
its oncogenic potential is greater. This explains the fact that KRAS (ubiquitously 
expressed) is mutated in many cancer types, including pancreas, lung and colon, 
while NRAS is typically found in melanoma and leukemia (Downward, 2003). 
2. The probability of mutation is constant but the function is slightly different. 
Although the RAS trio shares ~85% of their protein sequence, if the function is 
different so it is their oncogenic potential. This could be true both at wild type 
level and in the mutated form. It has demonstrated, for example, that NRAS and 
HRAS are not essential for mouse embryonic development while KRAS knock-
down showed embryonic lethality (Johnson et al., 1997). Furthermore, drugs 
developed on HRAS models showed no effect on KRAS mutations, confirming 
different behaviors also in the mutated form (Baines et al., 2011). 
3. The probability of mutation is different from gene to gene. While this is certainly 
true, because mutation rate depends on replication time, expression and 
upstream epigenetic factors (Lawrence et al., 2013), these differences were seen 
on large portion of the genome and it is probably hard to demonstrate for genes 
within the same family. 
5.3 Bridging the gap between genetics and genomics 
As briefly mentioned in the introduction of this final discussion, the scope of section 4.3 
was an attempt at bridging the gap between genetic and genomic analysis. Broadly 
speaking, the two main categories of genetic studies can be summarized as case-control 
(our case) and trait association studies. Case-control genetic studies follow a scheme 
starting from statistical evaluation of variants enriched in cases compared to controls 
and subsequently fine-maps variants with a biological meaning. This is certainly a 
rigorous approach from the statistical point of view but it has its drawbacks. Sample size, 
for example, is a crucial point because the more positions are tested the higher is the 
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probability to find false positive results. In the same way, rare pathogenic variants are 
more prone to be called as false negative because of their scarce odds to find them. Rare 
variants play an important role in disease predisposition because they are generally 
associated with penetrant phenotypes. Genomic studies, on the other hand, do not 
always follow such scheme. Often, a knowledge-based approach that exploits ontologies, 
pathways or simply literature enters in the decision process of highlighting relevant 
results from the very beginning of the study. These information sources could be used as 
simple filters to retain the best candidates for the analysis or in other cases through what 
we can call an “approach by prototypes”. This methodology is based on previous 
knowledge on how a predisposing gene or variant should present (the prototypes) and 
searches for all the variations that are as closed as possible to known pathogenic events. 
At the same time, variants that are proved not to be pathogenic can be used as a negative 
control. This is not any different from any machine learning approach with a training 
and test set. 
As mentioned in section 4.3.2, our approach wants to use a typical genomic (knowledge-
based) approach applied to genetic data. Using regular genetic techniques is not 
particularly indicated with exome sequencing data and up to the date, very few examples 
have proven to work on cancer data (see section 4.3.5). Both the examples reported 
(Kanchi et al., 2014; Lu et al., 2015) used a sort of pre filtering technique, in particular to 
show the ability to highlight genes like BRCA1 or BRCA2 that are known CPGs and are 
usually tested via small target sequencing panels. Most of their results, however, are 
aimed at pinpointing genes rather than variants. On the contrary, we wished to maintain 
a variant-wise approach (that is way more informative as it highlights potential 
pathogenic variations), but that comes at the cost, again, of losing statistical power. We 
therefore tried to move a step forward and add new layers of complexity to the problem. 
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Under our framework, only coding non-synonymous variants are retained and various 
genomic-style methodologies are used: 
1. Use variants that overlap with somatic mutations, in known driver genes, with a 
high deleteriousness score (see section 4.3.4.2 and 4.3.3.3). This approach is 
based on the assumption that what is seen in cancer as somatic could probably be 
harmful in the germline too. Passenger mutations are possibly filter out using the 
knowledge from what are the driver gene candidates (Rahman, 2014) and a 
prediction of damage based on the estimation of phenotypic effect (Liu et al., 
2013) 
2. Select truncating variants on tumor suppressor candidates, which is a technique 
borrowed from DOTS-Finder, adapted to take into account a case-control 
scheme that is not present when dealing with somatic mutations only 
3. Develop a hybrid approach based first on selecting those variants that have 
characteristics similar to known pathogenic variants (prototype approach). Use 
the genotype of the selected variants like an association trait study, by running a 
regression over age at disease onset (GWAS-like approach) 
In the same way as LowMACA represented a shortcut for a lack of sufficient sample size 
when dealing with rare somatic mutations, this approach can be seen as a shortcut to 
overcome the same lack on different data. The 673 cases we used in this study are orders 
of magnitude smaller than GWAS studies on cancer like the COGs consortium that 
comprises over 200’000 genotyped samples (Sakoda et al., 2013). In fact, an approach 
based on alignment that emphasizes oncogenes (gain-of-function) rather than tumor 
suppressors (loss-of-function) was also hypothesized in the early phase of this analysis. 
Unfortunately, there are potential pitfalls in following this approach: 
• While oncogenes are common in cancer, they are very rare in the germline. A 
part from a few cases (like for example RET), at least 90% of known cancer 
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predisposing genes are in fact loss-of-function. This is not surprising since 
oncogenes are dominant and with a strong neoplastic transformation potential. 
This is in most cases, deleterious for embryonal development. 
• LowMACA doesn’t take into account the minor allele frequency of the variant in 
both cases and controls because the individual itself represents the control in 
cancer and somatic mutations are generally rare by definition. An extra effort 
should be considered to implement an approach that take into account cases and 
controls that is a potentially fruitful follow-up of this work. 
5.4 Conclusion 
In this work, by the results of three distinct studies, we built a comprehensive 
computational framework to study cancer mutations. Cancer is indeed a unique disease 
where the edge between predisposition and disease development factors does not create a 
defined distinction that can be exploited as a source of mutual biological information. In 
the NGS era, we envisage a unified approach that clearly defines cancer etiology from 
DNA somatic mutations based on a deep understanding of the genetic risk components. 
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8 Appendix 
Multiple	Mieloma	 Carcinoid	
205	 54	
53	 33	
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
TP53	 0.0732	 0.0000	 CDKN1B	 0.093	 0.000	
SP140	 0.0293	 0.1088	 PRDM9	 0.056	 0.035	
FGFR3	 0.0244	 0.2249	 CACNA1E	 0.074	 0.054	
PLXDC2	 0.0195	 0.2249	 LAX	
EZR	 0.0146	 0.3487	
Gene 
name NS freq q-value	
NRAS	 0.1805	 0.0000	 CDKN1B	 0.0926	 0.0000	
CCND1	 0.0439	 0.0000	 PRDM9	 0.0556	 0.0182	
TP53	 0.0732	 0.0000	 ATM	 0.0741	 0.0291	
ACTG1	 0.0341	 0.0000	 ERN2	 0.0370	 0.1107	
BRAF	 0.0634	 0.0000	 TP53BP1	 0.0741	 0.1005	
EGR1	 0.0341	 0.0003	
	 	 	KRTDAP	 0.0098	 0.0003	
	
  tumor	suppressors	
DTX1	 0.0293	 0.0010	
	
		 oncogenes	
MOGAT3	 0.0195	 0.0056	
	
		
additional	genes	below	the	threshold	of	
significance	
TRAF2	 0.0049	 0.0150	
	
NS freq 
frequency	of	non	silent	mutations	in	
the	patients	
IDH1	 0.0146	 0.0817	
	 	 	
Lung	Small	Cell	Carcinoma	 Rhabdoid_Tumor	
73	 33	
178	 5	
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
RB1	 0.4384	 0.0000	 SMARCB1	 0.2121	 0.0000	
TP53	 0.7808	 0.0000	 LAX	
MYH2	 0.1644	 0.0009	
Gene 
name NS freq q-value	
MNDA	 0.0822	 0.0045	 SMARCB1	 0.2121	 0.0000	
HCN1	 0.2192	 0.0045	 ZNF433	 0.0606	 0.0165	
KIF21A	 0.1507	 0.0045	 SMARCB1	 0.2121	 0.0000	
NLRP8	 0.0685	 0.0518	 GABRB2	 0.0606	 0.0167	
ZIM3	 0.0685	 0.0531	
	 	 	IL1RAPL2	 0.0959	 0.0557	
	 	 	IL26	 0.0411	 0.0572	
	 	 	ROBO4	 0.0959	 0.0572	
	 	 	SLIT2	 0.0959	 0.0572	
	 	 	ELAVL2	 0.1096	 0.0733	
	 	 	TP53	 0.7808	 0.0000	
	 	 	COL22A1	 0.2055	 0.0000	
	 	 	OR4K17	 0.0548	 0.0142	
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MCF2	 0.0822	 0.0159	
	 	 	OR5F1	 0.0411	 0.0159	
	 	 	IL1RAPL2	 0.0959	 0.0249	
	 	 	UBE2NL	 0.0411	 0.0249	
	 	 	NPAP1	 0.1096	 0.0479	
	 	 	OR5B2	 0.0411	 0.0479	
	 	 	DIP2C	 0.0959	 0.0771	
	 	 	
Neuroblastoma Liver Hepatocellular Carcinoma 
283 152 
14 44 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
ZNF717	
0.02120141
3	 0.000151487	 ALB	
0.07894736
8	 0	
ALK	
0.08480565
4	 0	 ARID1A	
0.09868421
1	 1.03E-09	
IL18RAP	
0.01413427
6	 0.094614427	 AXIN1	
0.05921052
6	 1.30E-09	
SIGLEC1	
0.01413427
6	 0.094614427	 ERRFI1	
0.02631578
9	 0.000314282	
LAX	 ARID2	
0.05921052
6	 0.000542467	
Gene 
name NS freq q-value	 RPS6KA3	
0.03947368
4	 0.001846214	
ZNF717	
0.02120141
3	 0.000540186	 SIGLEC12	
0.02631578
9	 0.019178482	
ALK	
0.08480565
4	 0	 ZNF226	
0.02631578
9	 0.019580451	
MYCN	
0.01766784
5	 0.002450297	 ACVR2A	
0.03289473
7	 0.051847305	
		
	
		 BRD7	
0.01973684
2	 0.133207108	
		
	
		 CTNNB1	
0.11842105
3	 0	
		
	
		 TP53	
0.26315789
5	 0	
		
	
		 WWP1	
0.05263157
9	 2.25E-06	
		
	
		 NFE2L2	
0.04605263
2	 2.62E-05	
		
	
		 UBR3	
0.05263157
9	 0.001837446	
		
	
		 USP25	
0.02631578
9	 0.00675368	
		
	
		 IGSF10	
0.04605263
2	 0.01772374	
		
	
		 VIM	
0.02631578
9	 0.020421845	
		
	
		 ZNF804B	
0.03289473
7	 0.036041033	
Biliary Tract Astrocytoma 
9 52 
22 1 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
TP53	
0.66666666
7	 7.87E-09	 FGFR1	
0.07692307
7	 6.84E-06	
ROBO2	
0.22222222
2	 0.014403669	
	 	 	
MLL3	
0.22222222
2	 0.033543191	
	 	 	LAX	
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Gene 
name NS freq q-value	
	 	 	
TP53	
0.66666666
7	 5.11E-08	
	 	 	
SMAD4	
0.44444444
4	 1.68E-05	
	 	 	
RNF43	
0.33333333
3	 0.001132554	
	 	 	
NDC80	
0.22222222
2	 0.007054856	
	 	 	
ROBO2	
0.22222222
2	 0.037449541	
	 	 	
MLL3	
0.22222222
2	 0.109015372	
	 	 	
ARID1A	
0.11111111
1	 0.945938479	
	 	 	
TP53	
0.66666666
7	 6.71E-10	
	 	 	
SMAD4	
0.44444444
4	 7.31E-06	
	 	 	
GNAS	
0.22222222
2	 0.008241586	
	 	 	
RNF43	
0.33333333
3	 0.057650829	
	 	 	
Hematological	NS	 Lymphoma B-cell 473	 83 10	 70 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
MLL2	
0.06342494
7	 0	 SGK1	
0.12048192
8	 0	
FAM46C	
0.01902748
4	 4.94E-08	 TNFRSF14	
0.10843373
5	 2.02E-13	
NPM1	
0.01479915
4	 1.08E-07	 FBXO11	
0.09638554
2	 1.58E-10	
WT1	
0.01902748
4	 1.08E-07	 CREBBP	
0.24096385
5	 1.30E-08	
TMEM30A	
0.01479915
4	 0.000904284	 B2M	
0.07228915
7	 1.33E-08	
RUNX1	
0.01691331
9	 0.001985932	 DUSP2	
0.04819277
1	 0.000766125	
FAM5B	
0.01057082
5	 0.087584538	 HNRNPU	
0.04819277
1	 0.0430406	
ZRSR2	 0.00845666	 0.087584538	 PFN1	
0.02409638
6	 0.091884294	
ASXL1	
0.01268498
9	 0.226676493	 NFKBIA	
0.03614457
8	 0.105566134	
BCOR	 0.00845666	 0.634568733	 C10orf12	
0.04819277
1	 0.222787593	
BCL2	
0.09090909
1	 0	 ETS1	
0.04819277
1	 0.409245387	
CCND3	
0.02959830
9	 0	 MLL2	
0.16867469
9	 0.937228598	
CREBBP	
0.03805496
8	 0	 BCL2	
0.24096385
5	 0	
EZH2	
0.07399577
2	 0	 MYC	
0.20481927
7	 0	
ID3	
0.03171247
4	 0	 PIM1	
0.18072289
2	 0	
MYC	
0.04439746
3	 0	 SGK1	
0.12048192
8	 0	
MYD88	
0.02536997
9	 0	 TP53	 0.21686747	 0	
SF3B1	
0.03594080
3	 0	 ACTB	
0.08433734
9	 4.96E-10	
SGK1	 0.02536997 0	 MYD88	 0.08433734 2.98E-09	
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9	 9	
TP53	
0.09090909
1	 0	 CREBBP	
0.24096385
5	 3.94E-09	
CARD11	
0.03171247
4	 2.90E-13	 SMARCA4	
0.07228915
7	 1.18E-07	
NRAS	
0.02748414
4	 6.62E-12	 EZH2	
0.07228915
7	 0.000143132	
MEF2B	
0.02325581
4	 1.08E-11	 CARD11	 0.13253012	 0.00068373	
PIM1	
0.02325581
4	 1.47E-11	 STAT6	
0.04819277
1	 0.00246889	
IRF4	
0.01479915
4	 2.92E-09	 BCR	
0.08433734
9	 0.003671572	
FLT3	
0.02325581
4	 5.74E-07	 ZNF608	
0.06024096
4	 0.010139367	
Chronic Lymphocytic Leukemia (CLL) Soft Tissue Sarcoma 
223 15 
15 5 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
ATM	
0.03587443
9	 1.03E-06	 ZIC3	
0.06666666
7	 0.00425854	
CHD2	 0.02690583	 0.001993193	
	 	 	
KDM6A	
0.02242152
5	 0.00913055	
	 	 	ARID1A	 0.01793722	 0.968290143	
	 	 	SPEN	 0.01793722	 0.968290143	
	 	 	
MYD88	
0.05381165
9	 0	
	 	 	
SF3B1	
0.11210762
3	 0	
	 	 	
TP53	
0.09417040
4	 0	
	 	 	RPS15	 0.01793722	 1.77E-08	
	 	 	MED12	 0.01793722	 0.018970565	
	 	 	
LYN	
0.01345291
5	 0.020293661	
	 	 	
Oligodendroglioma	 Acute	Lymphoblastic	Leukemia	(ALL)	
16	 125	
17.5	 7	
Gene 
name NS freq q-value	 LAX	
FUBP1	 0.125	 0.04722897	
Gene 
name NS freq q-value	
CIC	
0.41666666
7	 0	 PHF6	 0.056	 3.99E-06	
IDH1	
0.41666666
7	 0	 TP53	 0.048	 6.92E-05	
LAX	 PHF6	 0.056	 2.30E-05	
Gene 
name NS freq q-value	
	 	 	
CIC	
0.41666666
7	 0	
	 	 	FUBP1	 0.125	 0.173117289	
	 	 	CIC	 0.9375	 0	
	 	 	IDH1	 0.9375	 0	
	 	 	NOTCH1	 0.3125	 5.12E-05	
	 	 	PIK3CA	 0.25	 0.00027747	
	 	 	PDCD6IP	 0.125	 0.019122225	
	 	 	PKD1L2	 0.125	 0.022348156	
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SLC26A3	 0.125	 0.022348156	
	 	 	FARP2	 0.125	 0.034964368	
	 	 	HIVEP2	 0.125	 0.039569068	
	 	 	KCNH6	 0.125	 0.039569068	
	 	 	RIN1	 0.125	 0.039569068	
	 	 	RNPEPL1	 0.125	 0.039569068	
	 	 	
Stomach Adenocarcinoma Head and neck squamous cell carcinoma 
300 416 
127.5 116	
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
CBWD1	 0.0967	 0.0000	 CASP8	 0.0841	 0.0000	
SEC31A	 0.0300	 0.0000	 CDKN2A	 0.1731	 0.0000	
TP53	 0.3867	 0.0000	 FAT1	 0.1947	 0.0000	
ARID1A	 0.1667	 0.0166	 NOTCH1	 0.1707	 0.0000	
TP53	 0.3867	 0.0000	 TP53	 0.6779	 0.0000	
PGM5	 0.0833	 0.2196	 MLL2	 0.1538	 0.0000	
		
	
		 AJUBA	 0.0433	 0.0000	
		
	
		 EPHA2	 0.0409	 0.0000	
		
	
		 NSD1	 0.0962	 0.0001	
		
	
		 ZNF750	 0.0361	 0.0003	
		
	
		 RASA1	 0.0409	 0.0009	
		
	
		 B2M	 0.0168	 0.0035	
		
	
		 BAGE5	 0.0264	 0.0150	
		
	
		 PRB3	 0.0216	 0.0252	
		
	
		 ITGA8	 0.0361	 0.0422	
		
	
		 HRAS	 0.0409	 0.0000	
		
	
		 PIK3CA	 0.1755	 0.0000	
		
	
		 TP53	 0.6779	 0.0000	
		
	
		 NFE2L2	 0.0505	 0.0000	
		
	
		 FBXW7	 0.0505	 0.0004	
		
	
		 EP300	 0.0673	 0.0022	
		
	
		
HIST1H2B
F	 0.0096	 0.0048	
		
	
		 RHOA	 0.0120	 0.0477	
Esophageal Adenocarcinoma Medulloblastoma 
159 336 
117 9 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
TP53	 0.3208	 0.0000	 TCH1	 0.0506	 0.0000	
CDKN2A	 0.0566	 0.0000	 MLL2	 0.0565	 0.0000	
ARID1A	 0.0566	 0.1499	 CTDNEP1	 0.0238	 0.0000	
CNTNAP4	 0.0566	 0.1499	 CREBBP	 0.0268	 0.0005	
SMARCA4	 0.0629	 0.1499	 GPS2	 0.0089	 0.0151	
TP53	 0.3208	 0.0000	 LDB1	 0.0119	 0.0510	
DOCK2	 0.1069	 0.0000	 FBXW7	 0.0149	 0.1464	
ZNF208	 0.0755	 0.0000	 TCF4	 0.0179	 0.1464	
EPHA6	 0.0440	 0.0204	 BCOR	 0.0149	 0.1512	
CNBD1	 0.0314	 0.0318	 ARID2	 0.0089	 0.2960	
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ELMO1	 0.0629	 0.0425	 CTNNB1	 0.0744	 0.0000	
RYR3	 0.1069	 0.0484	 DDX3X	 0.1101	 0.0000	
NYAP2	 0.0377	 0.0662	 SMARCA4	 0.0565	 0.0000	
GABRA6	 0.0503	 0.0897	 TP53	 0.0298	 0.0000	
		
	
		 SMO	 0.0208	 0.0000	
		
	
		 CREBBP	 0.0268	 0.0001	
		
	
		 SF3B1	 0.0089	 0.0090	
		
	
		 TBR1	 0.0089	 0.0090	
		
	
		 CLEC12B	 0.0119	 0.0387	
Skin Melanoma Low Grade Glioma 
390 228 
237.5 42 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
CDKN2A	 0.1385	 0.0000	 ATRX	 0.4211	 0.0000	
DNAH7	 0.2487	 0.0000	 CIC	 0.1886	 0.0000	
TP53	 0.1641	 0.0000	 FUBP1	 0.0965	 0.0000	
PTEN	 0.0897	 0.0000	 TCF12	 0.0395	 0.0000	
B2M	 0.0231	 0.0282	 IL32	 0.0263	 0.0000	
BRAF	 0.5154	 0.0000	 EMG1	 0.0175	 0.0009	
C10orf71	 0.0718	 0.0000	 IDH1	 0.7675	 0.0000	
CCDC141	 0.0949	 0.0000	 TP53	 0.5088	 0.0000	
CDKN2A	 0.1385	 0.0000	
	 	 	MUC16	 0.4487	 0.0000	
	 	 	NPAP1	 0.1564	 0.0000	
	 	 	NRAS	 0.2564	 0.0000	
	 	 	PRB3	 0.0615	 0.0000	
	 	 	RAC1	 0.0795	 0.0000	
	 	 	RGPD4	 0.1154	 0.0000	
	 	 	STK19	 0.0385	 0.0000	
	 	 	TCEB3CL	 0.0590	 0.0000	
	 	 	TRIOBP	 0.1231	 0.0000	
	 	 	HNRNPCL1	 0.0641	 0.0001	
	 	 	IDH1	 0.0385	 0.0057	
	 	 	
Kidney Papillary Cell Carcinoma Kidney	Chromophobe	
111 65	
66 11	
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
IL32	 0.0360	 0.0006	 PTEN	 0.0923	 0.0000	
NF2	 0.0631	 0.0006	 CDKN1A	 0.0308	 0.0187	
SETD2	 0.0631	 0.0086	 KIAA0947	 0.0462	 0.0232	
SCAF11	 0.0450	 0.0098	 TP53	 0.2000	 0.0000	
KDM6A	 0.0450	 0.0595	
	 	 	SMARCB1	 0.0270	 0.0595	
	 	 	SRCAP	 0.0721	 0.0643	
	 	 	SAV1	 0.0270	 0.0690	
	 	 	DARS	 0.0270	 0.0917	
	 	 	CDC27	 0.0360	 0.0993	
	 	 	OGG1	 0.0270	 0.0993	
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MET	 0.0811	 0.0002	
	 	 	ATP10A	 0.0450	 0.0688	
	 	 	NFE2L2	 0.0270	 0.0688	
	 	 	PCF11	 0.0631	 0.0688	
	 	 	
Kidney	All	 Kidney	Clear	Cell	Carcinoma	
534	 355	
64	 71	
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
BAP1	 0.0712	 0.0000	 BAP1	 0.0958	 0.0000	
PBRM1	 0.2416	 0.0000	 KDM5C	 0.0620	 0.0000	
SETD2	 0.0899	 0.0000	 PBRM1	 0.3465	 0.0000	
VHL	 0.3052	 0.0000	 SETD2	 0.1127	 0.0000	
KDM5C	 0.0412	 0.0000	 VHL	 0.4479	 0.0000	
PTEN	 0.0356	 0.0000	 SCAF4	 0.0254	 0.0355	
NF2	 0.0243	 0.0049	 BAP1	 0.0958	 0.0000	
GFRAL	 0.0131	 0.0337	 MTOR	 0.0901	 0.0000	
STAG2	 0.0281	 0.0685	 MUC4	 0.1183	 0.0000	
SMARCB1	 0.0131	 0.0852	 SETD2	 0.1127	 0.0000	
MTOR	 0.0693	 0.0000	 TP53	 0.0254	 0.0038	
MUC4	 0.0843	 0.0000	 MUC2	 0.0338	 0.0108	
TP53	 0.0449	 0.0000	 TRIM51	 0.0113	 0.0376	
MUC2	 0.0300	 0.0145	 SPAM1	 0.0169	 0.0405	
SMARCA4	 0.0243	 0.0145	 OR5H1	 0.0085	 0.0501	
SPAM1	 0.0150	 0.0145	 SMARCA4	 0.0225	 0.0603	
NFE2L2	 0.0150	 0.0255	
	 	 	
Pancreatic Adenocarcinoma Glioblastoma 
401 361 
16 65 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
RNF43	 0.0449	 0.0000	 NF1	 0.1191	 0.0000	
SMAD4	 0.1471	 0.0000	 PIK3R1	 0.1136	 0.0000	
TP53	 0.2195	 0.0000	 PTEN	 0.2825	 0.0000	
ARID1A	 0.0349	 0.0000	 RB1	 0.0776	 0.0000	
MLL3	 0.0574	 0.0002	 TP53	 0.2521	 0.0000	
MEN1	 0.0175	 0.0497	 NOX4	 0.0249	 0.0000	
KRAS	 0.3541	 0.0000	 RPL5	 0.0194	 0.0000	
TP53	 0.2195	 0.0000	 ZNF431	 0.0111	 0.0000	
CTNNB1	 0.0224	 0.0000	 STAG2	 0.0332	 0.0001	
GNAS	 0.0224	 0.0000	 TPTE2	 0.0222	 0.0052	
SF3B1	 0.0200	 0.0001	 ATRX	 0.0443	 0.0054	
CDH10	 0.0200	 0.0019	 CHD8	 0.0277	 0.0378	
ANKRD20A
4	 0.0050	 0.0025	 NBPF9	 0.0166	 0.0669	
GABRQ	 0.0100	 0.0091	 EGFR	 0.2188	 0.0000	
PRAMEF11	 0.0075	 0.0142	 PIK3CA	 0.1025	 0.0000	
CHGB	 0.0150	 0.0223	 PIK3R1	 0.1136	 0.0000	
MYH6	 0.0150	 0.0406	 TP53	 0.2521	 0.0000	
TEX2	 0.0175	 0.0566	 IDH1	 0.0388	 0.0000	
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GPR133	 0.0150	 0.0910	 ABCC9	 0.0305	 0.0117	
KANSL1	 0.0175	 0.0910	 KCNB2	 0.0194	 0.0273	
		
	
		 PIK3R5	 0.0305	 0.0283	
		
	
		 TRABD2A	 0.0111	 0.0283	
		
	
		 AMER3	 0.0194	 0.0658	
		
	
		 KHDC3L	 0.0083	 0.0658	
Colorectal Adenocarcinoma Lung Squamous Cell Carcinoma 
328 179 
90	 290 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
APC	 0.6463	 0.0000	 CDKN2A	 0.1453	 0.0000	
TP53	 0.5152	 0.0000	 CSMD3	 0.4525	 0.0000	
TGIF1	 0.0183	 0.0813	 TP53	 0.7877	 0.0000	
KRAS	 0.4329	 0.0000	 COL11A1	 0.1955	 0.0000	
SMAD4	 0.1372	 0.0000	 MROH2B	 0.1453	 0.0000	
TP53	 0.5152	 0.0000	 EPB41L3	 0.0950	 0.0006	
NRAS	 0.0762	 0.0000	 CLSTN2	 0.0950	 0.0013	
KRTAP1-3	 0.0122	 0.0157	 PTEN	 0.0782	 0.0032	
		
	
		 REG3G	 0.0447	 0.0035	
		
	
		 MYH8	 0.1173	 0.0054	
		
	
		 DPPA4	 0.0670	 0.0061	
		
	
		 MLL2	 0.1955	 0.0070	
		
	
		 BAI3	 0.1229	 0.0086	
		
	
		 PRIM2	 0.0726	 0.0086	
		
	
		 RB1	 0.0670	 0.0086	
		
	
		 ADAM2	 0.0670	 0.0137	
		
	
		 DNAH5	 0.1788	 0.0174	
		
	
		 ELTD1	 0.1006	 0.0284	
		
	
		 ACSM2B	 0.0726	 0.0371	
		
	
		 NFE2L2	 0.1508	 0.0000	
		
	
		 TP53	 0.7877	 0.0000	
		
	
		 ZNF208	 0.1341	 0.0004	
Uterin Carcinoma Ovarian Adenocarcinoma 
248 503 
66 51 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
ARID1A	 0.3347	 0.0000	 TP53	 0.6759	 0.0000	
ARID5B	 0.1169	 0.0000	 BRCA1	 0.0398	 0.0000	
CTCF	 0.1815	 0.0000	 NF1	 0.0497	 0.0000	
IK	 0.0323	 0.0000	 CDK12	 0.0298	 0.0005	
PIK3R1	 0.3347	 0.0000	 RB1	 0.0278	 0.0007	
PTEN	 0.6492	 0.0000	 IL21R	 0.0159	 0.0212	
RPL22	 0.1250	 0.0000	 SNTG1	 0.0159	 0.0418	
ZFHX3	 0.1774	 0.0000	 TP53	 0.6759	 0.0000	
CTNNB1	 0.2984	 0.0000	 PPP2R1A	 0.0139	 0.4807	
KRAS	 0.2137	 0.0000	
	 	 	PIK3R1	 0.3347	 0.0000	
	 	 	PTEN	 0.6492	 0.0000	
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TP53	 0.2782	 0.0000	
	 	 	PPP2R1A	 0.1089	 0.0016	
	 	 	
Lung Adenocarcinoma Prostate Adenocarcinoma 
244 403 
231 39 
Gene 
name NS freq q-value	
Gene 
name NS freq q-value	
COL11A1	 0.2049	 0.0000	 PTEN	 0.0496	 0.0000	
STK11	 0.0820	 0.0000	 KDM6A	 0.0273	 0.0001	
TP53	 0.5205	 0.0000	 OR2T35	 0.0099	 0.0001	
TPTE	 0.1025	 0.0000	 CDKN1B	 0.0174	 0.0009	
CDKN2A	 0.0574	 0.0070	 GPATCH4	 0.0124	 0.0954	
CHDC2	 0.0451	 0.0073	 APC	 0.0323	 0.1001	
RBM10	 0.0492	 0.0435	 SPOP	 0.0844	 0.0000	
TAAR5	 0.0328	 0.0486	 TP53	 0.1315	 0.0000	
PNLIP	 0.0287	 0.2889	 FOXA1	 0.0298	 0.0000	
SMARCA4	 0.0697	 0.2889	 NKX3-1	 0.0174	 0.0059	
KRAS	 0.2746	 0.0000	 AR	 0.0223	 0.0253	
TP53	 0.5205	 0.0000	 CTNNB1	 0.0199	 0.0337	
EGFR	 0.1189	 0.0287	 LPAR1	 0.0149	 0.0974	
NPAP1	 0.1393	 0.0568	
	 	 	Appendix Table 1 Application of DOTS-Finder to 30 tumor types. The frequency of non-silent 
mutation is reported for every gene (NS Freq) with a q-value < 0.1. Genes around the threshold of 
significance are reported in yellow. In white, detected oncogenes are reported, in green, detected tumor 
suppressors. Under each tumor type name, number of samples and median number of non-silent 
mutations per sample are reported in the order. 
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Breast	
Cancer	
	 	 	 	 	 	1046	 	
	 	 	36	 	
	 	 	
DOTS-Finder	 TCGA	-	Publication	 Music	
TUSON	
Explorer	 Mutsig	
Gene	name	 NS	freq	 q-value	 		 		 		 		
CBFB	 0.0210	 0.0000	 TP53	 MAP2K4	 TP53	 PIK3CA	
CDH1	 0.0621	 0.0000	 PIK3CA	 PIK3CA	 GATA3	 TP53	
GATA3	 0.0946	 0.0000	 GATA3	 KRAS	 MAP3K1	 GATA3	
MAP2K4	 0.0392	 0.0000	 MAP3K1	 TP53	 CDH1	 MAP3K1	
MAP3K1	 0.0698	 0.0000	 MLL3	 TBL1XR1	 MLL3	 PTEN	
PTEN	 0.0402	 0.0000	 CDH1	 PIK3R1	 PTEN	 AKT1	
TP53	 0.3375	 0.0000	 MAP2K4	 CBFB	 MAP2K4	 CTCF	
TBX3	 0.0220	 0.0000	 RUNX1	 GATA3	 RB1	 CBFB	
MLL3	 0.0650	 0.0000	 PTEN	 MAP3K1	 NCOR1	 MLL3	
AOAH	 0.0191	 0.0000	 TBX3	 CDH1	 TBX3	 MAP2K4	
CTCF	 0.0210	 0.0000	 PIK3R1	 NCOR1	 AOAH	 RUNX1	
RUNX1	 0.0239	 0.0000	 AKT1	 RB1	 RUNX1	 CDH1	
NCOR1	 0.0382	 0.0000	 CBFB	 MALAT1	 MED23	 SF3B1	
RB1	 0.0210	 0.0000	 TBL1XR1	 TBX3	 ARID1A	 PIK3R1	
NCOR2	 0.0315	 0.0003	 NCOR1	 PTEN	 RBMX	 ARID1A	
STXBP2	 0.0096	 0.0004	 CTCF	 ARID1A	 NF1	 NCOR1	
AQP7	 0.0076	 0.0017	 ZFP36L1	 CTCF	 CDKN1B	 KRAS	
ZFP36L1	 0.0115	 0.0046	 GPS2	 AKT1	 HNF1A	 SPEN	
RBMX	 0.0124	 0.0056	 SF3B1	 RUNX1	 CCDC144NL	 RB1	
GPS2	 0.0067	 0.0095	 CDKN1B	 MLL3	 MYB	 MLL	
CASP8	 0.0153	 0.0104	 USH2A	 SF3B1	 KDM6A	 ERBB2	
CDKN1B	 0.0076	 0.0125	 RPGR	 NF1	 ZFP36L1	 TBL1XR1	
UBC	 0.0076	 0.0155	 RB1	 FOXA1	 SETD2	 CDKN1B	
MED23	 0.0134	 0.0224	 AFF2	 VEZF1	 NCOR2	 HIST1H3B	
MYB	 0.0115	 0.0407	 NF1	 CDKN1B	 TBL1XR1	 FOXA1	
CCDC144NL	 0.0076	 0.1268	 PTPN22	 		 ARID2	 CASP8	
GNRH2	 0.0029	 0.2062	 RYR2	 		 FOXA1	 MED23	
HNF1A	 0.0086	 0.7280	 PTPRD	 		 DUSP16	 TBX3	
AKT1	 0.0220	 0.0000	 OR6A2	 		 BRCA2	 CUL4B	
PIK3CA	 0.2849	 0.0000	 HIST1H2BC	 		 CBFB	 STAG2	
TP53	 0.3375	 0.0000	 GPR32	 		 CTCF	 MYB	
TBX3	 0.0220	 0.0000	 CLEC19A	 		 PIK3CA	 RAB40A	
SF3B1	 0.0172	 0.0000	 CCND3	 		 AKT1	 EP300	
FOXA1	 0.0172	 0.0001	 SEPT13	 		 SF3B1	 FGFR2	
HIST1H3B	 0.0076	 0.0001	 DCAF4L2	 		 		 GNPTAB	
MEF2A	 0.0143	 0.0002	 		 		 		 ERBB3	
PIK3R1	 0.0249	 0.0008	 		 		 		 ACVR1B	
ATN1	 0.0172	 0.0425	 		 		 		 		
AKD1	 0.0182	 0.0431	 		 		 		 		
Thyroid	
Carcinoma	
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326	 	
	 	 	19	 	
	 	 	
DOTS-Finder	
	 	 	 	Gene	name	 NS	freq	 q-value	 	TUSON	Exlorer	
	 	 	TG	 0.0491	 0.0000	 TG	
	 	 	EMG1	 0.0184	 0.0000	 RPTN	
	 	 	RPTN	 0.0245	 0.0000	 MLL3	
	 	 	PPM1D	 0.0153	 0.0054	 DNMT3A	
	 	 	TMCO2	 0.0092	 0.0056	 CHD2	
	 	 	IL32	 0.0092	 0.0152	 BRAF	
	 	 	DNMT3A	 0.0153	 0.2896	
	 	 	 	BRAF	 0.5613	 0.0000	
	 	 	 	HRAS	 0.0368	 0.0000	
	 	 	 	NRAS	 0.0798	 0.0000	
	 	 	 	TG	 0.0491	 0.0000	
	 	 	 	DNASE2	 0.0092	 0.0694	
	 	 	 	PRDM9	 0.0184	 0.0816	
	 	 	 	DICER1	 0.0092	 0.1070	
	 	 	 	ZNF845	 0.0184	 0.1070	
	 	 	 	PRG4	 0.0123	 0.1085	
	 	 	 	PTTG1IP	 0.0123	 0.1085	
	 	 	 	
AML	
	 	 	 	 	 	196	 	
	 	 	11	 	
	 	 	
DOTS-Finder	 	 	 	
	
Gene	name	 NS	freq	 q-value	
TCGA	-	
Publication	 Music	 Mutsig	
	CEBPA	 0.0663	 0.0000	 CEBPA	 NPM1	 FLT3	
	NPM1	 0.2755	 0.0000	 DNMT3A	 FLT3	 DNMT3A	
	RUNX1	 0.0918	 0.0000	 FLT3	 DNMT3A	 NPM1	
	TET2	 0.0867	 0.0000	 IDH1	 IDH2	 IDH2	
	TP53	 0.0765	 0.0000	 IDH2	 IDH1	 IDH1	
	WT1	 0.0612	 0.0000	 NPM1	 RUNX1	 TET2	
	RAD21	 0.0255	 0.0000	 NRAS	 TET2	 NRAS	
	PHF6	 0.0306	 0.0000	 RUNX1	 NRAS	 RUNX1	
	STAG2	 0.0306	 0.0000	 TET2	 TP53	 WT1	
	EZH2	 0.0153	 0.0007	 TP53	 CEBPA	 U2AF1	
	ASXL1	 0.0255	 0.0014	 WT1	 WT1	 TP53	
	HNRNPK	 0.0102	 0.0083	 KRAS	 KRAS	 KRAS	
	CALR	 0.0102	 0.0142	 U2AF1	 KIT	 PTPN11	
	CBFB	 0.0102	 0.0572	 KIT	 U2AF1	 KIT	
	CBX7	 0.0051	 0.0948	 PTPN11	 PTPN11	 SMC3	
	BCOR	 0.0102	 0.1971	 PHF6	 MIR142	 STAG2	
	CEBPA	 0.0663	 0.0000	 SMC3	 PHF6	 PHF6	
	DNMT3A	 0.2602	 0.0000	 FAM5C	 SMC3	 RAD21	
	FLT3	 0.2704	 0.0000	 SMC1A	 SMC1A	 CEBPA	
	IDH1	 0.0969	 0.0000	 RAD21	 STAG2	 ASXL1	
	IDH2	 0.1020	 0.0000	 STAG2	 RAD21	 SFRS2	
	NRAS	 0.0765	 0.0000	 HNRNPK	 ASXL1	 SMC1A	
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TP53	 0.0765	 0.0000	 EZH2	 EZH2	 PAPD5	
	U2AF1	 0.0408	 0.0000	
	
		 EZH2	
	
	 	 	
		 		 PDSS2	
	
	 	 	
		 		 MXRA5	
	
	 	 	
		 		 KDM6A	
	Bladder	
Carcinoma	
	 	 	 	 	 	145	 	
	 	 	177	 	
	 	 	
DOTS-Finder	 TCGA	-	Publication	 Music	
TUSON	
Explorer	 Mutsig	
Gene	name	 NS	freq	 q-value	 		 		 		 		
ARID1A	 0.2414	 0.0000	 UTX	 TP53	 ARID1A	 TP53	
CDKN1A	 0.1448	 0.0000	 TP53	 ARID1A	 KDM6A	 KDM6A	
KDM6A	 0.2138	 0.0000	 ARID1A	 KDM6A	 CDKN1A	 RB1	
TP53	 0.2621	 0.0000	 CREBBP	 MALAT1	 MLL2	 PIK3CA	
ELF3	 0.0759	 0.0000	 EP300	 CDKN1A	 TP53	 ARID1A	
MLL2	 0.2621	 0.0000	 HRAS	 MLL2	 MLL	 MLL2	
EP300	 0.1517	 0.0000	 RB1	 RB1	 FAT1	 CDKN1A	
RB1	 0.1103	 0.0000	 PIK3CA	 ELF3	 MLL3	 ERCC2	
SPTAN1	 0.0966	 0.0000	 FGFR3	 PIK3CA	 ELF3	 STAG2	
MLL3	 0.2000	 0.0000	 STAG2	 FBXW7	 RB1	 RXRA	
CREBBP	 0.1310	 0.0000	 SYNE1	 PRX	 STAG2	 TBC1D12	
STAG2	 0.0897	 0.0001	 ERCC2	 ERCC2	 FBXW7	 NFE2L2	
FOXQ1	 0.0483	 0.0060	 KRAS	 EP300	 EP300	 C3orf70	
TXNIP	 0.0552	 0.0079	 MLL	 MLL3	 CREBBP	 ERBB3	
FAT1	 0.1103	 0.0370	 NF1	 FGFR3	 ARHGAP35	 ELF3	
FBXW7	 0.0690	 0.0428	 SYNE2	 STAG2	 ASXL2	 FBXW7	
GCC2	 0.0690	 0.0800	 ANK3	 		 TSC1	 FGFR3	
ZNF513	 0.0552	 0.0911	 CSMD3	 		 FOXQ1	 FOXQ1	
KLF5	 0.0621	 0.1184	 ELF3	 		 PIK3C2B	 CREBBP	
GPS2	 0.0276	 0.2599	
ESPL1	
		
No	
Oncogenes	 HRAS	
NHLRC1	 0.0207	 0.2635	 LRP2	 		 		 SNX25	
FOXA1	 0.0414	 0.2872	 ANK2	 		 		 TSC1	
TP53	 0.2621	 0.0000	 ATM	 		 		 MGA	
NFE2L2	 0.0759	 0.0000	 CHD6	 		 		 EZR	
ERBB3	 0.1172	 0.0000	 ERBB2	 		 		 CDKN2A	
RARG	 0.0690	 0.0000	 ERBB3	 		 		 DDX5	
IRS4	 0.0138	 0.6550	 FAT4	 		 		 RHOA	
ELP5	 0.0138	 0.6550	 KALRN	 		 		 PHF6	
RPS6	 0.0207	 0.6550	 LAMA4	 		 		 MLL3	
	 	 	
MLL3	 		 		 BCLAF1	
	 	 	
NCOR1	 		 		 TGFBR2	
	 	 	
NFE2L3	 		 		 EPHA2	
	 	 	
PDZD2	 		 		 SETD2	
	 	 	
PIK3R4	 		 		 		
	 	 	
TRAK1	 		 		 		
	 	 	
TRRAP	 		 		 		
Appendix Table 2 Results of DOTS-Finder on 4 tumor types and comparison with existing tools. The 
frequency of non-silent mutation is reported for every gene (NS Freq) with a q-value < 0.1. Genes around 
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the threshold of significance are reported in yellow. In white, detected oncogenes are reported, in green, 
detected tumor suppressors. Under each tumor type name, number of samples and median number of 
non-silent mutations per sample are reported in this order. 
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Lung adenocarcinoma non smoker Lung Adenocarcinoma 
62 244 
83.5	 231 
Gene name NS freq q-value	 Gene name NS freq q-value	
TP53	 0.3065	 0.0000	 COL11A1	 0.2049	 0.0000	
NBPF1	 0.1290	 0.0000	 STK11	 0.0820	 0.0000	
IL32	 0.0645	 0.0005	 TP53	 0.5205	 0.0000	
KEAP1	 0.0806	 0.0005	 TPTE	 0.1025	 0.0000	
STK11	 0.0806	 0.0005	 CDKN2A	 0.0574	 0.0070	
RPL5	 0.0484	 0.0008	 CHDC2	 0.0451	 0.0073	
SDHA	 0.0484	 0.0008	 RBM10	 0.0492	 0.0435	
OR5B3	 0.0484	 0.0012	 TAAR5	 0.0328	 0.0486	
PSME2	 0.0323	 0.0019	 PNLIP	 0.0287	 0.2889	
OR4C16	 0.0484	 0.0098	 SMARCA4	 0.0697	 0.2889	
SETD2	 0.0645	 0.0100	 KRAS	 0.2746	 0.0000	
ECI1	 0.0323	 0.0200	 TP53	 0.5205	 0.0000	
FKBP2	 0.0323	 0.0495	 EGFR	 0.1189	 0.0287	
CEBPZ	 0.0484	 0.0495	 NPAP1	 0.1393	 0.0568	
SMAD4	 0.0968	 0.0517	
	 	 	RBM10	 0.0484	 0.0665	
	 	 	UXS1	 0.0323	 0.0764	
	 	 	MET	 0.0645	 0.0904	
	
  tumor	suppressors	
EGFR	 0.3226	 0.0000	
	
		 oncogenes	
KRAS	 0.1290	 0.0000	
	
		
additional	genes	below	the	
threshold	of	significance	
CASP8	 0.0484	 0.0000	
	
NS freq 
frequency	of	non	silent	
mutations	in	the	patients	
PLP2	 0.0323	 0.0024	
	 	 	AQP10	 0.0323	 0.0029	
	 	 	PAPPA2	 0.1129	 0.0029	
	 	 	REG1B	 0.0484	 0.0029	
	 	 	BROX	 0.0323	 0.0030	
	 	 	MC5R	 0.0323	 0.0030	
	 	 	OR52I1	 0.0323	 0.0030	
	 	 	SPTA1	 0.1290	 0.0030	
	 	 	KCNMB1	 0.0484	 0.0047	
	 	 	NDUFAF3	 0.0323	 0.0050	
	 	 	PAQR9	 0.0323	 0.0074	
	 	 	EFCAB12	 0.0323	 0.0084	
	 	 	PRSS45	 0.0161	 0.0134	
	 	 	OR2T4	 0.0323	 0.0162	
	 	 	C11orf63	 0.0484	 0.0195	
	 	 	HSD17B6	 0.0323	 0.0228	
	 	 	MCF2	 0.0484	 0.0228	
	 	 	TCRB	 0.0323	 0.0228	
	 	 	PSG3	 0.0323	 0.0272	
	 	 	ITGA2B	 0.0323	 0.0296	
	 	 	COL25A1	 0.0645	 0.0379	
	 	 	OR1M1	 0.0484	 0.0410	
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OR2W3	 0.0484	 0.0410	
	 	 	PROKR2	 0.0484	 0.0410	
	 	 	WRN	 0.0484	 0.0410	
	 	 	NCKIPSD	 0.0323	 0.0488	
	 	 	PLD2	 0.0323	 0.0603	
	 	 	CR2	 0.1129	 0.0619	
	 	 	DPY19L2	 0.0484	 0.0622	
	 	 	HSPA5	 0.0323	 0.0622	
	 	 	OR14A16	 0.0323	 0.0695	
	 	 	GRM1	 0.0484	 0.0869	
	 	 	Appendix Table 3 Results of DOTS-Finder obtained from the complete LUAD dataset and the non-
smoker LUAD subset. The frequency of non-silent mutation is reported for every gene (NS Freq) with a 
q-value < 0.1. Genes around the threshold of significance are reported in yellow. In white, detected 
oncogenes are reported, in green, detected tumor suppressors. Under each tumor type name, number of 
samples and median number of non-silent mutations per sample are reported in this order. 
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Gene 
Symbol 
Protein 
change SIFT 
Polyp
hen2 LRT 
Mutation 
Taster 
Mutation 
Assessor FATHMM 
Radial 
SVM 
Met
a LR 
% 
Damaging 
RAB29 A16T T P N D N T T T 0.25 
RAB29 E116K T B N D L T T T 0.125 
RAB29 E68Q D D D D M D D D 0.875 
RAB29 P117L T P N D L T T T 0.25 
RAB29 Q60E D P D D M T D D 0.75 
RAB29 R69H D D D D M T D D 0.75 
RAB29 R79L D D D D M T D D 0.75 
RAB29 R79W D D D D H T D D 0.875 
RAB29 V13E D D D D M T D D 0.75 
RAB29 W151* T . D D . . . . 0.25 
RAB29 W62L D D D D H D D D 1 
RAC1 A159V D D D D H D D D 1 
RAC1 A59T D D D D M D D D 0.875 
RAC1 A88E D P D D N T T T 0.5 
RAC1 C18F D D D D H T D D 0.875 
RAC1 C18Y D D D D H T D D 0.875 
RAC1 D63H D D D D H T D D 0.875 
RAC1 D63N D D D D M T D D 0.75 
RAC1 D65N D P D D M T D D 0.75 
RAC1 E31D D B D D N T T T 0.375 
RAC1 G142S D D D D H T D D 0.875 
RAC1 G15S D D D D H D D D 1 
RAC1 I21M D D D D L T D D 0.75 
RAC1 K116N D D D D H D D D 1 
RAC1 K116R D D D D H D D D 1 
RAC1 K116T D D D D H D D D 1 
RAC1 L177V D B D D L T T T 0.375 
RAC1 L53V D P D D M D D D 0.875 
RAC1 N39S D P D D L T D D 0.75 
RAC1 N92I D D D D H T D D 0.875 
RAC1 N92K D P D D M T D D 0.75 
RAC1 P140L D B D D N T T T 0.375 
RAC1 P29L D D D D M T D D 0.75 
RAC1 P29S D P D D L T T D 0.625 
RAC1 P29T D P D D M T D D 0.75 
RAC1 P34H D D D D H T D D 0.875 
RAC1 P34S D D D D M T D D 0.75 
RAC1 P87L D B D D M T D D 0.625 
RAC1 Q162R D D D D N T T T 0.5 
RAC1 Q61R D D D D M D D D 0.875 
RAC1 R102L T B D D L T T T 0.25 
RAC1 R68H D P D D H T D D 0.875 
RAC1 S71F D D D D M T D D 0.75 
RAC1 S86I D P D D M T D D 0.75 
RAC1 V14E D D D D H D D D 1 
RAC1 V46G D D D D H T D D 0.875 
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RAC1 V85M D P D D M T D D 0.75 
RAC1 Y32C D D D D H T D D 0.875 
RAC1 Y40S D P D D M T D D 0.75 
RAC2 A27V T B D D L T T T 0.25 
RAC2 C18R D D D D H T D D 0.875 
RAC2 D124E T B D D N T T T 0.25 
RAC2 E62K D P D D H D D D 1 
RAC2 F82L D B D D H D D D 0.875 
RAC2 G15D D D D D H D D D 1 
RAC2 G30R D P D D L T T T 0.5 
RAC2 I110F T B D D L T T T 0.25 
RAC2 I21M D D D D L T D D 0.75 
RAC2 K130R T B D D N T T T 0.25 
RAC2 P136H D D D D M T D D 0.75 
RAC2 P29L T T T T T T T T 0 
RAC2 Q162H D P D D M T D T 0.625 
RAC2 R102Q T B D D L T T T 0.25 
RAC2 R102W D D D D H T D D 0.875 
RAC2 R174W D D D D M T D D 0.75 
RAC2 T35I D D D D H D D D 1 
RAC2 V168M D D D D M T D D 0.75 
RAC2 V36A . B D D M T D D 0.5 
RAC2 V93I D B D D N T T T 0.375 
RAC2 W97* T . D D . . . . 0.25 
RHOC D120N D D U D H D D D 0.875 
RHOC D124fs D D D D D D D D 1 
RHOC D59E D P D D M D D D 0.875 
RHOC E125Q T B . D N T T T 0.125 
RHOC E142K D B . D M T T T 0.25 
RHOC E64K D D D D H D D D 1 
RHOC G178D D B . D N T T T 0.25 
RHOC K162N T B . D H T T T 0.25 
RHOC P31S D D D D L T T T 0.5 
RHOC R145W D D . D L T T T 0.375 
RHOC R150W D P . D M T T T 0.375 
RHOC R168L D P . D L T T T 0.375 
RHOC R68Q D B D D L T T T 0.375 
RHOC S73A D B D D L T T T 0.375 
RHOC S73fs D D D D D D D D 1 
RHOC V24I D B D D M T T T 0.375 
RHOC Y42C D P D D M T D T 0.625 
RHOT1 A83V T D D D M T D D 0.625 
RHOT1 D106H T B D D N T T T 0.25 
RHOT1 D91N D B D D L T T T 0.375 
RHOT1 E12K D D D D M T D D 0.75 
RHOT1 E39Q T D D D M T D D 0.625 
RHOT1 P30L T D D D M T D D 0.625 
RHOT1 P43S D D D D M T D D 0.75 
RHOT1 P48fs D D D D D D D D 1 
RHOT1 R104K T B D D N T T T 0.25 
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RHOT1 S156L D D D D M T D D 0.75 
RHOT1 V84I T D D D L T T T 0.375 
RHOT1 Y82H D D N D M D D D 0.75 
Appendix Table 4 Breakdown of the analysis of some Rab and Rho subfamily members. This table 
represents all the mutations found in more than 10000 cancer patient (cBioportal Database) on the RAS 
superfamily Pfam (PF00071). An extended version comes as a supplementary of (Melloni et al., 2016).  
SIFT - D: Deleterious (sift<=0.05); T: tolerated (sift>0.05) 
Polyphen2 - D: Probably damaging (>=0.957), P: possibly damaging (0.453<=pp2_hdiv<=0.956); B: benign 
(pp2_hdiv<=0.452) 
LRT - D: Deleterious; N: Neutral; U: Unknown 
Mutation Taster - A" ("disease_causing_automatic"); "D" ("disease_causing"); "N" ("polymorphism"); "P" 
("polymorphism_automatic") 
Mutation Assessor - H: high; M: medium; L: low; N: neutral. H/M means functional and L/N means non-
functional 
FATHMM - D: Deleterious; T: Tolerated 
Radial SVM - D: Deleterious; T: Tolerated 
LR - D: Deleterious; T: Tolerated 
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LowMACA VS 
Disease Associated 
snps Fisher Test Result         
p-value 5.30E-27 
  
Disease Associated 
Mutations 
alternative 
hypothesis: OR different from 1 
  
no yes 
Confidence Interval 18.30 - 84.98 LowMACA 
Not 
Predicted 2257 11 
Odds Ratio 38.17336152 Predicted 172 32 
Accuracy 0.156862745  
  
  
Recall 0.744186047  
  
  
F1-Score 0.259109312         
      dbNSFP VS Disease 
Associated snps Fisher Test Result         
p-value 3.56E-05 
  
Disease Associated 
Mutations 
alternative 
hypothesis: OR different from 1 
  
no yes 
Confidence Interval 1.98 - 10.11 dbNSFP Tolerated 1286 9 
Odds Ratio 4.250413143 Damaging 1143 34 
Accuracy 0.028887001 
   
  
Recall 0.790697674 
   
  
F1-Score 0.055737705         
      LowMACA VS 
Cancer Associated 
snps Fisher Test Result         
p-value 1.36E-22 
  
Cancer Associated 
Mutations 
alternative 
hypothesis: OR different from 1 
  
no yes 
Confidence Interval 41.14 - 9985.34 LowMACA notPredicted 2267 1 
Odds Ratio 260.147541 Predicted 183 21 
Accuracy 0.102941176  
  
  
Recall 0.954545455  
  
  
F1-Score 0.185840708         
      dbNSFP VS Cancer 
Associated snps Fisher Test Result         
p-value 1.89E-03 
  
Cancer Associated 
Mutations 
alternative 
hypothesis: OR different from 1 
  
no yes 
Confidence Interval 1.64 - 20.40 dbNSFP Tolerated 1291 4 
Odds Ratio 5.012510785 Damaging 1159 18 
Accuracy 0.015293118 
   
  
Recall 0.818181818 
   
  
F1-Score 0.030025021         
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Appendix Table 5 Statistical Results from the comparison of dbNSFP results and LowMACA results. A 
set of known pathogenic variants taken from Humsavar and Clinvar and a set of known cancer related 
mutations taken from DoCM and CiviC was compared to the results detected by LowMACA and the 
aggregated score from 8 different predictors of phenotypic effect. 
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Pfam 
ID Pfam Name 
Multiple 
Alignment 
Position 
Consensus 
Amino 
Acid 
Trident 
Conservation 
Score 
Genes Mutated in Multiple 
Align Position 
Position 
Qvalue 
PF00454 PI3_PI4_kinase 57 C 0.4922 MTOR 1.31E-02 
PF00454 PI3_PI4_kinase 365 L 0.3596 
ATM|ATR|PI4KAP2|MTOR|
PIK3C2A|PIK3CA|PRKDC 1.35E-03 
PF00613 PI3Ka 24 E 0.1122 PIK3C2A|PIK3CA 5.68E-61 
PF00613 PI3Ka 27 E 0.2313 PIK3CA|PIK3CB|PIK3CG 1.31E-136 
PF00613 PI3Ka 28 E 0.2391 PIK3CA|PIK3CB 1.90E-16 
PF00792 PI3K_C2 1 E 0.1445 PIK3C2A|PIK3CA 4.21E-02 
PF00792 PI3K_C2 16 E 0.3616 PIK3CA|PIK3C2A|PIK3CB 4.21E-02 
PF00792 PI3K_C2 108 C 0.1332 PIK3CA|PIK3C2A 1.15E-08 
PF00792 PI3K_C2 140 E 0.3173 
PIK3C2G|PIK3CA|PIK3CG|P
IK3CD 4.21E-02 
PF00792 PI3K_C2 142 E 0.1362 PIK3CA|PIK3CB 5.44E-08 
PF00792 PI3K_C2 173 A 0.2408 PIK3CA|PIK3CD|PIK3CG 4.87E-02 
PF02192 PI3K_p85B 8 R 1.0000 PIK3CA|PIK3CB|PIK3CD 1.57E-07 
PF02192 PI3K_p85B 51 E 1.0000 PIK3CA|PIK3CD 1.10E-03 
PF02192 PI3K_p85B 58 R 1.0000 PIK3CA|PIK3CD 1.90E-12 
PF02192 PI3K_p85B 63 R 0.3856 PIK3CA|PIK3CB 2.03E-04 
PF02192 PI3K_p85B 76 G 0.3591 PIK3CA 5.27E-03 
PF02192 PI3K_p85B 78 R 0.3661 PIK3CA 1.67E-04 
Appendix Table 6 Results of LowMACA on the main PI3K families. In purple, the main Pfam PF00613 
encompasses the family I of PIK3, composed by known cancer genes PIK3CA and PIK3CB. 
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Variant Humsavar Disease ClinVar Disease 
SDHB - 1,17354297,A,G   Neoplastic_Syndromes\x2c_Hereditary 
MUTYH - 1,45798475,T,C   Endometrial_carcinoma|Neoplastic_Syndromes\x2c_Hereditary 
RNASEL - 1,182554557,C,T   Prostate_cancer\x2c_susceptibility_to 
RET - 10,43613908,A,T 
Multiple_neoplasia_2A_(MEN2A)_[MIM
:171400] Familial_medullary_thyroid_carcinoma 
RET - 10,43614996,G,A 
Medullary_thyroid_carcinoma_(MTC)_[
MIM:155240] MEN2A_and_FMTC,MEN2_phenotype 
PRF1 - 10,72358722,T,C 
Familial_hemophagocytic_lymphohistioc
ytosis_2_(FHL2)_[MIM:603553] Malignant_lymphoma\x2c_non-Hodgkin 
ASCC1 - 10,73892817,T,C   Barrett_esophagus|Esophageal_adenocarcinoma 
TYR - 11,89017961,G,A   Cutaneous_malignant_melanoma_8 
SDHD - 11,111957665,G,A   
Cowden_disease_3|Paragangliomas_1|Carcinoid_tumor_of_intestin
e|Pheochromocytoma 
SDHD - 11,111958677,A,G   
Carcinoid_tumor_of_intestine|Neoplastic_Syndromes\x2c_Heredita
ry 
BRCA2 - 13,32907129,T,C Breast_cancer_(BC)_[MIM:114480] 
BRCA1_and_BRCA2_Hereditary_Breast_and_Ovarian_Cancer|Neo
plastic_Syndromes\x2c_Hereditary 
BRCA2 - 13,32912007,C,T   
BRCA1_and_BRCA2_Hereditary_Breast_and_Ovarian_Cancer|Neo
plastic_Syndromes\x2c_Hereditary 
BRCA2 - 13,32912553,C,T   
BRCA1_and_BRCA2_Hereditary_Breast_and_Ovarian_Cancer|Neo
plastic_Syndromes\x2c_Hereditary 
BRCA2 - 13,32914974,ACAA,-   
BRCA1_and_BRCA2_Hereditary_Breast_and_Ovarian_Cancer|Neo
plastic_Syndromes\x2c_Hereditary 
BRCA2 - 13,32972852,C,T   
BRCA1_and_BRCA2_Hereditary_Breast_and_Ovarian_Cancer|Neo
plastic_Syndromes\x2c_Hereditary 
TSHR - 14,81609723,A,C   Malignant_melanoma 
AKT1 - 14,105246551,C,T 
Breast_cancer_(BC)_[MIM:114480]|Prote
us_syndrome_(PROTEUSS)_[MIM:17692
0] 
Breast_adenocarcinoma|Carcinoma_of_colon|Neoplasm_of_ovary|P
roteus_syndrome 
CDH1 - 16,68845646,G,A   
not_provided|Neoplastic_Syndromes\x2c_Hereditary|Hereditary_dif
fuse_gastric_cancer 
ELAC2 - 17,12896274,C,T   Prostate_cancer\x2c_hereditary\x2c_2 
ELAC2 - 17,12915009,G,A 
Prostate_cancer,_hereditary,_2_(HPC2)_[
MIM:614731] Prostate_cancer\x2c_hereditary\x2c_2 
FLCN - 17,17119708,-,G   
Multiple_fibrofolliculomas|Pneumothorax\x2c_primary_spontaneou
s|not_provided|Neoplastic_Syndromes\x2c_Hereditary 
FLCN - 17,17125879,G,A 
Renal_cell_carcinoma_(RCC)_[MIM:144
700]   
BRCA1 - 17,41245664,ACTG,-   
BRCA1_and_BRCA2_Hereditary_Breast_and_Ovarian_Cancer|Brea
st-ovarian_cancer\x2c_familial_1 
BRCA1 - 17,41245683,G,A   Familial_cancer_of_breast|Breast-ovarian_cancer\x2c_familial_1 
BRIP1 - 17,59793412,G,A   
Fanconi_anemia\x2c_complementation_group_J|Neoplastic_Syndro
mes\x2c_Hereditary 
MSH6 - 2,48030639,-,C   
Lynch_syndrome|not_provided|Neoplastic_Syndromes\x2c_Heredit
ary 
CHEK2 - 22,29121058,C,T Prostate_cancer_(PC)_[MIM:176807]   
CHEK2 - 22,29121087,A,G   Li-Fraumeni_syndrome_2|Colorectal_cancer\x2c_susceptibility_to 
VHL - 3,10183605,C,T 
Pheochromocytoma_(PCC)_[MIM:17130
0] not_specified|Von_Hippel-Lindau_syndrome|not_provided 
COL7A1 - 3,48619779,G,A   Malignant_melanoma 
APC - 5,112154969,C,T   
Gardner_syndrome|not_provided|Neoplastic_Syndromes\x2c_Here
ditary|not_specified|Adenomatous_polyposis_coli 
PKHD1 - 6,51947999,G,A 
Polycystic_kidney_disease,_autosomal_re
cessive_(ARPKD)_[MIM:263200] 
Polycystic_kidney_disease\x2c_infantile_type|COLORECTAL_CAN
CER\x2c_PROTECTION_AGAINST|not_provided 
MSR1 - 8,16012594,G,A   
Malignant_tumor_of_prostate|BARRETT_ESOPHAGUS/ESOPHA
GEAL_ADENOCARCINOMA 
NBN - 8,90983460,G,A   
Microcephaly\x2c_normal_intelligence_and_immunodeficiency|Neo
plastic_Syndromes\x2c_Hereditary|not_specified 
FANCC - 9,97912338,G,A   
Fanconi_anemia\x2c_complementation_group_C|Neoplastic_Syndr
omes\x2c_Hereditary 
GALNT12 - 9,101594229,G,A 
Colorectal_cancer_1_(CRCS1)_[MIM:608
812]   
TSC1 - 9,135779052,G,A   Neoplastic_Syndromes\x2c_Hereditary 
AR - X,66937326,G,T   Prostate_cancer_susceptibility 
Appendix Table 7 Positive set of cancer associated variants. This set of 38 variants is composed by 
mutations associated with any kind of cancer, including breast, and is used as a reference set of positive 
controls in our age-dependent polygenic model (see sections 4.3.3.5.3 and 4.3.4.4). 
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Variant log2FoldFreq 
Control 
MAF 
Case 
MAF avsnp142 
Protein 
Change 
Deleteriousness 
Score 
MYH7B,20,33585277,33585277,C,A 25.7930 0.0000 0.0058 rs540290584 A1236D 0.78 
NAALADL1,11,64812885,64812885,G,A 23.6046 0.0000 0.0013   P694L 0.89 
FKBP8,19,18650369,18650369,C,T 23.4982 0.0000 0.0012   V152I 0.89 
SLC12A7,5,1075570,1075570,G,A 23.3124 0.0000 0.0010 rs372681736 A628V 0.67 
EHBP1L1,11,65348582,65348582,C,T 23.1859 0.0000 0.0010   R230* 1.00 
PELI3,11,66241362,66241362,G,A 23.1318 0.0000 0.0009   R162Q 0.78 
TET2,4,106164793,106164793,T,C 22.9502 0.0000 0.0008   C1221R 0.56 
NF2,22,30069387,30069387,C,T 22.9362 0.0000 0.0008   R335C 0.78 
COL1A1,17,48263191,48263191,C,T 22.8817 0.0000 0.0008 rs146035171 R1399H 0.89 
AMPD1,1,115218614,115218614,G,A 22.8794 0.0000 0.0008 rs587779370 R496C 1.00 
MYH7B,20,33577664,33577664,G,A 22.8639 0.0000 0.0008   R612Q 0.56 
DFFA,1,10523562,10523562,C,T 22.8464 0.0000 0.0008 rs574523820 R186H 0.67 
SGCA,17,48246600,48246600,G,A 22.8356 0.0000 0.0007   W244* 1.00 
ANO8,19,17441686,17441686,G,A 22.8291 0.0000 0.0007   T315M 0.56 
DHTKD1,10,12126673,12126673,C,T 22.8248 0.0000 0.0007 rs141125831 R149W 0.67 
NAALADL1,11,64824854,64824854,G,A 22.8248 0.0000 0.0007   R198C 0.67 
COLGALT1,19,17690300,17690300,C,T 22.8248 0.0000 0.0007   R426W 0.78 
NDUFA6,22,42482261,42482261,G,A 22.8248 0.0000 0.0007   R131W 0.89 
ARHGEF5,7,144075893,144075893,C,T 22.8248 0.0000 0.0007   R1524* 1.00 
PIK3R2,19,18266970,18266970,G,A 7.1063 0.0003 0.0357   R94H 0.56 
CORO1B,11,67209552,67209552,C,T 6.3551 0.0000 0.0015   R70H 0.78 
NEFH,22,29881809,29881809,C,T 5.6188 0.0000 0.0008   A394V 0.89 
BBS1,11,66297334,66297334,C,T 5.4727 0.0000 0.0008 rs577426256 R462C 0.78 
SYVN1,11,64896178,64896178,-,G 5.4211 0.0001 0.0025   R534fs 1.00 
DDX49,19,19035507,19035507,C,T 5.3482 0.0000 0.0007   R310W 0.89 
PIK3C2B,1,204438071,204438071,-,G 5.3437 0.0000 0.0008   R287fs 1.00 
SF3A1,22,30733026,30733026,G,A 5.3352 0.0000 0.0007   R699C 0.56 
DUSP18,22,31059662,31059662,C,T 5.3349 0.0000 0.0007 rs202138261 R110H 1.00 
RAD51B,14,68352609,68352609,G,A 5.3349 0.0000 0.0007 rs548280411 R159H 0.56 
MRPS30,5,44811233,44811233,C,T 5.3344 0.0000 0.0007 rs201364888 R242* 1.00 
SLC12A7,5,1064287,1064287,G,A 4.9346 0.0000 0.0011   R840C 1.00 
OR2A5,7,143747859,143747859,G,A 4.3353 0.0000 0.0007 rs372476887 R122Q 0.78 
PDE4DIP,1,144879312,144879312,G,A 4.3352 0.0000 0.0007 rs371331495 R1380W 0.56 
APITD1-CORT,1,10511574,10511574,-
,C 4.0169 0.0003 0.0056   A80fs 1.00 
CEP250,20,34067191,34067191,C,T 3.8338 0.0001 0.0008 rs199810583 R744W 0.56 
TBX10,11,67400532,67400532,C,T 3.7520 0.0001 0.0007 rs535008516 V198M 0.89 
GDF5,20,34025551,34025551,-,G 3.7513 0.0001 0.0009   L53fs 1.00 
RIN1,11,66100043,66100043,G,A 3.5774 0.0002 0.0022 rs2282532 P686S 0.56 
RAD51B,14,68352608,68352608,C,T 3.3348 0.0001 0.0007 rs61755649 R159C 0.67 
SLC6A19,5,1221267,1221267,T,G 3.1453 0.0002 0.0016 rs483352699 F514V 0.89 
TP53INP2,20,33296585,33296585,-,C 3.0891 0.0001 0.0008   S14fs 1.00 
EP300,22,41574637,41574637,C,T 3.0133 0.0001 0.0007 rs145312648 R2308C 0.78 
MYO9B,19,17311582,17311582,C,T 2.7561 0.0001 0.0007   R1503C 1.00 
NNT,5,43655960,43655960,G,A 2.7455 0.0002 0.0015 rs139987446 R693H 1.00 
CNBD2,20,34560629,34560629,C,T 2.6349 0.0002 0.0015 rs150690141 R44W 0.67 
ARHGEF5,7,144077001,144077001,A,G 2.5476 0.0001 0.0008   E1549G 0.67 
GHR,5,42718765,42718765,C,T 2.5409 0.0001 0.0007 rs34853905 R364C 0.78 
PC,11,66616566,66616566,G,A 2.3293 0.0003 0.0016 rs148492494 A1114V 1.00 
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EP300,22,41573050,41573050,T,G 2.1793 0.0011 0.0050   C1779G 1.00 
PLEKHH1,14,68045912,68045912,G,A 2.0428 0.0006 0.0023 rs201225859 G971R 0.89 
PDE4DIP,1,144866636,144866636,C,T 2.0135 0.0002 0.0007 rs367741522 R1869Q 0.56 
SPAG4,20,34207652,34207652,G,T 1.9482 0.0003 0.0010 rs369926602 R354L 0.67 
SGSM3,22,40800319,40800319,C,T 1.9127 0.0002 0.0009 rs138251871 R13W 0.56 
FBN1,15,48704816,48704816,G,A 1.8760 0.0008 0.0030 rs61746008 R2726W 0.56 
PDE4DIP,1,144866687,144866687,C,T 1.7908 0.0006 0.0022 rs139494606 R1852Q 0.56 
PPA2,4,106320294,106320294,G,A 1.7468 0.0002 0.0007 rs138215926 P62L 0.89 
NOBOX,7,144096940,144096940,C,T 1.7361 0.0002 0.0008 rs201947677 R355H 1.00 
CLSTN1,1,9804590,9804590,T,C 1.4929 0.0003 0.0008 rs375488055 N356S 0.89 
PDE4DIP,1,145015874,145015874,G,A 1.4282 0.0003 0.0007   R72* 1.00 
TRIP13,5,916035,916035,A,G 1.0875 0.0003 0.0007 rs143798038 S384G 0.89 
MVB12A,19,17535470,17535470,C,T 0.9719 0.0004 0.0008 rs143800574 A248V 0.56 
TMEM134,11,67235051,67235051,G,A 0.9680 0.0066 0.0129 rs143199541 R84* 1.00 
FAM83C,20,33876601,33876601,T,G 0.9654 0.0024 0.0047 rs200589769 H225P 0.56 
CYP2D6,22,42524814,42524814,A,G 0.7631 0.0045 0.0076 rs199535154 L162P 0.78 
NIM1K,5,43246067,43246067,G,C 0.6935 0.0005 0.0007 rs55663207 E64Q 0.78 
MYH7B,20,33582133,33582133,C,T 0.6846 0.0029 0.0046 rs200371401 R919C 0.89 
MYH7B,20,33575964,33575965,AT,- 0.6768 0.0009 0.0015 rs571047145 M538fs 1.00 
DPP3,11,66249736,66249736,C,T 0.2753 0.0006 0.0008 rs142478050 A22V 0.67 
HNF4G,8,76470800,76470800,C,T 0.2467 0.0006 0.0007 rs201625743 R251C 1.00 
FCHO1,19,17886852,17886852,G,A 0.2403 0.0007 0.0008 rs199761608 R305H 0.56 
CARNS1,11,67191572,67191572,C,T 0.2290 0.0020 0.0024 rs200939791 R662C 0.78 
DNAJB7,22,41257815,41257815,G,A 0.1175 0.0027 0.0030 rs149771105 R62W 1.00 
PDE4DIP,1,144857705,144857705,G,A 0.0125 0.0022 0.0022 rs146619065 R2117W 0.56 
Appendix Table 8 List of variants falling in GWAS LD blocks of breast cancer associated SNPs. A list of 
437 variants falls in this category, of wich 73 are also found somatically mutated in cancer and are hereby 
reported. For the complete list of filters used to obtain this table, refer to Figure 22. 
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PIK3CB,3,138413709,138413709,-,G 25.2329 0.0039   R116fs 1.00 
KMT2C,7,151945349,151945349,T,A 23.8270 0.0015 rs201039690 K724* 1.00 
NBN,8,90990520,90990536,ATTGGACGTCCACAAAT,- 23.8270 0.0015   I166fs 1.00 
HNF1A,12,121416792,121416792,C,T 23.4119 0.0011   T74M 0.78 
ASXL1,20,31022331,31022331,C,T 23.2945 0.0010   R606W 0.56 
POLE,12,133225574,133225574,G,A 23.0025 0.0008   R1364C 0.89 
PTCH1,9,98211539,98211539,G,A 22.9761 0.0008   R1206C 0.89 
AKT1,14,105246551,105246551,C,T 22.9666 0.0008 rs121434592 E17K 0.67 
TET2,4,106164793,106164793,T,C 22.9502 0.0008   C1221R 0.56 
NF2,22,30069387,30069387,C,T 22.9362 0.0008   R335C 0.78 
MAP2K2,19,4117473,4117473,C,T 22.9201 0.0008   G83S 0.89 
MSH6,2,48027887,48027887,G,A 22.8884 0.0008   R792Q 0.67 
APC,5,112177788,112177788,G,A 22.8573 0.0008   R2148Q 0.78 
FGFR1,8,38275843,38275843,G,A 22.8421 0.0008   R356W 1.00 
DDB2,11,47256422,47256422,C,T 22.8399 0.0008   R273C 0.89 
FMR1,X,147011711,147011711,G,A 22.8323 0.0007   R193H 0.67 
ASPM,1,197073484,197073484,G,A 22.8313 0.0007 rs200202166 R1633C 0.56 
CEP57,11,95546134,95546134,C,T 22.8291 0.0007 rs387906977 R81* 1.00 
FANCD2,3,10133905,10133905,G,A 22.8291 0.0007   R1273Q 0.56 
ASPM,1,197073381,197073381,C,T 22.8270 0.0007   R1667H 1.00 
NOX4,11,89088203,89088203,G,A 22.8270 0.0007 rs374112961 R357* 1.00 
SETBP1,18,42532994,42532994,C,T 22.8270 0.0007   T1230I 0.56 
FAT1,4,187549401,187549401,C,G 22.8270 0.0007 rs138797966 E1573Q 0.78 
JAK2,9,5069154,5069154,C,T 22.8270 0.0007   R487C 0.89 
DHX9,1,182841496,182841496,C,T 22.8248 0.0007   R528C 0.67 
DHX9,1,182841497,182841497,G,A 22.8248 0.0007   R528H 0.67 
ATM,11,108235818,108235818,T,C 22.8248 0.0007 rs371619067 Y2954H 0.56 
KCNJ5,11,128781800,128781800,G,A 22.8248 0.0007   R211Q 1.00 
ABCC11,16,48234267,48234267,C,T 22.8248 0.0007 rs200200325 V668M 0.89 
TP53,17,7578407,7578407,G,A 22.8248 0.0007 rs138729528 R43C 1.00 
TRIM37,17,57165733,57165733,C,T 22.8248 0.0007 rs201317687 R67H 0.56 
EPB41L3,18,5396207,5396207,G,A 22.8248 0.0007 rs138017302 S767L 0.78 
POLQ,3,121195392,121195392,C,T 22.8248 0.0007   A2134T 0.78 
FAT1,4,187584680,187584680,G,C 22.8248 0.0007   P1118R 0.56 
FBN2,5,127641568,127641568,C,T 22.8248 0.0007 rs140276399 R1832H 0.67 
MYB,6,135539105,135539105,C,T 22.8248 0.0007   T552M 0.67 
KMT2C,7,151945051,151945051,A,G 22.8248 0.0007 rs2838171 I823T 0.78 
Appendix Table 9 List of variants that overlap with cancer somatic mutations. From a total of 185 
overlapping variants on candidate driver genes, we reported all the monomorphic sites in the ExAC 
database (MAF in the controls = 0). 
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Symbol 
REF 
count 
ALT 
count 
Exac REF 
count 
Exac ALT 
count 
Number of truncating 
events 
Stouffer Compoud 
Qvalue 
ALK 1093 189 55873 809 1 1.13E-115 
HNF1B 1204 142 64362 1052 1 9.89E-64 
CNOT3 1216 66 63843 184 1 1.09E-52 
MSH6 1270 34 64712 138 1 1.22E-22 
HNF1A 688 22 32536 88 1 2.94E-14 
ASXL1 341 13 43003 85 1 2.48E-11 
SMOX 1174 8 61840 47 1 1.09E-04 
CRIPAK 28672 521 1490842 3057 27 1.16E-04 
FLCN 854 6 62572 34 1 1.61E-04 
ANAPC1 2476 22 105814 269 2 5.67E-04 
FGFR3 1244 4 64820 13 1 2.07E-03 
AHNAK2 3865 5 193999 10 3 2.50E-03 
PIK3CB 1263 5 65030 29 1 3.15E-03 
KMT2C 6174 134 296450 5956 5 7.93E-03 
JAG1 1314 2 64504 2 1 1.43E-02 
CHEK2 1342 2 65439 3 1 2.23E-02 
POLR1A 1162 24 58860 664 1 2.79E-02 
FANCM 2627 3 130509 99 2 4.59E-02 
SPRY4 351 1 61286 1 1 4.66E-02 
HLA-B 1050 6 87400 2338 2 4.66E-02 
COL18A1 278 105 44002 33065 2 4.66E-02 
IL32 141 1 10067 0 1 4.66E-02 
CDC27 1193 1 63698 0 1 4.66E-02 
BBS10 1249 1 64820 0 1 4.66E-02 
PARP1 1273 1 65248 0 1 4.66E-02 
IKBKB 1279 1 65106 0 1 4.66E-02 
FBN2 1295 1 65443 0 1 4.66E-02 
BRCA2 1315 1 64690 0 1 4.66E-02 
ERCC6 1331 1 65474 0 1 4.66E-02 
UROD 1339 1 65431 0 1 4.66E-02 
CEP57 1341 1 65470 0 1 4.66E-02 
RNASEL 1343 1 65468 0 1 4.66E-02 
BRCA1 1343 1 65444 0 1 4.66E-02 
POLN 1339 1 65234 0 1 4.66E-02 
ATR 1345 1 65482 0 1 4.66E-02 
SIN3A 1345 1 65412 0 1 4.66E-02 
PTPRB 1345 1 65360 0 1 4.66E-02 
TYR 1343 1 65176 0 1 4.66E-02 
MSH4 1343 1 65122 0 1 4.66E-02 
NLRP3 1345 1 65138 0 1 4.66E-02 
NOX4 1343 1 59130 0 1 4.99E-02 
Appendix Table 10 List of candidate loss-of-function genes. We report all those genes with an excess 
of truncating events in cases compared to controls with a compound q-value < 0.05. 
